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Abstract 
The gastrointestinal (GI) hormone, gastrin, promotes cancer 
progression and its down-regulation has been linked to reduced cancer 
stem cell numbers. Gastrin acts through the cholecystokinin-2 receptor 
(CCK-2R) and its biological effects are blocked by CCK-2R inhibitors. 
We investigated the regulation of the CCK-2R and its potential role in 
promoting survival of cancer stem cells (CSC).  
 
A panel of cancer cell-lines, including GI, glioblastoma and lung, with 
CCK-2R-transfected cells as a positive control, were grown either as 
monolayers, or, to provide a 3D in vitro tumour model, as spheres. 
Linear-after-the-Exponential (LATE)-PCR was used to quantify CCK-2R 
gene expression and this was validated using siRNAs. Flow cytometry 
was used to investigate receptor protein expression. Activity of CCK-2R 
promoter reporters was quantified using luciferase assays.  
 
LATE-PCR for CCK-2R gene expression is 10,000-fold more sensitive 
than the Taqman-based assay, and provides a highly precise method 
for detection of genes which have important biological functions but low 
expression. This assay showed that primary non-small-cell lung 
tumours have significantly more expression than normal lung tissue, 
indicating a potential therapeutic marker. CCK-2R siRNAs resulted in 
up to 97% (p<0.05) knockdown of the receptor in cancer cells, 
confirming the specificity of LATE-PCR and offering a therapeutic 
possibility.  
 
The CCK-2R promoter constructs were active in lung, glioma and 
colorectal cancer cell-lines, demonstrating a potential drug target; 
however, transcriptional activity did not correlate with gene expression, 
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suggesting post-transcriptional or translational regulation is a factor 
affecting CCK-2R expression.  
 
Flow cytometry suggests the presence of a small population of cells 
within each of these cell-lines which expresses CCK-2R very highly, 
which was not correlated to CSC markers. However, CCK-2R 
expression was enriched when cells were grown as spheres, and 
inhibition caused a delay in sphere-forming, implying that the CCK-2R 
may play a role in tumour, and CSC, expansion. Thus, CCK2R provides 
a potential target for therapeutic intervention in cancer. 
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Abbreviations 
5FU 5-Fluorouracil 
A 
ABCG2 
ABI 
 
ATP-binding cassette G2 
Applied Biosystems 
AC133 
Akt  
Epitope of CD133 
Protein kinase B 
ALDH1 
APC 
Aldehyde dehydrogenase 1 
Adenomatous polyposis coli 
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Arg 
ATF4 
Arginine 
Activating transcription factor 4 
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B 
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Bcl2-associated agonist of cell death 
Bcl2 B-cell lymphoma 2 gene 
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C 
CagA 
 
Cytotoxin-associated gene product A 
CAT Chloramphenicol acetyltransferase 
CCK Cholecystokinin 
CCK-1R  Cholecystokinin 1 receptor  
CCK-2R  Cholecystokinin 2 receptor  
CCK-2Ri4sv CCK-2R intron 4-retained variant 
CCKR 
CD133 
CD24 
CD26 
CD44 
CDH1 
Cholecystokinin 1 receptor (in Figure 1.13) 
Prominin1 
Signal transducer 24 
A T-cell activation molecule 
A cell surface glycoprotein 
E-Cadherin (1) gene 
CI-988  PD134308; CCK-2R inhibitor 
CK20 Cytokeratin 20 
CNS 
COX-2 
Central nervous system 
Cyclooxygenase 2 
CSC Cancer stem cell(s) 
Ct 
CTFP 
Cycle threshold 
C-terminal flanking peptide 
D 
DAG 
 
1,2-diacylglycerol 
DNA Deoxyribonucleic acid 
E 
ECF 
ECL 
 
Epirubicin, cisplatin and 5FU combination therapy 
Enterochromaffin-like 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
eIF-4E 
ER 
ERK 
An mRNA cap-binding protein 
Endoplasmic reticulum 
Extracellular signal-related kinase 
F 
FAP 
 
Familial adenomatous polyposis 
Fas 
FcRc 
FITC 
FF1/2R 
FGF 
An apoptosis ligand 
Primer pairs for LATE-PCR 
Fluorescein 
Neuropeptide FF receptor type 1/2  
Fibroblast growth factor 
Fos 
FS lin 
G 
An early response TF (with JUN) 
Forward light scatter 
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G17 or G34 Amidated gastrin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GASR 
gDNA 
Gastrin/Cholecystokinin 2 receptor (in Figure 1.13) 
Genomic DNA 
gERE Gastrin EGF response element 
GI Gastrointestinal 
Glioma 
Gly-gastrin 
Glioblastoma 
Glycine-extended gastrin 
GnRH-I/II 
GnRH-R 
GPCR 
Gonadotrophin releasing hormone-I/II 
Gonadotrophin releasing hormone receptor 
G-protein coupled receptor 
GRHR 
GRP 
Gonadotropin releasing hormone receptor 
Gastrin releasing peptide 
GRP78 78 kDa glucose-regulated protein 
GV150013 
H 
HB-EGF 
CCK-2R inhibitor 
 
Heparin-binding epidermal growth factor  
HDGC Hereditary diffuse gastric carcinoma 
HIF-1Į/2Į Hypoxia-inducible factor 1ĮĮ 
HPNCC Hereditary non-polyposis colorectal cancer 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HuR 
I 
IC50 
ARE binding protein 
 
Half maximal inhibitory concentration 
IHC Immunohistochemistry 
IL-1 Interleukin 1 
IL-8 Interleukin 8 
IF Immunofluorescence 
IFN-Ȝ Interferon-gamma  
,ț%Į Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor-alpha 
IP3 Inositol 1,4,5-triphosphate 
IRES 
J 
JAK 
Internal ribosome entry site 
 
Janus kinase 
JMV 320 
JNK 
CCK-2R inhibitor 
c-Jun NH2 terminal kinase 
JUN An early response TF (with Fos) 
K 
Kras 
L 
L-365,260 
L-740,093 
L primer 
 
Kirsten rat sarcoma viral oncogene homolog 
 
CCK-2R inhibitor 
CCK-2R inhibitor 
Limiting primer 
LATE-PCR Linear-after-the-exponential PCR 
M 
MAPK 
 
Mitogen-activated protein kinase 
miRNA 
MLH1 
MMP 
MicroRNA 
mutL homologue 1 gene 
Matrix metalloproteinase 
MRP5 
MSH2 or 6 
mTOR 
Multidrug resistance related protein 5 
Mismatch repair homologue 2 or 6 gene 
Mammalian target of rapamycin 
N 
NICE 
 
National Institute for Clinical Excellence 
NF-țB Nuclear factor-kappa B 
NPGPR 
NPAF 
NPFF 
NSCLC 
Alternative splice variant of FF-2R 
A-18-F-amide 
F-8-F-amide 
Non-small cell lung cancer 
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O 
Oct4 
OX1/2R 
OXRs 
OXYR 
P 
P120 
PCR 
 
 
Octamer-binding transcription factor 4 
Orexin (hypocretin) receptor type 1/2 
Orexin (hypocretin) receptors 
Oxytocin receptor 
 
Proliferation-associated protein 
Polymerase chain reaction 
PEI 
PI3K 
Poly(ethylene-imine) 
Phosphotidylinositol 3 kinase  
PIP2 Phosphotidylinositol bisphosphate 
P/&ȕ Phospholipase Cȕ 
PKB See Akt 
PKC Protein kinase C 
PMS2 
PMT1 lin 
PPI 
Mismatch repair endonuclease gene 
Side light scatter 
Proton pump inhibitor 
PTEN Phosphatase and tensin homolog 
PTX Pertussis toxin 
Q 
qRT-PCR 
 
Quantitative real-time PCR 
R 
raf 
ras 
 
A serine/threonine-protein kinase 
Rat sarcoma protein 
REG1Į Regenerating islet-derived 1Į 
(m)RNA (messenger) Ribonucleic acid 
RNAi RNA interference 
S 
SCLC 
 
Small cell lung cancer 
SCM 
Shc 
Stem cell medium 
Src homology domain containing protein 
siRNA Short interfering RNA 
SP Signal peptide 
SP1 Specificity protein 1 
Sox-2 SRY-box 2 
Src 
SRY 
SSTR2 
T 
TCF-4 
Sarcoma-inducing tyrosine kinase 
Sex determining region Y 
Somatostatin receptor 2 
 
Transcription factor 4 
TF Transcription factor 
Tm Melting temperature  
TNF-Į  Tumour necrosis factor-alpha 
U 
U 
 
Undetectable (in qRT-PCR) 
U2AF35 A splicing factor 
V 
V1A/1B/2R 
 
Vasopressin receptor type 1A/1B/2 
VRs 
VC 
Vasopressin receptors 
Vector control 
VEGF Vascular endothelial growth factor  
W 
wt 
 
Wild-type 
X 
X primer 
 
Excess primer 
XIAP X-linked inhibitor of apoptosis 
Y 
YM022 
 
CCK-2R inhibitor 
Z  
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Z360 CCK-2R inhibitor 
ZBP89 Zinc-binding protein 89 
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1.1. Cancer 
Cancer is a cellular disease with many different causes. The cells 
involved become deregulated and do not respond to normal growth 
limitations, allowing a mass of cells, or a tumour, to develop in a 
process called carcinogenesis. 5-10% of cancers are caused by an 
inherited genetic fault, whereas environmental factors, such as infection 
or exposure to radiation, are the cause of the DNA damage in the rest 
of cases [1]. Genes become mutated, allowing loss of tumour 
suppressor genes; which stop excess growth in the normal situation, or 
gain of oncogenes; those genes which promote expansion and 
replication. The cells lose normal function and can begin to spread to 
other tissues, causing damage throughout the body. This is called 
metastasis and along with invasion of the lymph nodes is a late stage in 
cancer and usually associated with a poor prognosis of survival. This, 
however, varies between cancers, as do treatment options, drug 
effectiveness and initial risk factors. 
 
Cancers are different with regard to cell type, position, blood vessel 
recruitment and genotype, but they all display certain hallmarks. These 
were originally six physical properties of cancer cells themselves [2], but 
have evolved into 12 hallmarks, including those of the environment in 
which the tumour grows, for example oxidative stress (Figure 1.1) [3]. 
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Figure 1.1: The hallmarks of cancer [3] 
 
The cancers of relevance to this project include gastrointestinal (GI) 
forms: gastric adenocarcinoma, colorectal carcinoma, oesophageal 
carcinoma and pancreatic carcinoma. GI cancers are clinically 
important due to their late progression and consequent poor prognosis. 
They are all solid cancers of the epithelium. Also of particular interest 
are lung carcinomas, especially small cell lung cancer (SCLC), and 
glioblastoma brain tumours.  
 
1.1.1. Gastric adenocarcinoma 
Gastric adenocarcinoma, is the second most common cause of cancer 
death in the world [4, 5], with over 900,000 cases diagnosed annually 
worldwide. It is a lingering disease, normally caused by long-term 
inflammation of the gastric epithelium. This inflammation has multiple 
causes such as regular use of anti-inflammatory drugs, tobacco and 
alcohol, or consuming large quantities of pickled foods [4], but the most 
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common is known to be Helicobactor pylori infection [5]. Once the 
stomach lining has become inflamed, the cells start to develop 
mutations in their DNA, causing atrophic gastritis, a premalignant 
condition. The epithelial cells progress through intestinal metaplasia 
and dysplasia until eventually gastric adenocarcinoma is diagnosed [6].  
 
H. pylori can cause up-regulation of various cellular factors including 
pro-angiogenic proteins, and so this pathogen is a potent carcinogenic 
risk [7]. This conclusion is supported, cautiously, by Danesh [8] in their 
1999 review of the many trials carried out. But in 2004 Correa [9], 
stated that infection with H. pylori LV WKH µGULYLQJ IRUFH¶ LQ JDVWULF
carcinogenesis, and that eradicating the bacteria from certain patients 
led to no cases of the cancer in those people. Certain strains of H. 
pylori are considered to be more of a risk, such as cytotoxin-associated 
gene product A (CagA)-positive bacteria. CagA-strains are associated 
with greater virulence and far more cases of gastric cancer than CagA-
negative strains [6].   
 
Gastric cancer can also be hereditary, with the best known of these 
arising from the mutated E-cadherin gene, CDH1, a tumour suppressor 
gene. This produces hereditary diffuse gastric carcinoma (HDGC) which 
often presents in younger patients (<age 45) with a strong family history 
of the condition [10]. This gene is screened for in those families thought 
to be at risk, so that prophylaxis can be an option.  
 
The treatment for gastric cancer generally starts with major surgery to 
eliminate the tumour, and in some cases this will mean removing the 
entire stomach [4]. Chemotherapy can reduce tumour size before the 
operation or it can be used as palliative care, to keep the carcinoma 
from growing. The most effective combination therapy for gastric cancer 
is ECF, which includes the drugs Epirubicin, Cisplatin and 5-
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Fluorouracil (5FU) [4]. However, other drugs can be used if these fail to 
produce a decrease in tumour size, and radiotherapy can be 
undertaken if these are unsuccessful. The latter is not a normal 
treatment for gastric carcinoma though, and is usually used only as 
palliative care. 
 
1.1.2. Oesophageal carcinoma 
In direct opposition to the above, it has been found that infection with H. 
pylori, and the cytokines expressed, may protect the oesophageal 
mucosa from developing adenocarcinoma [9]. Although there are half 
as many diagnoses of this cancer (400,000 worldwide per annum) 
compared to that of gastric carcinoma, the 5-year survival rate is lower 
at 8% as opposed to 15% [11, 12]. This is due to the fact that 
metastasis has often already taken place by the time of diagnosis, 
allowing for fewer treatment strategies. Again this disease is a 
consequence of chronic inflammation of epithelial cells, this time always 
caused by repeated acid reflux from the stomach into the oesophagus. 
Alcohol consumption, smoking tobacco and being excessively 
overweight are also powerful risk factors, as they are for most cancers 
[11, 12]. Hormones too, can play an important paUWLQFDXVLQJ%DUUHWW¶V
oesophagus, a premalignant condition, to progress to adenocarcinoma, 
E\ LPSDLULQJ WKH FHOO¶V DSRSWRVLV SDWKZD\V [13]. This cancer is 
associated with a mutation in p53, a critical tumour suppressor gene, 
involved in cell cycle control, DNA repair and instigating apoptosis.  
 
Treatment for oesophageal carcinoma normally involves removal of 
most of the oesophagus, causing these patients major problems with 
nutrition [11]. Once the tumour is removed a part of the stomach or 
colon is positioned in its place in order to allow digestion but this is not 
ideal. If the cancer cannot be removed a stent is put inside the 
RHVRSKDJXV LQ RUGHU WR LPSURYH D SDWLHQW¶V TXDOLW\ RI OLIH DQG
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chemotherapy, radiotherapy or a combination of both are used to 
reduce tumour size [11]. In some cases this can completely cure the 
cancer, but in others it will be used for palliative purposes. 
 
1.1.3. Colorectal carcinoma 
Colorectal carcinoma was diagnosed in over one million people across 
the world in 2002 [14]. However, the five-year survival rate is much 
higher than the cancers above, at around 51% [14]. This is likely to be 
due to the fact that this is one of the few cancers for which screening is 
possible. Risk groups (those aged 60-69 in England [15], or 50-74 in 
Scotland [16]) are screened for faecal blood and if this is found then a 
colonoscopy is performed. This procedure examines the bowel lining for 
polyps or other anomalies, and these can then be treated, sometimes 
before the adenocarcinoma develops. This cancer is often caused by 
environmental factors, the most common being excessive red meat and 
fat, and lack of fibre in the diet [17]. There are also two hereditary 
causes of colorectal cancer, accounting for 5% of all cases. These are a 
mutated adenomatous polyposis coli (APC) gene, causing familial 
adenomatous polyposis (FAP) [18], or a mutated variant of one of a set 
of DNA repair genes, MSH2, MSH6, MLH1 and PMS2, which bring 
about hereditary non-polyposis colorectal cancer (HPNCC) [19].  
 
In the normal colon APC binds and down-regulates ȕ-catenin, a role 
which regulates the transcription of many genes including those 
involved in control of the cell cycle and migration. Mutation (point or 
gross deletion) of the APC gene in FAP leads to the introduction of a 
premature stop codon and therefore truncation of the APC protein in 
94% of cases [20]. This protein cannot bind to ȕ-catenin causing 
constitutive activation of the Wnt pathway, and more transcription of 
growth promoting genes, allowing adenomas to develop in the colon 
[20]. The mutation site is important since it predicts the severity of the 
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disease; if it falls within codons 1250-1464 then the patient will develop 
far more adenomas than if the mutation is at the very ends of the gene 
[18]. The number of adenomas ranges from 5000 in the first group to 
100 in the second, and this in turn correlates with the likelihood and age 
at which colorectal carcinoma develops; the more adenomas the worse 
the prognosis [18].  
 
Most patients with colorectal cancer are subjected to some kind of 
surgery to remove their tumour [14]. This treatment is successful if the 
cancer is in its early stages, and often the bowel section is removed and 
the ends are joined up to cause little digestive disruption. However, if 
the carcinoma is advanced a large portion of the colon can be taken out 
and a colostomy bag will replace it. Chemotherapy can be used to 
reduce colorectal tumour size and the most commonly used drug is 5FU 
[14]. Irinotecan, cisplatin and oxaliplatin can also be used for more 
advanced carcinoma cases. Radiotherapy is not often used, except in 
palliative cases [14].  
 
1.1.4. Pancreatic carcinoma 
Over 200,000 people worldwide were diagnosed with pancreatic cancer 
in 2002 [21, 22], and due to the late appearance of symptoms this 
disease has an appalling five-year survival rate of 2-3% [21, 23]. It is 
associated with smoking and is most often seen in the elderly [22, 23]. 
The three cancers above can be at least partially treated with surgery to 
remove tumour growth. However, with pancreatic carcinoma this is not 
very successful, due to the late stage of most diagnoses and the 
complexity of the surrounding tissues [24]. An almost universal mutation 
in pancreatic carcinoma is that of Kras, an oncogene capable of 
activating many pathways in carcinogenesis [25].  
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Radiotherapy or chemotherapy or a combination of the two can be used 
to shrink the tumour either to prepare for surgery or to relieve pain and 
discomfort [26]. Chemotherapy is the first line of treatment for advanced 
cancer, with the drug, gemcitabine, being recommended by the National 
Institute for Clinical Excellence (NICE). However, this is only 
undertaken if the patient is well enough to cope with the side-effects 
[26]. It was hoped that perhaps hormonal therapy, such as blocking 
some growth-enhancing receptors, may have worked to impede tumour 
expansion. Many studies of the trophic effects of gastrointestinal 
hormones have been carried out, but have come up with no clear 
conclusion. Some studies seem to show that these hormones could 
enhance tumour growth and carcinogenesis, and others the opposite 
effect [24].  
 
1.1.5. Lung carcinoma  
Lung cancer is the most common form of cancer diagnosed throughout 
the world today, with 1.3 million new cases identified in 2002 [27]. 
Unfortunately it is also the most common cause of cancer death, with 
between 7 and 9% of patients surviving 5 years after diagnosis [27]. 
The disease is largely restricted to the elderly, and is most frequent in 
smokers; however, passive smoking, exposure to industrial carcinogens 
and air pollution all contribute to the risk of developing lung cancer.  
 
SCLC makes up between 20 and 25% of lung cancer cases, and 
despite being highly responsive to chemotherapy; most patients relapse 
and die from chemo-resistant disease [28]. The accepted regimen for 
early-stage SCLC is cisplatin plus etoposide, and this is effective short-
term in 85% of cases [27, 28]. Radiation therapy is considered as 
palliative care for those with late-stage disease or recurrent tumours. 
Non-SCLC (NSCLC) has a better diagnosis, with patients detected at 
an early stage being eligible for major surgery, allowing a 60% 5-year 
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survival rate [27]. Surgery is the first resort for patients, and then 
chemotherapy or radiotherapy can be used instead of surgery. In 
palliative cases chemotherapy and relief of symptoms such as lung 
obstructions are combined. 
 
1.1.6. Glioblastoma  
Brain tumours make up around 2% of all cancers in the UK and there 
were over 4500 diagnoses in 2006 [29]. Glioblastomas (gliomas) make 
up about 50% of these cases and often develop from astrocyte cells in 
the brain [30]. Survival rates for high and low grade gliomas range from 
a few months to a few years [31]. 
 
Focal gliomas tend to develop in children, meaning that the border of 
the tumour is easily defined allowing for more successful surgery. 
Unfortunately adult gliomas are more diffuse, and can form in very 
difficult areas such as the brain stem. In this case neither surgery or 
radiotherapy are treatment options and survival will be very limited [30]. 
However, in certain situations of age, location and growth rate surgery, 
chemotherapy and radiotherapy are all options for treatment of 
glioblastoma [30]. 
 
1.2. Cancer stem cells  
Cancer stem cells (CSC) are postulated to exist within many, if not all, 
cancers [32-34]. CSC are the cells which initiate and maintain the 
tumour, which makes them especially relevant in the case of 
chemotherapy, where they can lie dormant and allow recurrence. There 
are three defining characteristics of CSC identified by Schatton et al. 
and these are a) the capacity to produce tumours, b) identical 
regeneration and c) to produce non-stem cancer cells (Figure 1.2) [35]. 
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Figure 1.2: In order to be 
classed as such, cancer stem 
cells must show the ability to 
proliferate into a tumour, self-
renew and produce 
differentiated cells [35] 
 
 
 
 
 
 
 
 
 
CSC were first identified when it was found that only a subset of 
leukemic cells taken from an acute myeloid leukaemia patient could 
regenerate the disease in immunocompromised mice [36]. This 
challenged the old stochastic model of tumour initiation; where any cell 
in the tumour could propagate the cancer [37]. A review by Schatton et 
al. indicates that CSC have been found in breast, brain and ovarian 
cancer and melanoma, and more recently in colon carcinoma [34, 35]. 
However, the membrane markers that distinguish the CSC in each 
cancer type are different. For example the markers of stemness in 
leukaemia are those that mark normal stem cells; CD24 and CD44 [38]. 
The main cancer stem cell marker known in brain cells is CD133; 
however this molecule is not sufficient in colorectal cancer cells to 
indicate a cancer-initiating cell.  
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1.2.1. Cancer stem cells in tumour formation and growth 
One of the major problems with identifying CSC markers is that in some 
cases CSC can generate a xenograft tumour from just 20 cells [39, 40]. 
The CSC model of tumour growth asserts that the actual number of 
cells needed to form a tumour is just one; however, the nature of 
xenograft formation does not make this simple to demonstrate (Figure 
1.3). This means that the probability of contamination with cells of a 
different phenotype is very high, however the CSC are isolated [39].  
 
Figure 1.3: Models of tumour propagation 
There are several theories about tumour initiating cells. a) shows the normal tissue 
situation, where stem cells give rise to differentiated cells, which form an organ. b) is 
the stochastic model or clonal evolution; where all cells have the same tumourigenic 
capacity. c) the CSC model; one cell gives rise to the tumour cell bulk while renewing 
itself. d) shows the clonal evolution of the CSC into a second distinct cell (CSC2) 
which becomes dominant due to further mutations and goes on to propagate the 
tumour.[39] 
 
Another debate which continues is whether the CSC arises from a 
mutated stem cell or a progenitor cell which has mutated to become 
stem-like, i.e. demonstrates self-renewal [41, 42]. There are even 
suggestions that a somatic cell merges with a stem cell in some 
cancers to form the CSC [41]. Unfortunately this question will remain 
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unanswered until a definitive population of CSC can be found within any 
given tumour.  
 
1.2.2. Cancer stem cell markers 
The only way to diagnose the tumour initiating cell for certain is to test 
its ability to produce the same tumour in an immunodeficient mouse 
[43]. In vitro assays such as sphere-forming have also been used to 
select for the CSC population, since these 3D spheres are more similar 
to the tumour environment than 2D culture [44, 45]. However, there is 
some controversy over exactly which markers illustrate CSC. CD133 
was the first marker linked to CSC in neural cancer cells [46], but in 
colorectal carcinoma cells different groups have found that CD133- cells 
cannot [47] and can [48] produce tumours in mice.  The first study 
states that since only CD133+ cells can produce tumours, these must 
be the tumour-initiating population and therefore the CSC [47]. The 
second study overturns this research, showing widespread CD133 
expression in the primary tumour colonic epithelium, and demonstrating 
that the CD133- cells are in fact the more tumourigenic population [48].  
 
There have been many markers linked to colon CSC. These include 
survivin and multidrug resistance related protein 5 (MRP5), which were 
shown to be related to faster progression of colon cancer by Gazzaniga 
et al. [49]. They also showed that aldehyde dehydrogenase 1 (ALDH1) 
was associated with poor prognosis but that CD44 and CD133 
expression were not, in colorectal cancer patients. Conversely, Lugli et 
al. suggest that loss of CD166 and CD44s may lead to a worse 
prognosis [43].  
 
Another study by Pang et al. showed that CD26 was up-regulated in 
metastasis compared to unpaired primary tumour samples [50], which 
they relate to CSC status. CD26+ tumour cells were capable of liver 
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metastasis in a mouse model, with or without CD133/CD44 expression, 
but expression of these 2 markers did increase tumourigenicity. CD26- 
cells could not metastasise independent of CD133/CD44 status [50]. 
From this data they hypothesise that two types of CSC exist; a 
stationary one promoting tumour growth and a metastatic CSC.  
 
Drug-resistant tumour cells display up-regulation of drug transporters, 
for example ABCG2, which allows the cell to pump out any 
chemotherapy used in the treatment of cancer patients [51]. This has 
led to the hypothesis that ABCG2 is a CSC marker, since CSC are the 
cells from which the tumour recurs after chemotherapy has been 
applied and therefore must be resistant to such therapy. ALDH1 has 
also been put forward as a marker since this would enhance CSC 
survival by detoxification of cellular aldehydes [52].  
 
Very recently Vermeulen et al. have hypothesised that the HCT116 
(colorectal carcinoma) cell-line does not contain a CSC fraction as they 
are not hierarchical in organisation [53]. They implicate Wnt in a 
hierarchical organisation, showing that Wnt activity is correlated with 
many possible CSC markers, CD133, CD166, CD24, CD29 and CD44. 
This hypothesis is supported by various experiments in which they grew 
tumours from cells displaying high Wnt activity. They assert that their 
previous data illustrated that colon CSC lose their markers when grown 
in medium with serum, therefore stroma must be a part of the CSC 
niche, and more particularly the myofibroblasts. When myofibroblasts 
were mixed with low Wnt activity cells (which are differentiated), they 
induced several cells to revert to the CSC phenotype of high Wnt 
activity [53]. 
 
Another Wnt target gene, Lgr5, has been associated with CSC since it 
is a stem cell marker in colon cells [54]; the Lgr5+ cells at the base of 
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each colon crypt undergo rapid cycling, and appear to give rise to other 
cells in the crypt. Vermeulen et al. found that Lgr5 expression correlated 
with their high Wnt activity CSC [53]. Lgr5 is also implicated in the 
metastasis of colorectal carcinoma cells, although the authors admit 
more research should be done to prove this connection [37]. 
 
In lung cancer, the consensus so far is that stem cells can be identified 
by CD133 and ABCG2 expression [55]; with the latter allowing efflux of 
Hoechst 33342 dye, allowing the cells to be seen as a side population 
using flow cytometry [56]. Increased Wnt signalling is also seen in the 
lung CSC subset, and this can be confirmed by build up of ȕ-catenin in 
the nuclei of the cancer cells [57]. 
 
Glioblastoma CSC markers are less controversial than those in either 
colorectal or lung cancers. CD133-positive cells alone can initiate 
tumours [46] and are more highly associated with the most aggressive 
tumours [58]. These neural CSC have been linked to stress conditions, 
for example hypoxia allows for the maintenance of the CSC subset, 
through the activation of HIF2Į [55]. This molecule in turn up-regulates 
Oct4, which is a normal stem cell marker, recently validated as a CSC 
marker [59]. 
 
It is likely that CSC can be heterogeneous, which explains why certain 
markers have been proved and disproved in the same cancer type; e.g. 
CD133 in colorectal carcinoma [39, 47, 48, 53]. In the future cancer 
types may be separated due to their CSC subtype.  
 
1.3. Hormones in cancer 
The focus of this project is to find out how cancer is affected by the 
hormone, gastrin, via its receptor, the cholecystokinin 2 receptor (CCK-
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2R). Cancers as a group have many diverse direct causes and risk 
factors. The progression of cells from normal to cancerous; 
carcinogenesis, consists of disruption to cell proliferation, angiogenesis, 
cell adhesion and cell death or apoptosis. Since these processes are 
under hormonal control in the body, hormones can initiate, promote or 
be affected by cancer [60]. A potent initiator and promoter of 
carcinogenesis is oestrogen. This hormone can, in some cases, induce 
changes in cellular DNA and in this way can initiate endometrial cancer 
[61]. In its role as a promoter oestrogen can also augment cell division 
and proliferation, causing tumours to develop, often in reproductive 
tissues.  
 
The gastrointestinal cancers described above, as well as being initiated 
and promoted by hormones, also affect certain hormone expression. 
This in turn can lead to further promotion by the hormone which has 
been up-regulated, leading to a feedback mechanism. However, in 
modern medicine this link can be exploited, since these cancers are 
often responsive to hormone therapy, such as the use of hormone 
receptor antagonists [62]. Many GI hormones have been linked to 
carcinogenesis, for example cholecystokinin (CCK) has been 
associated with increased proliferation of pancreatic tumour tissues and 
also in facilitating invasion across basement membranes [60, 62, 63].  
 
Another GI hormone, gastrin, is a well-known promoter of all the GI 
cancers and although not usually expressed in the normal tissues, is 
produced in these and many other cancer cells [62]. Gastrin releasing 
peptide (GRP), its analogue; bombesin, and neurotensin have been 
found to have promoter activity in gastric carcinoma, although the latter 
was only studied in rats [60]. Neurotensin has been shown to stimulate 
human and murine colorectal cancer, though, and this seems to be due 
to its stimulation by certain fats [60]. This project will focus on the 
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effects of gastrin on GI and lung cancer and glioblastoma, and the 
receptor which mediates its effects.  
 
1.4. Gastrin 
Gastrin is the hormone which causes gastric acid to be secreted into 
the stomach. It is also able to cause epithelial proliferation leading to 
growth of the gastrointestinal mucosa [64], and eventually to stomach 
ulcers. In addition it can bring about enterochromaffin-like (ECL) and 
parietal cell maturation [65]. The translated product of the gastrin gene 
is preprogastrin, a 101-amino acid peptide. This is cleaved of its 21-
amino acid N-terminal signal peptide (SP) in the ER/Golgi apparatus, to 
become progastrin (Figure 1.4). Further processing in endocrine cells 
cleaves this peptide at Arg94-Arg95 to form glycine-extended gastrin 
(Gly-gastrin) and eventually amidated gastrin (G17 or G34) [66, 67]. 
 
Figure 1.4: Gastrin biosynthesis showing each of the intermediate, and biologically 
active, peptides  
(The dashed arrow has only been shown by certain authors (see [66] for more 
information.) [66] 
 
Gastrin is produced in the G cells of the antro-pyloric mucosa, where 
the enzymes necessary for processing (Figure 1.4) are expressed. 
These include signal peptidase, to remove the SP, prohormone 
convertase, which cleaves progastrin and peptidyO Į-amidating 
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monooxygenase to produce amidated gastrin [66, 67]. This is then 
exocytosed from secretory granules to be transported to the oxyntic 
mucosa [68]. Here it can interact with the CCK-2R on ECL cells. The 
stimulated ECL cells release histamine, inducing the parietal cells to 
produce and discharge gastric acid into the stomach lumen [69]. The 
stomach is therefore kept in a constant acidic state (pH 1-2) in order 
that various digestive enzymes can operate. Gastrin may also be able 
to directly stimulate parietal cells [70].  
 
1.4.1. Gastrin in cancer tissues 
However, gastrin is able to influence much more than just digestion 
[64]. It is transcribed in a lot of different pre-malignant and tumour cells. 
48% of gastric cancers are gastrin gene positive, along with 80-90% of 
colorectal polyps, 78% of pancreatic tumours [71] and 100% of 
oesophageal cancers [72]. Gastrin expression is also found in many 
non-GI cancers such as ovarian tumours and bronchogenic 
carcinomas. It is present in pre-malignant cells as well as full-blown 
cancer and is proved to be a promoter of the carcinogenic process 
when combined with a co-factor. Examples of co-factors are bacterial 
infection (e.g. H. pylori), inflammatory cytokines (tumour necrosis factor-
alpha (TNF-Į) and interleukin-1 (IL-1)) and the presence of mutant 
cells. Gastrin may also influence stem cells via regenerating islet-
derived 1Į 5(*Į [71]. It has been shown that increasing levels of 
gastrin correlate with rising severity of illness and a greater degree of 
metastasis [73], especially in pancreatic and colorectal cancer cells. 
 
Gastrin expression is regulated by a number of factors, some acting 
before transcription and others post-translation. Gastrin transcription 
can be significantly increased by infection with H. pylori [74] due to 
various proteins secreted by the bacterium itself (Figure 1.5). Gastrin 
transcription is also induced by epidermal growth factor receptor 
   Introduction 
31 
 
(EGFR) ligands (e.g. EGF) via the EGF response element on the 
gastrin promoter (gERE) [75]. EGF can increase expression of the 
gastrin gene through a transcription factor (TF), SP1, and this 
introduces the possibility that gastrin may be regulated by ras [75]. 
Another molecule, JUN, mediates this interaction, and is in turn 
negatively mediated by somatostatin, the hormone which causes 
inhibition of gastrin expression. Another transcriptional alteration can be 
achieved through the zinc-finger TF (ZBP89) binding to the gastrin 
promoter causing repression [76].  
 
Figure 1.5: Regulation of gastrin release from the G cell 
Peptides and amino acids are responsible for normal digestive release, however the 
other factors shown are either disease-led (H. pylori and its cytokines) or can be 
altered in cancer (GRP, EGF) [77]. SOM: Somatostatin, GRP: Gastrin releasing 
peptide, EGF: Epidermal growth factor. 
 
Post-translational up-regulation of gastrin occurs by altering secretion 
from G cells. This can be caused by administration of proton pump 
inhibitor (PPI) drugs [78]. PPI drugs are prescribed for the treatment of 
excess stomach acid and/or reflux and can bring about sustained 
hypochlorhydria (low stomach acid), which in turn can lead to 
compensatory hypergastrinaemia [79]. Another factor is the bacterium, 
H. pylori, which in addition to its direct effects, causes infected cells to 
produce high levels of cytokines (Figure 1.5). These include interferon-
gamma (IFN-Ȝ), TNF-Į and interleukin-8 (IL-8) [80] and can increase 
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proliferation of G cells and their secretion of gastrin into the stomach 
epithelium [80]. 
 
A third post-translational up-regulator of gastrin is GRP, although this 
actually has a negative effect on gastrin expression in the fundic 
mucosa [60]. Somatostatin is a negative regulator of gastrin up-
regulation and its release from G cells, and so can cause a large drop in 
levels of the hormone. The cytokines associated with H. pylori infection 
also cause a drop in D cell production of somatostatin (Figure 1.5), 
therefore increasing gastrin by removing this inhibition [80]. All three of 
these, gastrin, GRP and somatostatin, bind to G-protein coupled 
receptors (GPCRs) in order to affect a cell [71, 81]. 
 
1.4.2. Gastrin peptides in carcinogenesis 
When gastrin production takes place in non-endocrine cells, the 
process becomes less efficient at assembling amidated gastrin; the 
usual end result, due to the necessary enzymes being available only at 
limiting concentrations [77]. The consequence of this is that molecules 
of Gly-gastrin and progastrin; the normal intermediates (Figure 1.4), 
accumulate in the tissues [71]. This tends to occur in cancerous tissues, 
such as colorectal carcinomas, where immature forms of gastrin may 
overshadow its mature forms.  
 
Gly-gastrin, progastrin and the C-terminal flanking peptide (CTFP; 
cleaved from progastrin; dark grey portion in Figure 1.4) have been 
shown to be biologically active. They are linked to both the digestive 
function of amidated gastrin, maintaining acid secretion, and the 
carcinogenic function, accelerating tumour development [67]. Both 
progastrin and Gly-gastrin have been shown to enhance growth of 
many different cell-lines in vitro and in vivo and to up-regulate anti-
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apoptotic proteins [82]. However, these products do not have so large 
an effect on gastric secretion as amidated gastrin.  
 
Gly-gastrin was the first of these intermediates to be studied. Seva & 
colleagues [83] investigated the effect of gastrin and Gly-gastrin on 
AR42J cells (a rat exocrine pancreatic cell-line) and found that they 
could both stimulate cell proliferation to a similar degree. Since this 
discovery, proliferative activity has also been shown for progastrin and 
the CTFP [66]. Gly-gastrin is found in large quantities in human colon 
and lung carcinoma cells, and when over-expressed in mouse models it 
can cause intestinal polyposis and bronchoalveolar carcinomas [84]. It 
has also been found to increase metastasis of LoVo human colon 
cancer cells [85]. Müerköster et al. [86] agree that Gly-gastrin can 
stimulate colon carcinoma cell proliferation, but that gastrin alone is 
actually instrumental in inducing apoptosis in these cells. These claims 
would indicate a large role for Gly-gastrin in colorectal cancer, since the 
carcinogenic effects must be being accomplished by this peptide alone, 
and even against the effects of gastrin itself. 
 
Progastrin too has a strong link with colorectal cancer. In 2001, 
Siddheshwar et al. [87] found that progastrin levels were much higher in 
patients with colorectal cancer (26.8% had progastrin <15 pmol/l), than 
either those with polyps (58.6%) or the control group (92.5%). However, 
in the same groups, Gly-gastrin and amidated gastrin concentrations 
did not fluctuate significantly. Although amidated gastrin levels were 
higher in those patients infected with H. pylori in all three groups, the 
pathogen did not increase progastrin concentrations. Progastrin has 
now been found to have an anti-apoptotic effect on colon and 
pancreatic cancer cells, as well as provoking growth in these cells [88].  
 
   Introduction 
34 
 
The CTFP has been recently studied by Smith et al. and found to be 
able to promote growth in gastric and colon cancer cell-lines as well as 
encouraging invasion by the gastric cells [67]. It would also seem that 
concentrations of the CTFP in the circulation of healthy humans and 
cancer patients are far higher than that of progastrin or Gly-gastrin 
making this activity all the more significant [67].  
 
1.5. Regulation of gastrin expression  
The 1300bp upstream of the human gastrin gene has been reported as 
the promoter of gastrin gene expression by several groups [89, 90]. 
Godley & Brand [89] produced several plasmid reporter constructs 
containing between -1300 and -40bp of this upstream DNA, plus the 
first (non-coding) exon of the gastrin gene, attached to a 
chloramphenicol acetyltransferase (CAT) gene (Figure 1.6). All of the 
constructs show promoter activity, but the smallest (40 GASCAT) 
shows only 50% of that of all the rest (Figure 1.6) [89].  
Figure 1.6: Gastrin promoter constructs 
The top diagram shows how a series of 
gastrin promoter reporter constructs 
(1300, 600, 194, 82 and 40 GASCAT) 
were made by Godley & Brand. The 
graph shows the results of their transient 
transfection into GH4 cells, in order to 
test for promoter activity using CAT [89]. 
 
 
This result is supported by Merchant et al. [90] who showed that a 
construct containing the entire gastrin gene, plus 1300bp upstream and 
2500bp downstream of the gene, caused expression of gastrin when 
stably transfected into GH4 cells [90]. They also used constructs 
containing 82bp or 40bp of upstream DNA plus exon 1 and found that 
the latter had less activity. Further study of this section of DNA caused 
Wang & Brand to believe that a positive element lies between 82-79bp 
from the gastrin gene [91] (Figure 1.7). This report also found that 
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promoter activity in islet cells increased when the construct was 
shortened to only 82bp of upstream DNA. Again further investigation of 
the DNA between 194-82bp revealed an 8bp repressor element which 
matches that found in the ȕ-interferon promoter, at approximately 108bp 
from the gastrin gene [91] (Figure 1.7). 
 
The gastrin promoter is up-regulated by several factors, including EGF 
[89, 90], TNF-Į[92], IL-1 [93] and ras [94]. A gERE is located between -
69 and -40bp upstream of the gastrin gene (Figure 1.7), since removal 
of this section of DNA from the construct knocked out EGF induction of 
gastrin expression [92]. It was also found that TNF-Į DQG )RV FRXld 
stimulate gastrin expression via the promoter [92]. This work was 
supported and extended by Suzuki et al. who showed that TNF-ĮDQG
IL-1, both present in H. pylori infection, could stimulate gastrin 
expression in the gastric cancer cell-line, AGS [93]. The element(s) 
involved in the mechanism are unknown, but exist within 240bp of the 
gastrin promoter, and are not related to the gERE discussed above 
(Figure 1.7) [93]. In colon cancer cells the oncogene product, ras, has 
been implicated as an inducer of gastrin expression, again via the first 
200bp section of the DNA upstream of the gastrin gene [94]. 
 
Koh & colleagues found a transcription factor-4 (TCF-4) binding site 
between -103 and -93bp on the gastrin promoter (Figure 1.7), allowing 
gastrin to be up-regulated by the ȕ-catenin/TCF-4 signalling pathway, 
which has been linked to intestinal proliferation [95]. This can be a 
cyclical pathway, since gastrin also causes the stabilisation of ȕ-
catenin, and therefore enhances transcription of other ȕ-catenin target 
genes [96]. 
 
 
   Introduction 
36 
 
 
 
 
 
Figure 1.7: Diagram representing the putative gastrin promoter 
1300bp of the putative gastrin promoter has been investigated for positive and 
negative (shown as green and red boxes respectively) regulatory elements. Exon 1 of 
the gastrin gene is shown as a blue box.  
 
Although 1300bp of the putative gastrin promoter have been 
investigated so far, it seems to only be the first 200bp section which 
contains any regulatory elements. However, this may be due to the fact 
that the literature has focussed on those portions which cause a visible 
effect in reporter studies. There are many other transcription factor 
binding sites such as SP1 [75] in the promoter, along with more TCF-4 
binding sites, to be investigated in further studies [95].  
 
Additionally an internal ribosome entry site (IRES) has been found 
within the gastrin transcript in GI cancer cells, suggesting it may be 
translationally as well as transcriptionally regulated [97]. The IRES 
allows translation to continue through periods of cellular stress, 
meaning that angiogenesis can be maintained and apoptosis halted in 
these cells [97]. 
 
1.6. CCK-2R 
There are two CCK receptors; CCK-1R and CCK-2R [98], and they 
share 50% amino acid structure [99]. The CCK-2R (also called the 
CCKBR) has a higher affinity for gastrin than for CCK, unlike the CCK-
1R, and is the most well-characterised gastrin receptor [100, 101]. This 
7-transmembrane GPCR (Figure 1.8) sits on the surface of ECL cells, 
coupled to both a PTX (pertussis toxin)-sensitive (or Į-subunit) and a 
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PTX-insensitive (or ȕȖ subunit) G protein [100]. The latter permits the 
production of second messengers, inositol 1,4,5-triphosphate (IP3) and 
1,2-diacylglycerol (DAG), from phosphotidylinositol bisphosphate (PIP2), 
mediated by phospholipase Cȕ3/&ȕ [69]. This leads to an increase 
in intracellular calcium concentration ([Ca2+]i) as does the activation of 
protein kinase C (PKC) [100, 102]. The PTX-sensitive G-protein leads 
to activation of all three of the mitogen-activated protein kinase (MAPK) 
pathways (Figure 1.9) [66, 71, 100]. 
 
 
Figure 1.8: The structure of the cholecystokinin receptor or CCK-2R 
The main amino acids of the binding site are the white letters in filled black circles, and 
the 3rd cytoplasmic loop is indicated by the arrow (modified from [103]). 
 
In addition to being expressed on ECL cells, the CCK-2R is also found 
in many other normal and tumour cells [104]. These include brain cells, 
monocytes, T lymphocytes and parietal cells, and SCLC, gastric and 
colorectal cancers [104]. It has been shown to be up-regulated early in 
carcinogenesis and this often occurs beside up-regulation of gastrin 
itself [62], in fact in gastric carcinoma expression levels are correlated 
[99]. Despite this, its role in colorectal and other cancers has not been 
clarified due to the range of differing results in the literature [105].  
 
Chao et al. have shown that the presence of CCK-2R can change 
immortalised normal colon cells into tumourigenic cells [106]. They 
stably transfected NCM356 cells with CCK-2R, and found that these 
3rd cytoplasmic loop  
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cells grew significantly faster than the vector controls and that they 
could initiate tumours in nude mice, a trait not shared by the wild-type 
cells [106].  
 
1.7. The signalling pathways downstream of the CCK-2R 
The CCK-2R is coupled to many proteins involved in cell signalling [98], 
via several different pathways. Activation of the CCK-2R can induce Src 
(sarcoma-inducing tyrosine kinase) to phosphorylate Shc (Src 
homology domain containing protein) [66]. This allows the small G-
proteins, ras and then raf, to be stimulated. These events lead to 
activation of the three MAPK pathways; the extracellular signal-related 
kinases (ERKs), the p38 MAPKs and the c-Jun NH2 terminal kinases 
(JNKs) [102] (Figure 1.9).  
 
Figure 1.9: The signalling pathways of the gastrin-activated CCK-2R [66] 
 
Each of these pathways lead to the up-regulation of TFs and therefore 
to the transcription of genes involved in carcinogenic processes. The 
phosphotidylinositol 3-kinase (PI3K) class I pathway shown above (PIP2 
cleaved to IP3 and DAG), regulates proliferation, cell adhesion and 
apoptosis. Specifically the anti-apoptotic protein, Akt, can be activated 
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via the PI3K pathway, which not only represses apoptosis but also 
inactivates pro-apoptotic factors [13].  
 
Gastrin can directly stimulate ECL cells to proliferate, however its 
effects on other cells, such as parietal cells are induced via growth 
factors in a paracrine fashion [65]. An example of these growth factors 
is heparin-binding epidermal growth factor (HB-EGF). 
 
1.7.1. HB-EGF  
One of the important effects of the constitutively active form of the CCK-
2Ri4sv (see Section 1.9.1 below), or of gastrin binding to the wild-type 
CCK-2R, is the increased expression of HB-EGF (Figure 1.10). This 
growth factor is produced as a propeptide and cleaved by matrix 
metalloproteinases (MMP) [107], which are also up-regulated by 
activation of the CCK-2R [74]. Many different carcinoma cell-lines have 
been found to contain excessive levels of HB-EGF, and it seems that 
infection with H. pylori can further increase these. This means that the 
combination of gastrin or a constitutive CCK-2Ri4sv with H. pylori 
infection can considerably increase tumour growth [74]. A further 
feedback mechanism occurs because H. pylori can also cause up-
regulation of both the gastrin and CCK-2R genes. This happens in the 
gastric mucosa in humans and in cultured gastric carcinoma cell-lines.  
 
In the HUVEC (endothelial) cell-line gastrin has been shown to cause 
tubule formation and therefore promotion of angiogenesis via HB-EGF 
[108]. Vasoconstriction in tumours can also be caused by the receptor, 
somatostatin receptor two (SSTR2), [109] allowing hypoxic conditions to 
persist within the cancer. When this happens gastrin is able to up-
regulate hypoxia-inducible factor-Į +,)-Į FDXVLQJ YDVFXODU
endothelial growth factor (VEGF) to induce further blood vessel 
formation. Despite GRP itself having the opposite effect, a GRP 
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homologue, bombesin, also causes angiogenesis by activating VEGF 
[81]. 
 
Figure 1.10: The carcinogenic pathways stimulated by gastrin [81] 
 
1.7.2. Akt /Protein kinase B 
Gastrin has an anti-apoptotic role in cancer (Figure 1.10). Akt, or 
Protein kinase B (PKB) as it is also known, is an anti-apoptotic protein. 
It is known that it can down-regulate pro-apoptotic factors as well as 
playing a direct role in cell survival [13]. These pro-apoptotic factors 
include Bad, caspase 9 and the transcription factors involved in 
activation of the cell death ligand, Fas. Gastrin activates Akt by 
degUDGLQJ ,ț%Į ZKLFK OHDGV WR WKH SKRVSKRU\ODWLRQ DQG LQKLELWLRQ RI
Bad. Harris et al. [13] found that Akt was highly activated in the 
presence of CCK-2R, when gastrin was applied to three different 
oesophageal cell-lines, compared with AR42J (rat pancreatic). A high 
proportion of phosphorylated (active) Akt was found in OE33 cells 
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transfected with the constitutive CCK-2Ri4sv too, despite no gastrin 
being present [13]. This indicates that the CCK-2Ri4sv could also be a 
potent stimulator of oesophageal carcinoma if it is present in these 
tissues. In addition gastrin can increase the transcription of X-linked 
inhibitor of apoptosis (XIAP), and in conditions of low somatostatin also 
leads to high levels of Bcl2 (an anti-apoptotic protein) [81]. 
 
1.7.3. Catenins 
Furthermore, gastrin is able to alter adhesion molecules such as p120, 
E-FDGKHULQDQGĮ-ȕ-catenin allowing a loss of adhesion and therefore 
greater cell movement [66, 81]. Activation of the CCK-2R activates JAK 
(Janus kinase) which in turn breaks the interaction between ȕ-catenin 
and E-cadherin. Į-catenin is also severed from ȕ-catenin cutting the 
cHOO¶V FRQQHFWLRQ WR RWKHU FHOOV YLD LWV DFWLQ ILODPHQWV [66]. During the 
carcinogenic process the cellular epithelium starts to lose its shape and 
function, and the combination of all these factors together leads to loss 
of tissue structure and eventually to cellular motility. At this stage the 
SDWLHQW¶V SURJQRVLV LV SRRU VLQFH PHWDVWDVLV is a late stage of any 
cancer. Two studies support this theory, one showing that gastrin can 
stimulate invasion of cancerous cells through a membrane [110], and 
the other an in vivo study of the pancreas of ElasCCK2 mice [111]. 
 
Bierkamp & colleagues [111] found that pancreatic cells of ElasCCK2 
mice stimulated with gastrin proved their hypothesis. This stated that 
the cells would lose normal morphology, the cell cytoskeleton would be 
rearranged and that crucial adherens molecules would be modified. 
They found that Į- DQGȕ-catenin and E- and N-cadherin (a pancreatic 
molecule similar to E-cadherin) were all altered leading to a break-down 
in cell-cell adhesion. This, along with a change in cell morphology leads 
to cell motility, allowing metastasis to occur. In a study of gastric 
epithelial remodelling [110], it was found that gastrin can induce MMP-9 
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expression in AGS cells and that this leads to cell motility and invasion 
through a basement membrane. 
 
1.7.4. COX-2 
Cyclooxygenase-2 (COX-2) is another factor up-regulated by gastrin 
[112], and can influence three of the main processes in carcinogenesis; 
circumvention of apoptosis [113], angiogenesis and invasion of tissues 
(Figure 1.10). This process has been shown to occur in colon 
carcinoma cells, via activation of ERK or Akt signalling pathways [37]. 
 
1.8. Regulation of the CCK-2R  
It is assumed that the DNA upstream of the CCK-2R gene start codon 
contains a promoter/regulator for this receptor. Ashurst et al. [114] 
amplified a 1.7kb section upstream of the rat CCK-2R gene, by classical 
polymerase chain reaction (PCR), and determined the binding sites for 
various transcription factors. This was investigated in AR42J (rat 
pancreatic) and RGM1 (rat gastric) cells and included SP1 and GATA, 
which, when mutated, reduced basal CCK-2R activity significantly [114]. 
These two sites were between 196 and 130bp upstream of the CCK-2R 
start codon, in a similar position to the TF-binding sites found on the 
gastrin promoter. Their data indicated that rat CCK-2R expression was 
altered by changes in the microenvironment, for example variation in 
growth factor concentration [114]. Chao & Hellmich [115] claim that a 
IFN-Ȗ regulatory site is present within the CCK-2R promoter region, 
causing gastrin to exhibit a pro-inflammatory role. Otherwise knowledge 
of CCK-2R regulation is limited to protein level up-regulation by gastrin 
[116, 117], and in cancer cells [62].  
 
The CCK-2R gene may be up-regulated in response to stress 
conditions such as injury, inflammation and repair of tissues [115]. 
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Levels of CCK-2R gene expression were shown by real-time PCR 
(qRT-PCR) WREHKLJKHULQ%DUUHWW¶VPHWDplasia patients than in healthy 
control individuals [118]. Similarly the stress condition of serum-
starvation caused increased transcription of the promoter constructs 
made by Ashurst et al. [114] in various cancer cell-lines.  
 
1.9. Other gastrin receptors 
1.9.1. CCK-2Ri4sv 
Several variants of the CCK-2R have been sequenced, some with 
different properties and localisation to the wild type receptor. An 
example is CCK-2Ri4sv [13, 105] which has retained intron 4 from the 
original gene. This receptor has been found in colorectal cancer tissues, 
but crucially not in the surrounding non-cancerous tissue, indicating that 
it may have a role to play in carcinogenesis. This splice variant happens 
to show constitutive behaviour, due to its lengthened third cytoplasmic 
loop domain (Figure 1.8) [105]. This loop is important because it is the 
point of interaction with G proteins, which in turn cause the signalling 
effects associated with the CCK-2R. The CCK-2Ri4sv can therefore 
activate Ca2+ pathways and cell proliferation cascades without a bound 
ligand [105]. 
 
This modified receptor was also found in colorectal adenomatous 
polyps, an example of rapidly proliferating but pre-malignant tissue. 
Again the normal colorectal tissue surrounding the polyps did not 
contain the CCK-2Ri4sv [101, 105]. This trend is repeated in pancreatic 
cancer with adjacent tissue bearing only the wild-type receptor [119]. 
The authors of this work, Ding et al., have investigated this splice 
YDULDQWIXUWKHUILQGLQJWKDWPRGLILFDWLRQRIWKH¶HQGRIWKHIRXUWKLQWURQ
of the CCK-2R gene is critical in its retention. More specifically the 
splicing factor, U2AF35, was shown to be down-regulated in cancer 
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tissues, in addition to being polymorphic. However, the latter was found 
to be insignificant in preventing intron 4 from being removed [119].  
 
1.9.2. Other CCK-2R isoforms 
Due to the fact that gastrin peptides have only some of the effects of 
amidated gastrin (Figure 1.11) it is thought unlikely that they work 
through the normal gastrin receptor, CCK-2R [66, 88]. Progastrin and 
Gly-gastrin have also been shown to have a biological effect in many 
cells which do not express the CCK-2R, and to be unimpeded by 
selective CCK-2R antagonists [83]. It has been hypothesised that there 
may be another receptor which can be activated by one or both of these 
intermediaries. It is possible also that gastrin can stimulate certain 
cancer cells through a receptor other than the CCK-2R [120], or through 
an isoform of the CCK-2R itself. 
 
Figure 1.11: The signalling pathways of progastrin and Gly-gastrin, two intermediates in 
the synthesis of amidated gastrin [66] 
 
Isoforms of the CCK-2R, other than the CCK-2Ri4sv, have been 
identified in the literature. These include a truncated form with a 
deletion in exon 1b [121]DµORQJLVRIRUP¶ZLWKDVHFWLRQRIWKHLQWURQ
spliced into the protein [122] and several frameshift mutation variants 
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[123]. The first of these, the truncated form, does not appear to have 
different binding affinities or activity, compared to the wild-type, due to 
WKHIDFWWKDWWKHPXWDWLRQRFFXUVLQWKH¶non-coding region [121]. The 
long isoform (where the wild-type CCK-5LVWKHµVKRUW LVRIRUP¶GXHWR
loss of intron 4), is similar to CCK-2Ri4sv in that the third cytoplasmic 
loop is enlarged, but the authors did not study the role of these 
receptors [122]. Some of the variants with frameshift mutations have 
been found to be shortened due to a premature stop-codon, and all 
were found in tumours with microsatellite instability [123].  
 
1.9.3. Heterodimerisation of CCK-1R and CCK-2R  
An alternative explanation for the fact that there are some effects of 
gastrin peptides which cannot be successfully attributed to the CCK-2R, 
yet no other CCK receptor subtypes have been discovered, is that the 
CCK-2R forms either homodimers, or heterodimers with the CCK-1R 
[124].  This has mostly been studied in the brain, where Cheng & 
colleagues [124] suggest that most of the cells where these two 
receptors co-localise are tumour cells, therefore suggesting a role for 
these heterodimers in gastrin peptide-induced tumour progression. 
 
1.9.4. Annexin II 
Singh et al. [125] identified a 33-36 kDa protein which seemed to bind 
gastrin-like peptides with much higher affinity than CCK-8 (Figure 1.12). 
They discovered that this protein correlated to annexin II, and that this 
is a receptor which can at least partially mediate the growth factor 
effects of progastrin and other gastrin intermediates [125, 126]. Annexin 
II was previously known to bind acid phospholipids and actin and to be 
present in actively replicating cells [126]. It has now been found on 
colon carcinoma cells, and indeed many other human cancer cells, 
which is in keeping with its role in rapidly proliferating cells. It is thought 
that when progastrin binds to and activates annexin II, NF-țB and p38 
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MAPK can be activated, causing proliferation of tissues (Figure 1.12) 
[126].  
 
Figure 1.12: Hypothetical model of the binding and down-stream effects of annexin II 
[126] 
 
1.10. Other GPCRs in relation to the CCK-2R  
In order to better understand the CCK-2R, other GPCRs can be studied 
to discover similarities and to investigate better techniques to observe 
the CCK-2R. GPCRs are very important to science since they make up 
30% of all licensed therapeutic drug targets. The CCK-2R is a peptide 
receptor in the Class A, or Rhodopsin-like, GPCRs [127]. This is a very 
large family with 19 subgroups, of which CCK-2R is in subgroup A6, 
along with the hypocretin (orexin) receptors (OXRs), vasopressin 
receptors (VRs) and the gonadotropin releasing hormone receptor 
(GnRH-R; Figure 1.13) [127].  
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Figure 1.13: Phylogenetic tree showing subgroup A6, 
of the peptide class A G-protein coupled receptors 
(GPCRs) 
Abbreviations: 
CCKR  Cholecystokinin 1 receptor  
FF1/2R  Neuropeptide FF 1/2 receptor  
GASR  Gastrin/Cholecystokinin 2 receptor  
GRHR  Gonadotropin releasing hormone    
receptor 
OX1/2R Orexin (hypocretin) receptor type   
1/2 
OXYR  Oxytocin receptor  
V1A/1B/2R Vasopressin 1A/1B/2 receptor  
The CCK-2R is indicated by a yellow box and 
orphan receptors are shaded. Adapted from Figure 
4 and Additional data file 1 of Joost & Methner 
[127]. 
 
1.10.1. Orexins 
According to Figure 1.13, the OXRs are the closest phylogenetically to 
the CCK receptors. Orexins also have two distinct receptors, OX-1R 
and OX-2R, where the former binds orexin-A, and the latter orexin-A 
and -B with equal affinity [128, 129]. This is a similar set-up to the CCK 
receptors; where CCK and gastrin are the ligands. The OXRs were first 
found throughout the human CNS [128], but are now known to be 
present in the GI tract [130], and their ligands have roles in appetite, 
cardiovascular, neuroendocrine and temperature regulation. 
 
Spinazzi et al. [129] investigated the expression of both OXRs in normal 
and tumour adrenocortical cells, and found that qRT-PCR showed gene 
expression similar to that of the protein expression shown by western 
blotting. They also showed an up-regulation of the receptors in the 
tumour adenoma tissue, compared to the normal [129]. 
 
1.10.2. Neuropeptide FF receptors 
These receptors bind two ligands; NPAF (A-18-F-amide) and NPFF (F-
8-F-amide) [127]. The neuropeptide FF 2 receptor (FF-2R) has been 
shown to have alternative splice variants, namely one which translates 
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exon 1 called the NPGPR [131], which is similar to the differences 
between the CCK-2R and the CCK-2Ri4sv isoform. FF-2R has been 
shown to be expressed in the hypothalamus by qRT-PCR, another 
similarity to the CCK-2R, although the detection problems in qRT-PCR 
were not replicated with this GPCR [131]. This receptor is involved with 
nociception and morphine-tolerance.  
 
1.10.3. Gonadotrophin releasing hormone receptor  
Another GPCR in the same subfamily as CCK-2R is the GnRH-R, which 
is expressed in the brain and ovaries and has also been found in 
pancreatic tumours [132]. In the ovary, where GnRH-R and its ligands, 
GnRH-I and -II, have been shown to be expressed by qRT-PCR, its role 
is to be a progesterone regulator [133]. Also, GnRH-R agonists are 
used clinically in prostate cancer, to reduce testosterone secretion and 
therefore reduce tumour size [132, 134]. 
 
1.10.4. GPCRs and the CCK-2R  
While the GPCRs examined here have very similar roles and 
expression patterns to the CCK-2R, they do not seem to be comparable 
in terms of detection. They are all expressed in the brain and other vital 
organs, some even in tumour cells, and they are all peptide, or 
hormone, receptors, however, they do not seem to share the same 
transcriptional regulation as the CCK-2R, which can be found easily at 
the protein level, but not so at the gene level. 
 
1.11. CCK-2R antagonists  
There have been many CCK-2R antagonists described, although not all 
of them are specific enough to eliminate CCK-1R blockade [135]. In 
1998, several benzodiazipine-derived antagonists were being used, 
such as L-365,260 and a second generation benzodiazipine, L-740,093 
   Introduction 
49 
 
[135]. The latter has a higher affinity for CCK-2R and also has better 
solubility in water. Many CCK-2R antagonists are used now, including a 
few which have been found to be useful in a clinical setting. For 
example, YM022 reversed the increase in CCK-2R effected by H. pylori 
infection [72]. Also Gastrozole (JB95008), a new CCK-2R antagonist 
has been trialled as a drug for pancreatic cancer [21]. It has activity 
against gastrin-induced cell proliferation and, although not orally 
bioavailable, via intravenous administration has been successful in 
increasing survival without toxicity.  
 
A new orally available CCK-2R antagonist, Z360, has also been 
developed and shown to compete with amidated gastrin in NIH3T3 and 
OE33 cells [72]. The drug has been shown to reduce angiogenesis in 
C170HM2 in vivo models, and pancreatic xenograft models, and to 
inhibit metastasis of MGLVA-1 cells. Z360 is known to be highly 
selective for the CCK-2R and is now in clinical trials for patients with 
advanced pancreatic cancer [72, 136]. 
 
Short interfering RNAs (siRNAs) are beginning to be used for this 
purpose too, and the use of these against CCK-2R has been shown to 
inhibit proliferation and promote apoptosis in gastric cancer cells [137].  
 
1.11.1. CCK-2R antagonists as a method of detection  
These inhibitors of the CCK-2R are extremely important in determining 
the expression of the receptor in cancer cell-lines, because CCK-2R 
mRNA is very difficult to detect by PCR [72]. Specific antagonists have 
been used to this effect in oesophageal [13], colorectal [138] and gastric 
[74] carcinoma cells, but an explanation for the low level gene 
expression is still required. 
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YM022 was used to block the CCK-2R in oesophageal cells (OE19 and 
OE33), which caused basal phosphorylation of Akt to drop, as opposed 
to the addition of gastrin, which caused an increase in phosphorylation 
[13]. In AGS cells YM022 was utilized to determine the role of the CCK-
2R in HB-EGF expression. Both basal and H. pylori-induced HB-EGF 
expression could be reduced when the antagonist was added [74].  
 
Colucci et al. have shown that blockade, by L-365,260 and GV150013, 
of the CCK-2R can reverse the growth-promoting effect of gastrin in 
HT29 (colorectal) cells, and also reduce COX-2 amplification induced 
by the presence of gastrin [138]. HT29 cells were also found to show 
this effect, when JMV 320 was used to inhibit the gastrin receptor [139]. 
Ishizuka et al. also found that JMV 320 blocked gastrin-stimulated 
proliferation or inhibition of LoVo or HCT116 cells, respectively. 
However, the effect is not universal in colonic carcinoma cell-lines, 
since the inhibitor had no effect on gastrin-stimulated growth of COLO 
320 cells [139]. 
 
1.12. siRNA 
An alternative method for blocking the CCK-2R is to use siRNA, specific 
for the receptor, to knock-out expression altogether [140, 141]. This 
method has been used to down-regulate gastrin [82], in order to 
investigate the role of endogenous gastrin alone. This was very 
successful and proved the technique to be extremely specific, and 
effective at reducing gastrin expression in several GI cell-lines [82].  
 
siRNA can be designed from the sequence of the gene in question 
using algorithms e.g. those available on the websites: Dharmacon, 
Genscript and siSEARCH. These algorithms apply a set of rules, which 
differs for each algorithm (an example is found in [140]), to find specific 
21 nucleotide sequences and then the results are analysed. Factors 
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such as position in the gene, GC content and seed frequency (number 
of modifications necessary) are taken into account.  
 
Since this method is very specific, it is likely that using it to knock-out 
the CCK-2R will be more successful than the antagonists described 
above. With this method it is assumed that only the CCK-2R will be 
down-regulated since a part of its mRNA sequence is being targeted, as 
opposed to a drug which may affect other receptors or proteins in the 
target cell. In the gastrin siRNA experiment the method was even able 
to overcome up-regulation by EGF, and so it may be possible to reverse 
the up-regulation of CCK-2R seen in cancer cells [82]. In short CCK-2R 
siRNA may provide a better tool for understanding the role of this 
receptor in cancer progression.  
 
1.13. Hypothesis and aims  
The hypothesis for this project is that the CCK-2R plays a role in the 
progression of cancer and that its effects may be up-regulated during 
stress conditions such as hypoxia and nutrient deficiency. It may play a 
vital role in the expansion or maintenance of a specific subset of cells 
within the tumour; possibly the cancer stem cells.  
 
The current qRT-PCR method used to detect gene expression of the 
CCK-2R is not sensitive enough to reveal endogenous expression in 
cell-lines where CCK-2R protein has been recognized previously [13]. A 
new method, called Linear-After-The-Exponential-PCR; LATE-PCR 
[142], has been hypothesised to increase sensitivity above that of 
normal PCR by altering primer concentrations to give linear product. 
This will be tested against the CCK-2R Taqman qRT-PCR currently in 
use in the laboratory, to establish whether lower concentrations of 
mRNA can be detected. Perhaps this assay will demonstrate CCK-2R 
gene expression in cancers where it has not been previously identified. 
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In order to validate the LATE-PCR assay siRNAs to the CCK-2R will be 
designed and tested on a range of cancer cell-lines in vitro. These cells 
will also be stimulated with a range of factors, including hypoxia, serum-
starvation and cytotoxics to investigate the effect of a stress 
environment on the CCK-2R. A 3D culture model will be used to select 
for stemness in the cell population and therefore determine if the 
receptor has any effect on the expansion or maintenance of the cancer 
stem cell subset. If up-regulation of the CCK-2R is observed in these 
situations the mechanism of action will be challenged using knock-down 
or inhibition of the receptor.  
 
Ultimately if the signalling mediated via the CCK-2R can be removed 
from tumour cells in vivo, this should reduce the carcinogenic effects of 
gastrin. Therefore the CCK-2R is a potential therapeutic target. 
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2.1. Cell culture  
2.1.1. Cell growth 
The cells used in this study (Table 2.1) were maintained at 37°C in a 
humidified CO2 incubator and cultured in normal growth medium (Table 
2.5), in 75cm2 flasks. All cell-lines were adherent cells, with the 
exception of H209. Transfected cell-lines had their growth medium 
VXSSOHPHQWHGZLWKȝOJHQHWLFLQSHUPOPHGLXPWRVHOHFWIRUWUDQVIHFWHG
cells.  
 
2.1.2. Sub-culture of cells 
The cells were split when they reached 60-100% confluency (judged 
under a microscope at low power). The medium was aspirated away 
and 3ml of either 0.025% EDTA or 0.25% Trypsin-EDTA, depending on 
cell-line, was used to detach the cells from the flask. The cells could be 
harvested after 5-10 min and were pelleted in the centrifuge at 1500rpm 
for 5 min. The medium plus EDTA was aspirated away and the cells re-
suspended in a suitable volume of normal culture medium. Lavaging 
through a green 10ml gauge needle was used to separate clumps of 
cells, then the cells were counted and a fraction returned to the flask in 
15ml of normal growth medium. 
 
2.1.3. Cell counting 
Trypan blue was made up as a 4:1 mixture of 0.2% trypan blue to 
4.25% NaCl. Equal volumes of cells and trypan blue were mixed and 
aȝO SLSHWWHG RQWR D 1HXEDXHU KDHPRcytometer covered with a 
coverslip. With the coverslip on the chamber of the haemocytometer a 
primary square holds 1mm3 of liquid. The cells in this volume were 
counted and the number (an average of several) was multiplied by 
2x104 to give a concentration in cells/ml. 
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2.1.4. Table of cell-lines used in this project 
Cell line Origin of cell line (all adherent unless 
stated) 
Transfected 
variants 
used 
Medium 
grown in 
A549 Human male non small cell lung cancer 
(NSCLC) [143] Mutated genes include 
CDKN2A and KRAS [144] Isolated from 
explant culture of lung carcinoma tissue 
[145] 
 RPMI 
AGS Human female gastric adenocarcinoma 
[143] Mutated genes include PIK3CA and 
KRAS [146] Isolated from fragments of a 
tumour removed from a patient who had 
received no therapy [145] 
CCK-2R, VC RPMI 
AR42J Rat exocrine pancreatic tumour [143]  RPMI 
BT4 Paediatric giant cell high grade (IV) 
glioblastoma later revised to malignant 
glioneuronal tumour (named GBM1 in [45]) 
 DMEM 
C170HM2 Hepatic invasive human colorectal, 
selected from the parent cell-line; C170 
[147] 
 RPMI 
CA20948 Rat pancreatic [148]  RPMI 
EKVX Human lung adenocarcinoma (NSCLC) 
[149] 
 RPMI 
(NCI-) 
H209 
Human male small cell lung cancer (SCLC) 
derived from bone marrow metastatic site 
(grows in suspension) [143] Mutated genes 
include RB1, and isolation was from bone 
marrow [145] 
 RPMI 
(NCI-)H23 Human male NSCLC [145]  RPMI 
HCT116 Human male colonic adenocarcinoma 
[150] Mutated genes include CDKN2A and 
BRCA2 [144] 
 RPMI 
HGT-1 Human male gastric adenocarcinoma from 
the body of the stomach [151] 
 RPMI 
HOP-62 Non small cell lung cancer [152] Mutated 
genes include CDKN2A and KRAS [144] 
 RPMI 
HOP-92 Non small cell lung cancer [152]  RPMI 
HT29 Human female colonic adenocarcinoma 
[143] Mutated genes include APC and 
BRAF [144] This cell-line has been seen to 
exhibit microvilli and expresses the 
oncogenes c-myc, and K-ras [145] 
 RPMI 
LoVo Human male colonic adenocarcinoma, at 
Dukes type C [143] 
 LoVo 
medium 
MCF-7 Human female breast carcinoma [143]  RPMI 
MDA-MB-
453 
Human female breast, mammary gland 
metastatic carcinoma [145] 
 RPMI 
MGLVA-1 An ascetic variant of the gastric cell-line 
MKN45G [153] 
 RPMI 
NIH3T3 Mouse embryonic fibroblast [150] CCK-2R RPMI 
OE19 Human male adenocarcinoma of the 
gastric cardia/oesophageal gastric junction, 
pathological stage III [150] 
 RPMI 
OE33 +XPDQIHPDOH%DUUHWW¶VPHWDSODVLDGHULYHG
oesophageal adenocarcinoma, 
pathological stage II [150] 
CCK-2R RPMI 
OLIG1 Paediatric glioma [45]  DMEM 
   
  Materials and Methods  
56 
 
OVCAR-8 Human ovarian [149]  RPMI 
PAN-1 Pancreatic (in house)  RPMI 
PANC-1 Human male pancreatic epithelial, ductal, 
carcinoma [143] 
 RPMI 
SKBR3 Human female breast, mammary gland 
(pleural effusion), adenocarcinoma [150] 
 RPMI 
SK-OV-3 Human female ovarian adenocarcinoma 
[143] 
 RPMI 
ST16 Human gastric (in house)  RPMI 
SW620 Human male colon adenocarcinoma [149] 
Mutated genes include KRAS and APC 
[144] Isolated from a recurrence of the 
malignancy, which resulted in a wide-
spread metastasis, taken from a lymph 
node [145] 
 RPMI 
T47D Human female breast, mammary gland 
(pleural effusion), ductal carcinoma [150] 
 RPMI 
UACC-257 Human melanoma [152]  RPMI 
U251 Human glioblastoma/astrocytoma [154] 
Mutated genes include CDKN2A and 
PTEN [144] 
 RPMI 
U373-MG Human male neuronal glioblastoma (brain; 
astrocytoma) at grade III [143] Mutated 
genes include PTEN and AKT1 [146] 
 RPMI 
U87-MG Human female neuronal glioblastoma 
(brain; astrocytoma) at grade III [143] 
 RPMI 
ZRS51 Human female breast, mammary gland 
metastatic site: ascites, ductal carcinoma 
[150] 
 RPMI 
Table 2.1: Cell-lines used in this project 
 
2.1.5. Freezing cells 
The cells were harvested and counted. Once counted the cells were 
pelleted and re-suspended in freezing medium to a concentration of 
2x106 cells/ml. 0.5ml was aliquoted into each cryogenic tube and 
labelled appropriately. The tubes were moved immediately to the -70°C 
freezer and to liquid nitrogen storage after at least 24 hours.  
 
2.1.6. Thawing cells 
15ml of medium was added to a 75cm2 flask, labelled and put at 37°C 
for 30 min. The frozen aliquot of cells was taken straight from liquid 
nitrogen storage to a 37°C water bath and swirled gently. Once 90% 
defrosted the tube was sprayed with 70% ethanol and the contents 
removed into the pre-warmed flask and incubated overnight. The cells 
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were re-fed with normal growth medium after 24 hours to remove traces 
of DMSO. 
 
2.1.7. Transfection with plasmid DNA in normoxic/hypoxic 
conditions 
CCK-2R promoter plasmids were used to investigate the regulation of 
this receptor. The cells were plated at 2x105 or 8x104 cells/ml in the 
middle 8 wells of a 24-well plate 24 hours before the transfection was to 
EHFDUULHGRXWȝORIPHGLXPZas added to the outside wells of a 24-
ZHOO SODWH LQ RUGHU WR DYRLG LQIHFWLRQ 0DVWHUPL[HV RI ȝO RI QJȝO
SODVPLG RI LQWHUHVW '1$ DQG ȝO RI QJȝO ȕ-galactosidase plasmid 
'1$ZLWKȝORI2SWL0(0PHGLXPZHUHPDGHXS,QDVHSDUDWHWXEH
ȝORIOLSRIHFWDPLQHZDVDGGHGWRȝORI2SWL0(0PHGLXPIRUHYHU\
well to be transfected plus one, and this was left to incubate for 5 min. 
7KH OLSRIHFWDPLQH PL[ ȝO SHU ZHOO ZDV WKHQ DGGHG WR WKH GLOXWHG
DNA and incubated for 20 min at room temperature. 
 
The plated cells were assessed for confluency, which should have been 
50-80%, and then the medium was aspirated from the wells and 
UHSODFHG ZLWK ȝO IUHVK QRUPDO JURZWK PHGLXP 7KH WUDQVIHFWLRQ
complex was dropped into the well slowly while on a rocking platform to 
ensure even distribution. The plates were incubated at 37°C in a 5% 
CO2 incubator for 6 hours after which the transfection medium was 
aspirated away to be replaced with 1ml serum-free medium. The plates 
were placed back in the incubator overnight.  
 
24 hours after the medium change, half the plates were placed in the 
hypoxia chamber, while half of them remained in the incubator (in 
normoxia). After 16 hours the cells were harvested, either for 
luminometer assay or RNA extraction. 
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2.1.8. Harvesting transfected cells for luminometer assay 
Firefly luciferase expression was used as a measure of promoter 
activity, wLWK ȕ-galactosidase expression as the control, and these 
values were assessed using a luminometer. Each plate was aspirated 
WRUHPRYHDOOPHGLXPIURPWKHFHOOVDQGWKHQȝORI3%6ZDVDGGHG
to each well to wash the cells. This was aspirated away before ȝORI
1x PLB per well, was added. The plates were rocked gently for 20 min 
to loosen the lysates from the wells then these were transferred to 
labelled eppendorf tubes and frozen at -70°C, ready for luciferase and 
ȕ-galactosidase assay on the luminometer. 
 
2.1.9. Harvesting transfected cells for RNA extraction 
If gene expression was to be assessed, RNA extraction was the first 
step. The medium was aspirated away from each well and cells were 
WUHDWHGZLWKȝO75,UHDJHQW7KH\ZHUHLQFXEDWHGIRUPLQDQGWKHQ 
transferred to eppendorf tubes for RNA extraction with half volumes. 
 
2.1.10. Sphere forming 
Sphere-forming was used to quantify the stem cell content of a cell-line 
population. The cells were harvested as above, then re-suspended; ~ 
1x106 cells in 12ml of stem cell medium, and plated into one 6-well plate 
at 2ml/well. A monolayer cell plate was also plated as a control in 
normal growth medium (1000 cells/plate due to growth restrictions over 
ten days). Cells were re-fed with EGF and FGF every three days (at day 
four, seven and ten). If YM022 was added to the plate, this was also re-
fed at a concentration of 10-8 every three days. 
 
2.1.11. Harvesting sphere cultures 
The spheres often floated in the medium, meaning they needed to be 
harvested and centrifuged to remove the medium, before normal RNA 
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extraction or luminometer assays or live cell staining could be carried 
out. 
 
However, for paraffin wax embedding the spheres needed to stay 
together so they were carefully transferred into a universal and left to 
settle for 2 hours at 4°C. Once settled the medium was carefully 
UHPRYHGXVLQJ WKHDVSLUDWRUDQG WKHQDSLSHWWHDQGȝORI3)$
was added. The spheres were incubated at room temperature for 10 
min, before as much supernatant was removed as possible. A small 
eppendorf KDGEHHQSUHSDUHGHDUOLHUZLWKȝOof set 1.5% agarose in 
LWȝORIFRROHGOLTXLGDJDURVHZDVSLSHWWHGLQWRWKHHSSHQGRUI
and the spheres were carefully pipetted into this (using a cut tip) and 
mixed once. The agarose was left to set. 
 
The end of the eppendorf was cut with a scalpel to expose the agarose 
plug with the spheres in it. This plug was carefully pushed into a bijou 
full of formal calcium, and left to fix overnight. The plug was placed into 
a processing cassette, and put through the processor, before 
embedding in wax. Sections were cut from this sample with the 
microtome, placed on polysine slides and stained. 
 
2.1.12. MTT assay 
The IC50 of a drug in a particular population of cells can be assessed 
using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. Cells were plated at 1x104 cells/well in 100µl of normal 
growth medium in the middle 60 wells of a 96-well plate. The outer wells 
had 100µl of normal growth medium added to them to prevent 
dehydration. The plate was incubated overnight at 37°C in a 5% CO2 
incubator, before treatment with a 1/2 dilution series of cisplatin (from 
200-0.3µg/ml). These were added in 100µl aliquots to five wells each 
and, with 2 sets of medium-only wells, made up 12 conditions per plate. 
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This was added to the medium already there in order to disturb the cells 
as little as possible. The cells grew in the incubator for 48 hours before 
MTT solution was added, 50µl/well. After a 4 hour incubation at 37°C 
the plates were aspirated carefully into a waste bottle (for incineration, 
not sink disposal) and 75µl of DMSO added to each well, plus the five 
control wells with no cells. The plate was read at 550nM and the results 
analysed in GraphPad Prism in order to ascertain the IC50.  
 
2.2. siRNA 
2.2.1. siRNA design 
siRNAs were designed to target different sites within the receptor 
mRNA, using a number of different algorithms available on the internet 
(Dharmacon, Ambion, siSEARCH and Genscript). Each yielded a list of 
potential siRNAs, which were ranked due to several factors. For 
H[DPSOH RQ 'KDUPDFRQ¶V ZHEVLWH WKHUH LV D FROXPQ IRU µ/RZ VHHG
IUHTXHQF\¶ZKLFKLIµ<HV¶PHDQVWKDWWKHVL51$LVOHVVOLNHO\WRELQGWR
other genes in the genome of that organism and act as a micro RNA 
(miRNA).  
 
2.2.2. siRNA synthesis 
Each siRNA was ordered as two oligonucleotides, a sense and an 
antisense strand. These had to be annealed into a double-stranded 
molecule using the Ambion Silencer siRNA construction kit. To prepare 
WKHWUDQVFULSWLRQWHPSODWHȝORIDȝ0VROXWLRQRIHDFKVWUDQGZere 
SODFHGLQVHSDUDWHWXEHVDORQJZLWKȝORI7SURPRWHUSULPHUDQGȝO
of DNA hyb buffer in each. Both tubes were heated to 70°C for 5 min, 
and then left at room temperature for 5 min more. Klenow DNA 
polymerase mix was added to each tube consisting of ȝO RI ;
.OHQRZUHDFWLRQEXIIHUȝO;G173PL[ȝOQXFOHDVH-free water and 
ȝO ([R-Klenow. The tubes were mixed by gentle pipetting, then 
centrifuged and incubated at 37°C for 30 min.  
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The next step was the double-VWUDQGHG51$V\QWKHVLVȝORIHDFK of 
WKH SUHYLRXV PL[WXUHV ZHUH DGGHG WR WZR QHZ WXEHV DORQJ ZLWK ȝO
nuclease-IUHHZDWHUȝO;7UHDFWLRQEXIIHUȝO;G173PL[DQG
ȝO RI 7 HQ]\PH LQ HDFK 7KHVH WUDQVFULSWLRQ UHDFWLRQV ZHUH PL[HG
gently, centrifuged and incubated at 37°C for 2 hours. The sense and 
antisense reactions were then combined into one tube and incubated at 
37°C overnight.  
 
The final stage prepared and purified the siRNA. The tube containing 
WKH DQQHDOHG VWUDQGV IURP DERYH KDG ȝO GLJHVWLRQ EXIIHU ȝO
nuclease-free wDWHUȝO51DVHDQGȝO'1DVHDGGHGWRLW7KLVZDV
mixed gently then incubated at 37°C for 2 hours, before the 
concentration was measured to ensure it was appropriate for 
WUDQVIHFWLRQaȝ0 
 
2.2.3. Transfection with siRNA 
The cells were plated at 5x104 cells/ml in a 6-well plate, 24 hours before 
WKH WUDQVIHFWLRQ ZDV WR EH FDUULHG RXW 0DVWHUPL[HV RI ȝO RI ȝ0
VL51$ZLWKȝORIVL3257$PLQHZHUHPDGHXS WRD WRWDOYROXPHRI
ȝO SHU ZHOO ZLWK 2SWL0(0  PHGLXP 7KH PHGLXP DQG VL3257
Amine were mixed, vortexed and incubated for 30 min at room 
temperature. Then the siRNA was added and left to incubate for 20 min, 
also at room temperature. The medium was aspirated from the wells 
DQGUHSODFHGZLWKȝOIUHVKQRUPDOJURZWKPHGLXP7KHWUDQVIHFWLRQ
complex was dropped into the well slowly while on a rocking platform to 
ensure even distribution. The plates were incubated at 37°C in a 5% 
CO2 incubator for 6 hours then 1ml medium was added to each 
transfected well. The plates were then put back in the incubator 
overnight.  
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24 hours after transfection the cells were harvested either for RNA 
extraction or, if fluorescent siRNA was used, for cytospins.  
 
2.2.4. Reverse transfection with siRNA 
This method was used for non-DGKHUHQW FHOOV VXFK DV + ȝO RI
siPORT Amine was DGGHG WR ȝO RI 2SWL0(0  SHU ZHOO LQ D
PDVWHUPL[DQGLQFXEDWHGDWURRPWHPSHUDWXUHIRUPLQȝORIWKH
FRUUHFWVL51$ZDVDGGHGWRȝORI2SWL0(0SHUZHOODQGWKHQ
ȝORIWKH$PLQHPL[ZDVDGGHGWRHDFKWXEH7KLVZDVLQFXEDWHGIRU
10 miQDQGWKHQȝOZDVVSUHDGDURXQGWKHERWWRPRIDQHPSW\ZHOO
Each 24-ZHOOSODWHKDGLWVRXWHUZHOOVILOOHGZLWKȝORIQRUPDOJURZWK
medium. 8x105 FHOOV LQȝO RI QRUPDO JURZWKPHGLXPZHUHRYHUODLG
into each middle well and the plate placed on a rocking platform for 5 
min. The plate was incubated at 37°C for 6 hours and then 1ml of 
normal growth medium was added to each transfected well. The plate 
was then left in the incubator at 37°C overnight.  
 
2.2.5. Harvesting siRNA-transfected cells for RNA extraction 
If the cells grew in suspension they were transferred to eppendorfs, 
spun down at maximum speed for 3 min, aspirated, then placed in 
ȝO 75, UHDJHQW $GKHUHQW FHOOV ZHUH WUHDWHG ZLWK PO 75, UHDJHQW
per well after the medium was aspirated away. The cells were 
incubated for 5 min and then the lysates were transferred to eppendorf 
tubes for RNA extraction. 
 
2.2.6. Harvesting siRNA-transfected cells for cytospins 
In order to see the location of the fluorescent TAMRA-siRNA within the 
cells, they were put on slides, nuclear-stained with DAPI, and observed 
through a microscope.  Suspension cells were placed in eppendorfs, 
pelleted, aspirated, ZDVKHG LQ ȝO 3%6 and centrifuged again. 
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Adherent cells had their medium aspirated away and the cells were also 
ZDVKHGLQȝO3%6(LWKHUZD\WKH3%6ZDVDVSLUDWHGȝORI
formalin was added to each well and the plate left on a rocking platform 
for 20 min. If still in the plate, the lysate from each well was transferred 
to an eppendorf, making sure all the cells had been removed from the 
bottom of the well.  
 
2.3. Histology 
2.3.1. Cytospins 
A volume containing 1x104 cells was added to an assembled cytospin 
module with labelled slide. These were spun in the cytospin for 5 min at 
1500rpm. The modules were disassembled and the slides left in a dark 
place to dry for 30 min. The slides were put into a holder and briefly 
ZDVKHG LQ 3%6 ȝO RI WKH FRXQWHUVWDLQ +RHFKVW DW ȝJȝO ZDV
placed over the circle of cells on the slide for 5 min. The slides were 
again washed briefly in PBS in their holder and then dried slightly. One 
drop of either Citifluor or ProLong was placed on a coverslip (one per 
slide) and the slide was pressed into this, with the cells underneath the 
coverslip. The slides were then visualised straight-away if in Citifluor, or 
left overnight first if in ProLong, under a Leica fluorescent microscope, 
with DAPI (filter A) and Texas Red (filter TX2).  
 
2.3.2. Live cell staining 
This method was used to investigate protein expression in cells. All 
centrifugation steps were carried out at 4000rpm for 2 minutes at 4°C, 
and HEPES buffer was used instead of PBA to improve cell viability. 
The cells were harvested from a 75cm2 flask or 6-well plate (sphere and 
monolayer samples), lavaged if necessary, and counted. 5x105 cells 
were put into an eppendorf, centrifuged and the supernatant removed 
by tipping up the tube. The pellet of cells was re-suspended in the small 
amount of medium still present, and washed in 500µl of HEPES buffer. 
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The cells were centrifuged again and the supernatant poured away, 
before re-suspension and a further wash with 500µl HEPES buffer.  
 
When the cells had been re-suspended in the residual HEPES buffer, 
300µl of a 1:10 dilution of goat serum (or mouse serum for CD44 
staining) was added to the tube as a blocking agent. The cells were 
kept at 4°C in the dark to incubate for one hour. The cells were then 
spun, the block removed and the pellet re-suspended before washing 
with 500µl HEPES buffer twice. When the cells had been re-suspended 
after the last wash, 5µl of a 1:5 dilution of the primary antibody was 
added. This primary antibody was rabbit anti-CCK-2R, mouse anti-
CD133 or mouse universal antibody (or mouse anti-CD44 conjugated or 
the isotype control). Nothing was added to the CCK-2R negative control 
at this point; a species-matched universal control was used in initial 
experiments to show specificity of the primary antibody, however it 
became unavailable for later experiments. The cells were then 
incubated for one hour at 4°C in the dark. 
 
500µl of HEPES buffer was added to the tubes before they were spun 
in order to remove the excess primary antibody. The cells were then 
washed two times in 500µl of HEPES buffer, before adding 300µl of a 
1:1000 dilution of the goat anti-rabbit FITC-labelled secondary antibody 
to the re-suspended pellet (the CD44 labelled cells were fixed at this 
point). Again the cells were incubated at 4°C in the dark for one hour. 
After this the cells were spun to remove the excess secondary antibody, 
washed two times in HEPES buffer and re-suspended in 300µl of the 
fixative, 0.5% formaldehyde. The fixed samples could then be stored at 
4°C in the dark, ready for flow cytometric analysis. 
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2.3.3. Flow cytometry 
The two secondary antibodies used and the conjugated primary CD44 
antibody were labelled with FITC. Flow cytometric analysis was run in 
clear tubes on the Coulter Altra Flow Cytometer in the flow cytometry 
facility, QMC. A programme was developed to detect FITC expression 
in 10,000 cells from each sample. 
 
2.3.4. Paraffin staining 
Paraffin staining (or immunohistochemistry, IHC) was carried out for 
CCK-2R (and -catenin) in order to locate these proteins within the 
spheres. The sections were dewaxed in 2x xylene baths, for 5 min 
each, and then rinsed in 2x 100% ethanol for 1 min each. The block 
consisted of 0.6% (1%) hydrogen peroxide in methanol for 10 min (15 
min), followed by 2x 100% ethanol baths, and a tap water (distilled 
water) bath for 1 min each. The slides for CCK-2R were microwaved in 
citric acid for 15 min at 98 C, and quenched in running tap water 
followed by PBS for 1 min, whereas those for -catenin were not. The 
sections were blocked in 20% rabbit (swine) serum at room temperature 
for 30 min (15 min), then rinsed for 3 min in 2x PBS. The primary 
antibody, goat anti-human CCK-2R (rabbit anti-human -catenin) was 
then added at a 1 in 50 (1 in 100) dilution in PBS to the positives. The 
negative controls had goat (rabbit) serum at 1/3000 (1/2000) added to 
them. These were incubated overnight at 4 C (at RT for 60 min) in a 
humid box. 
 
The sections were then rinsed 2x in PBS for 3 min, and incubated with 
the secondary biotinylated antibody, rabbit anti-goat (swine anti-rabbit), 
at a 1/300 dilution in PBS. The sections were rinsed again in 2x PBS for 
3 min, before incubation for 30 min (20 min) with ABC at room 
temperature. 2x rinses in PBS for 3 min were followed by incubation 
with AEC for 30 min (DAB for 5 min) at room temperature. The rinse 
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was 2x distilled water (1x running tap water) for 1 min, after which the 
sections were counterstained with haemalum for 5 min (1 min). The 
sections were rinsed in running tap water for 1 min. 
 
The CCK-2R slides were placed in distilled water for 1 min before 
coverslipping with VectaMount and sealing with nail varnish. The -
catenin slides were dehydrated in 3x 100% ethanol baths for 1 min 
each and cleared for 3 min in 2x xylene baths. DPX was used to mount 
these coverslips before air-drying overnight. 
 
2.4. Molecular biology 
2.4.1. RNA extraction 
The first step in demonstrating gene expression in cells involved the 
extraction of RNA. An eppendorf containing a pellet of 5x105 cells was 
taken from the -80°C freezer and 1ml of TRI-reagent added to it. This 
was used to re-suspend the pellet and then left to incubate for 5 min. A 
FRQWUROWXEHZDVPDGHZLWKRXWDFHOOSHOOHWȝORIFKORURIRUPSHUPO
of TRI reagent was added to the tube, which was shaken vigorously. 
This was incubated at room temperature for 15 min before centrifuging 
at 13,000 rpm for 15 min at 4°C. The aqueous phase, containing the 
51$ ZDV UHPRYHG LQWR D IUHVK WXEH FRQWDLQLQJ ȝO RI LVRSURSDQRO
and the tube inverted to mix. This was left at room temperature for 10 
min before centrifuging at 13,000 rpm for 10 min at 4°C. The 
supernatant was aspirated and the pellet washed in 1ml of 70% 
ethanol. The tube was centrifuged at 13,000 rpm for 5 min and the 
supernatant again removed. The pellet was left to dry for 30-60 min and 
then the RNA was re-sXVSHQGHGLQȝORIPROHFXODUJUDGHZDWHU7KH
RNA was stored at -80°C. 
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2.4.2. cDNA synthesis 
cDNA synthesis converts RNA to DNA template that can be amplified 
by Taq. All solutions were handled inside the PCR cabinet, and the kit 
used was the Invitrogen SuperScULSW,,5HYHUVH7UDQVFULSWDVHNLWȝORI
UDQGRPKH[DPHUVSULPHUVZHUHDGGHGWRȝORIHDFK51$VDPSOH$
negative control with water instead of primers and a positive control with 
water instead of RNA were also set up. The RNA extraction control was 
also run as a control reaction. The tubes were incubated for 10 min at 
70°C. A mastermix was set up for the number of tubes plus one amount 
RI UHDFWLRQ PL[ 7KH PDVWHUPL[ IRU RQH WXEH LQYROYHG ȝO PROHFXODU
JUDGHZDWHUȝO;%XIIHUȝO0'77ȝOP0 G173DQGȝO
6XSHUVFULSW HQ]\PH 2QFH WKH & LQFXEDWLRQ ZDV ILQLVKHG ȝO RI
mastermix was added to each tube. The tubes were then put into the 
WKHUPRF\FOHU RQ SURJUDPPH µF'1$¶ ZKLFK LQFXEDWHG WKH VDPSOHV DW
25°C for 10 min, 42°C for 60 min and 95°C for 5 min. The samples of 
cDNA were diluted 1:5 and then stored in the -20°C freezer. 
 
2.4.3. Genomic DNA wipeout cDNA synthesis 
All solutions were handled inside the PCR cabinet, and the kit used was 
Qiagen Quantitect Reverse Transcription kit to remove any traces of 
J'1$SUHVHQWZLWKLQWKH51$VDPSOHȝORIJ'1$:LSHRXW%XIIHUZDV
DGGHGWRȝORIHDFK51$VDPSOHZLWKȝORI51DVH-free water. The 
tubes were incubated for 5 min at 42°C. A mastermix was set up with 
the number of tubes plus one amount of reaction mix. The mastermix 
IRURQHWXEHLQYROYHGȝO[ 4XDQWLVFULSW%XIIHUȝO573ULPHU0L[DQG
ȝO 4XDQWLVFULSW 5HYHUVH 7UDQVFULSWDVH HQ]\PH 2QFH WKH &
LQFXEDWLRQ ZDV ILQLVKHG WKH WXEHV ZHUH SODFHG RQ LFH DQG ȝO RI
mastermix was added to each tube. A negative control with water 
instead of enzyme and a positive control with water instead of RNA 
were also set up (at half volumes). The RNA extraction control was run 
as a further control reaction. The tubes were then put into the heat 
block at 42°C for 30 min after which the temperature was increased to 
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95°C for 5 min. The samples of cDNA were diluted 1:5 and then stored 
in the -20°C freezer. 
 
2.4.4. Nanodrop 
The nanodrop protocol allows the measurement of the concentration of 
D 51$ RU '1$ VROXWLRQ ȝO RI ZDWHU ZDV SODFHG RQWR WKH QDQRGURS
machine, in order to initiate and then blank the measurement. Either 
DNA or RNA readings were chosen in the nucleic acid sHFWLRQ7KHQȝO
of solution was placed and measured. This gives the concentration of 
WKH'1$RU51$LQQJȝO 
 
2.4.5. Classical PCR 
The HotStarTaq DNA Polymerase kit was used to perform classical 
PCR to amplify the DNA of interest.  The mastermix for this method with 
or without Q solution is shown in Table 2.2, and the primers used are 
shown in Table 2.4ȝORIWKLVPL[ZDVSODFHGLQWRHDFKWXEHDQGȝO
of template DNA, or nuclease-free water as a negative control, was 
added. The tubes were placed in a thermocycler at 94°C for 15 min, 
then 40 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 3 min. 
The last extension step was 10 min at 72°C. The products were then 
visualised on a 0.8% agarose gel. 
 
2.4.6. Gel electrophoresis 
An agarose gel at either 0.8% or 2% was made up (Table 2.5). The gel 
was left to cool for at least 30 min and then could be placed in the gel 
tank with gel electrophoresis buffer (Table 2.5). ȝORI%OXH-XLFHORDGLQJ
buffer was added to each sample before loading into the wells of the 
gel. A marker (2log or 100bp) was loaded in the first well of each lane, 
ȝOSHUZHOO7KHSRZHUSDFNZDV WKHQFRQQHFWHG WR WKHJHO WDQNYLD
the lid and set to 120V for 45 min.  
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Once the gel had run, it was taken from the gel tank and placed in the 
gel doc machine. The gel was exposed to ultraviolet light for an 
automated length of time, and this was adjusted if necessary. A picture 
was taken in this machine and the DNA sample fragment sizes 
analysed compared to the marker.  
 
2.4.7. Real-Time PCR 
Real-time PCR (qRT-PCR) was used to amplify the DNA of the gene of 
interest and was carried out using qPCR Core kit for SYBR® Green I. 
The house-keeping gene, HPRT, was used to quantify expression of 
the target gene using the 2-ǻCt method. This procedure was either 
carried out with Sybr Green as the probe or with a specially made 
7DTPDQSUREH$%,SURWRFRO)RUWKHIRUPHUWKHILQDOYROXPHZDVȝO
IRUWKHODWWHUȝO$PDVWHUPLx with the number of reactions, plus one, 
was made up in the PCR cabinet. The reagents and quantities are 
shown below in Table 2.2. The conditions for the different PCR 
reactions carried out are in Table 2.3. qRT-PCR was performed on an 
ABI 7500 real-time PCR system. 
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Reagent Sybr 
Green 
qRT-PCR 
ȝO 
Taqman 
qRT-PCR 
for CCK-
5ȝO 
Classical 
3&5ȝO 
Classical 
PCR with Q 
VROXWLRQȝO 
LATE-PCR for 
CCK-5ȝO 
Water 12.63 8.90 15.05 10.05 6.90 
10X buffer 2.50 2.00 2.50 2.50 2.00 
50nM MgCl 1.75 2.00 - - 2.00 
5mM dNTP 1.00 0.80 0.25 0.25 0.80 
Sybr Green 0.75 - - - - 
HotGoldStar 
(enzyme) 
0.13 0.10 - - 0.10 
HotStarTaq 
(enzyme) 
- - 0.20 0.20 - 
UNG 0.25 0.20 - - 0.20 
5mM 
Primers 
(Table 2.4) 
1.00 - 1.00 of 
each 
1.00 of each - 
ABI primer 
/probe mix 
(Table 2.4) 
- 1.00 - - - 
LATE-PCR 
primers  
    1.00 (F+R 
together)  
LATE-PCR 
probe 
    1.00 
Q solution - - - 5.00 - 
Add to wells 20 15 20 20 15 
Template 5 5 5 5 5 
Table 2.2: Reagents for real-time and classical PCR 
 
2.4.8. LATE-PCR 
This assay is an alternative to qRT-PCR, but modified to make the 
detection more sensitive. As before the house-keeping gene, HPRT 
was used to quantify expression of the target gene using the 2-ǻCt 
method [155]. The reagents and conditions are detailed in Table 2.2 
and Table 2.3 respectively. The CCK-2R and HPRT probe and primers 
used were designed specifically for LATE-PCR. There was one limiting 
primer (reverse primer), at a final concentration of 50nM, and a primer 
in excess (forward primer), at a final concentration of 1µM. The probe 
was used at a final concentration of 1µM. The primers (together) and 
the probe were diluted in molecular grade water to the correct 
FRQFHQWUDWLRQLQRUGHUWRSXWȝORIHDFKLQWKH3&5PDVWHUPL[&\FOLQJ
was carried out on an ABI 7500 real-time PCR system, later changed to 
an ABI StepOnePlus real-time PCR system after similarity testing. 
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Stage Step qRT-PCR 
(Taqman) 
qRT-PCR 
(Sybr Green) 
1st LATE-
PCR 
2nd LATE-
PCR 
  Temp Time Temp Time Temp Time Temp Time 
1  50 2 m 50 2 m 50 2 m 50 2 m 
2  95 10 m 95 10 m 95 3 m 95 3 m 
3  1 95 15 s 95 15 s 95 10 s 95 10 s 
 2 60 1 m 60 1 m 53 10 s 53 10 s 
 3     72 20 s   
 4     45 20 s   
4 1       95 10 s 
 2       53 10 s 
 3       72 20 s 
 4       45 20 s 
Disso-
ciation 
1   95 15 s     
 2   60 1 m     
 3   95 15 s     
No. of 
cycles 
  40 
(st 3) 
 40 
(st 3) 
 60 
(st 3) 
 10 
(st 3) 
50 
(st 4) 
Table 2.3: Real-time PCR conditions, the detection step is shown in green 
 
For the cell-line experiments in Section 3.6 this was further modified to 
reduce gDNA detection, by elimination of the extension and detection 
step from the first ten cycles of the PCR (Table 2.3). This method was 
used for the LATE-PCR results detailed from Section 3.6 onwards. 
Method Primer Sequence Tm (°C) 
LATE-PCR CCK-2R Fc GGCACATTCATCTTTGGCACCGTCATC 63 
 CCK-2R Rc CGCTCCAGTGCGATGGCCACGAGGCTT
AGC 
68 
 HPRT Fc ACCTAATCATTATGCTGAGGATTTGGAA
AGGGTGT 
61 
 HPRT Rc GAGGGCTACAATGTGATGGCCTCCCAT
CTCCTTCATCAC 
70 
Taqman 
qRT-PCR 
Lui CCK-2R F TCATCTTTGGCACCGTCATC  
 Lui CCK-2R R GATGGCCACGAGGCTTAGC  
 HPRT F ATTATGCTGAGGATTTGGAAAGGG  
 HPRT R GCCTCCCATCTCCTTCATCAC  
Sybr Green HPRT F ATTATGCTGAGGATTTGGAAAGGG  
 HPRT R GCCTCCCATCTCCTTCATCAC  
 Gastrin F CGAGCCTCTCATCATCGAAGG  
 Gastrin R TTCTTCTTCTTCCTCCAGCCATG  
 CD133 4F AATCTCCCTGTTGGTGATTTG  
 CD133 5R TCCGGGTTCTTACCTGGTGAT  
 VEGF F ACGAGGGCCTGGAGTGTGT  
 VEGF R TTTGTTGTGCTGTAGGAAGCTCAT  
CCK-2R 
promoter 
F TTGACATCCTCTTGCAGCTC  
 F1 GAGCAAACAGGGAGCGTTAG  
 F2 CAGCTGAGGGCCATCTTTTA  
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 F3 AGAGGAAGCCAGGGGAAATA  
 F4 GGGTGACAGTCATTGGTGGT  
 F5 AATCCCCCATAAAGCCAGAC  
 F6 CAACTGCCCTCAACACTCAA  
 F7 TCTACCCAACCCCTCCTACC  
 F8 ACAGGGAGGGGCAGAACT  
 R CCGCCTTACTCAGCTCGAC  
 R1 TCCCTGTGCGACTGTCCT  
 R2 CCCCCTCCCTAGATGTGTC  
 R3 AGTTCTGCCCCTCCCTGT  
 R4 TTGCAGTTAAGGGTCCCAAG  
Table 2.4: Primers used in PCR reactions 
  
2.4.9. /XFLIHUDVH DQG ȕ-galactosidase assay on the 
luminometer 
7KHOXFLIHUDVHDQGȕ-galactosidase assays for transfection lysates were 
carried out together so that the second of these normalised the results 
IURPWKHILUVW(DFKDVVD\ZDVFDUULHGRXWLQWULSOLFDWHDQGWKHUHIRUHȝO
of each lysate was added to three wells in each of two black Nunc 
luminometer 96-well plates, leaving three ZHOOV DV EODQNV 7KH ȕ-
galactosidase reaction mix was made up as a 100-IROG GLOXWLRQ RI ȕ-
JDODFWRVLGDVH VXEVWUDWH LQ WKH GLOXHQW IURP WKH 7URSL[ ȕ-galactosidase 
NLW,PPHGLDWHO\ȝORIWKLVUHDFWLRQPL[ZDVDGGHGWRHDFKZHOOLQWKH
first 96-well plate, the lid was replaced and the plate covered with 
aluminium foil and left to incubate for 75 min.  
 
The second 96-ZHOO SODWH FRQWDLQLQJ WKH O\VDWHV KDG ȝO RI VLQJOH
reporter (firefly luciferase) substrate added to each well, and the 
luminometer was run immediately at 1 sec/well. After incubation tKHȕ-
galactosidase, the (first) 96-well plate was run in the luminometer at 1 
sec/well. The mean was taken of the triplicate values for luciferase and 
ȕ-galactosidase separately, and then the luciferase expression mean 
ZDV GLYLGHG E\ WKH ȕ-galactosidase expression mean in order to 
achieve normalised (to account for different living cell number) results 
for luciferase expression. 
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2.4.10. Western blotting 
This was a preliminary experiment only and was optimised by previous 
laboratory users. The cells were harvested using the Biovision 
nuclear/cytosolic fraction kit. The western blotting kit used was Novex 
from Invitrogen and the primary antibody was mouse anti-human HIF-
1Į (BD Biosciences) at 1:250, with a secondary biotinylated antibody 
and the ABComplex/Strept and ECL kits were used for development 
and visualisation of bands.  
 
2.5. Bacteria and cloning 
2.5.1. TOPO cloning 
This method was used to ligate classical PCR products into the TOPO 
plasmid, in order that they could then be moved into pGL4. The kit for 
this protocol was the TOPO TA Cloning® .LW)RUHDFKUHDFWLRQȝORI
FODVVLFDO 3&5 SURGXFW ȝO RI VDOW VROXWLRQ ȝO RI S&5®II-TOPO® 
plasmid  (Figure 2.1 DQG ȝO RI PROHFXODU JUDGH ZDWHU ZHUH PL[HG
together and incubated for 5 min at room temperature. This could then 
be transformed into One Shot® TOP10F´ chemically competent cells. 
 
2.5.2. Plasmids used 
a) pCR®II-TOPO® plasmid  b) pGL4.10[luc2] plasmid 
 
 
 
 
 
 
Figure 2.1: Plasmid vectors used in this project 
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2.5.3. Transformation of chemically competent cells 
ȝORIWKHVROXWLRQIURP7232FORQLQJZDVDGGHGWRDYLDORI2QH6KRW® 
TOP10F´ competent E. coli, mixed gently and incubated on ice for 5-30 
min. The cells were then heat-shocked at 42°C for 30 sec, and 
LPPHGLDWHO\WUDQVIHUUHGEDFNWRWKHLFHȝORIZDUPHG62&PHGLXP
was added to each vial and these were put into a universal and shaken 
at 200rpm in a 37°C incubator for 1 hour. 10-ȝORI WKLVPL[WXUHZDV
spread onto previously-prepared LB-Amp plates with X-gal/IPTG. The 
plates were placed in a 37°C incubator overnight and the blue colonies 
were picked for bacterial culture 24 hours later. 
 
2.5.4. Digest (for test or purification) 
DNA digestion was used to remove the promoter fragments from the 
TOPO plasmid and to linearise pGL4 with the same enzymes, to ensure 
DVLPSOHOLJDWLRQRIWKHVHPROHFXOHV$VDPSOHYROXPHRIȝOZDVXVHG
for most restriction endonuclease (RE) digests, except for those leading 
WRJHOH[WUDFWLRQ7KLVYROXPHFRQVLVWHGRIȝORIWHVW'1$ȝORI1(%
EXIIHUȝORIHDFK5(ȝORI%6$ if necessary and the rest made up 
with nuclease-free water. This solution minus the DNA was made up as 
a mastermi[DQGWKHQHDFKWXEHKDGȝORIWKLVDQGȝORI'1$DGGHG
The tubes were put into the incubator at 37°C for 90 min. The digest 
solution was run in gel electrophoresis to separate the fragments 
produced. 
 
2.5.5. DNA gel extraction  
The process of making promoter plasmids included removing fragments 
of DNA from TOPO plasmids and annealing them into the pGL4 
plasmid, and gel extraction was used to ensure only the correct 
fragments entered this ligation. Once the gel had separated the DNA 
fragments sufficiently that they could be confidently cut apart, and a 
picture taken, the gel was transferred to the UV bed. Each fragment 
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was carefully cut out of the gel with a clean scalpel blade and placed in 
a labelled eppendorf. The other fragments in the gel were not touched 
in order to keep the fragment as clean as possible. Each gel fragment 
was weighed compared to an empty eppendorf and the weight noted on 
the tube. 
 
The gel extraction protocol is taken from the Qiagen QIAquick Gel 
Extraction Kit. Each centrifugation was carried out at maximum speed 
XVLQJDEHQFKWRSFHQWULIXJH7KUHHJHOYROXPHVPJ§ȝORI4*
buffer were added to the eppendorf, and heated to 50°C for 10 min. 
Once the gel was dissolved, one gel volume of isopropanol was added 
to each tube and mixed together. This solution was added to a 
4,$TXLFN FROXPQ LQ ȝO DOLTXRWV FHQWULIXJLQJ IRU RQH PLQ WKHQ
UHPRYLQJWKHHOXDWHDIWHUHDFKDGGLWLRQȝORI4*EXIIHUZDVDGGHG
WR WKH FROXPQ DQG VSXQ IRU RQH PLQ EHIRUH ȝO RI 3( ZDVK EXIIHU
was added and again the column was centrifuged for 1 min. The eluate 
was discarded and the column spun again for one min to dry the filter. 
7KLV FROXPQ ZDV WKHQ WUDQVIHUUHG WR D QHZ FROOHFWLRQ WXEH DQG ȝO
nuclease-free water was added to the filter and the tube left to stand for 
one min. Centrifuging for one min produced the pure DNA fragment and 
this could be ethanol precipitated or stored at -20°C. 
 
2.5.6. Ethanol precipitation 
The DNA used for ligation and transfection needed to be pure, and 
ethanol precipitation was used to ensure this. The DNA solution was 
measured and 1/10th the volume of 3M NaAc was added to it. 2x the 
new total volume of 100% ethanol was added to this and the tube was 
placed at -20°C for one hour/overnight. The tubes were then centrifuged 
at maximum speed for 15 min at 4°C and the supernatant poured away. 
1ml of 70% ethanol was added to wash and the tubes centrifuged again 
at 4°C for 5 min, before pouring off all the wash solution. The pellets 
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were dried under tissue paper for 30 min and then re-suspended in 
enough nuclease-free water to make up the correct concentration (the 
DNA concentration was determined using the nanodrop before starting). 
 
2.5.7. Ligation 
This method ligated the DNA fragments cut from the TOPO plasmid and 
the linearised pGL4 vector. 100ng of vector (pGL4; Figure 2.1) and a 
1:3 ratio of insert DNA were used in each positive ligation, and the 
negative for each sample had vector alone. This meant that the volume 
of insert needed was 3x100x(insert bp/vector bp). If the volume of this 
PL[WXUH H[FHHGHG ȝO WKHQ WKH\ ZHUH PL[HG WRJHWKHU DQG HWKDQRO
precipitated to make them up to ȝOȝOHDFKRIOLJDWLRQEXIIHU$73DQG
OLJDVH ZHUH WKHQ DGGHG ,I WKH WRWDO YROXPH GLG QRW PDNH ȝO WKHQ
nuclease-free water was added. The tubes were then left overnight at 
4°C. 
 
2.5.8. Transformation of competent/supercompetent cells 
In order to produce enough of the ligated plasmid for transfection this 
was transformed into fast-growing Escherichia coli FHOOV ȝO RI ;/-
Blue competent or supercompetent cells per sample were defrosted on 
ice. These were then transferred to a cooled 15ml falcon tube, ȝORI
ȕ-mercaptoethanol was added and the tube swirled carefully. These 
were incubated on ice for 10 min with swirling every 2 min, and then 
50ng of the '1$ RU ȝO OLJDWLRQ PL[ ZDV DGGHG 7KLV ZDV DJDLQ
incubated on ice for 30 min, while heating a water bath to 42°C 
precisely. The cells were heat-shocked at 42°C for 45 sec before ice 
LQFXEDWLRQIRUPLQȝORIZDUPHG62&PHGLXPZDVDGGHGWRWKH
falcon tube and then it was left at 37°C with shaking at 230rpm for 1 
hour.  
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The cells were dropped and spread onto previously-prepared LB-Amp 
agar plates at a suitable volume. This was a small amount (10-ȝOIRU
certain DNA transformations and all of the cells on two plates for 
ligation transformations. The negative control transformations (from 
negative ligations) were plated only on one plate. Once dry, the plates 
were placed upside-down in the 37°C incubator overnight, and the 
colonies examined in the morning. If the plates were covered with 
colonies then these were re-streaked onto fresh plates and left 
overnight again.  
 
2.5.9. Bacterial culture 
For each culture, 2 or 5ml of LB-Amp was made up as a mastermix, 
and then aliquoted into universals. The bacterial stocks were defrosted 
on ice, if necessary. A new disposable loop was taken for each culture, 
and dipped in the bacterial stock eppendorf or touched to a bacterial 
colony from an agar plate. This was then mixed in the universal 
containing LB-Amp and disposed of in 10% Trigene. The cultures were 
put into the 37°C incubator, with shaking at 230rpm, overnight. 
 
2.5.10. Bacterial stocks 
0.5ml of each culture was taken into an eppendorf and 0.5ml of LB-
glycerol was added. This was mixed and the labelled tube of bacteria 
frozen down at -70°C. 
 
2.5.11. Plasmid mini-prep 
The plasmid DNA was removed from E. coli for use in transfections. 
The bacterial cells were harvested from the overnight cultures into 
1.5ml eppendorfs by centrifugation at 13,000rpm for 3 min. The 
plasmids from these bacteria were isolated using the Sigma Genelute 
Plasmid Mini-prep Kit, and all centrifugation was carried out at 
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maximum speed. The pellet was re-VXVSHQGHG LQȝOUH-suspension 
VROXWLRQDQGWKHQȝO O\VLVVROXWLRQZDVDGGHGDQGWKH WXEHPL[HG
The soOXWLRQZDVOHIWWRFOHDUIRUPLQDQGWKHQȝORIQHXWUDOLVDWLRQ
solution was added and the tube inverted 6 times. This was centrifuged 
for 10 min, and the supernatant from this was transferred to a spin 
column, which had been previously centrifuged for  PLQ ZLWK ȝO
preparation solution added.  
 
7KHVSLQFROXPQZDVFHQWULIXJHGIRUPLQDQGWKHQȝOZDVKEXIIHU
added, before being centrifuged for one min again. The eluate was 
removed and the column dried with another spin for 1 min, before the 
colXPQZDVWUDQVIHUUHGWRDQHZFROOHFWLRQWXEHDQGȝORIQXFOHDVH-
free water was applied to the centre of the filter. Centrifugation for one 
min produced the purified plasmid DNA and the tube was labelled and 
frozen at -20°C. The DNA concentration was often tested in the 
nanodrop before ethanol precipitation or freezing, and adjusted to 
QJȝOLILWZDVWREHXVHGIRUWUDQVIHFWLRQ 
 
2.6. Table of media 
Medium and Reagents Recipe 
0.8% Agarose gel 0.8g agarose powder and 100ml 1x TAE. 
Heated until dissolved. 5ȝO6DIHYLHZ
added, the mixture poured into a tray, 
and the comb placed in. Left to cool. 
2% Agarose gel As above with 2g of agarose powder. 
70% Ethanol 35ml 100% ethanol with 15ml molecular 
grade water. 
Freezing medium Normal growth medium with 10% DMSO. 
Gel electrophoresis buffer PO[7$(DQGȝO6DIHYLHZ 
HEPES buffer RPMI 1640 medium with 2% Foetal 
Bovine Serum (FBS) and 5mM HEPES. 
LoVo medium F-12 Ham medium with 10% FBS and 
2mM glutamine. 
Luria-Bertani medium with ampicillin (LB-
amp) 
5g NaCl, 2g MgSO4, 5g yeast extract 
and 10g casein hydrosylate added to a 
beaker and filled up to 900ml with 
distilled water. pH to 7.5 and autoclaved 
before use. 
LB-Ampicillin Agar plates One sachet of FastMedia LB Agar Amp 
poured into 200ml autoclaved distilled 
water, heated until dissolved. Poured into 
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petri dishes when cooler. 
LB-Ampicillin Agar plates with X-gal and 
IPTG 
$VDERYHEXWZKHQVHWȝORIP0
IPTG was spread on the plate, and then 
ȝORIPJPO;-gal was spread on 
top. 
LB-glycerol Autoclaved LB medium with 15% glycerol 
added. Filtered before use. 
Normal growth medium RPMI 1640 medium with 10% FBS and 
2mM glutamine. 
Phosphate buffered saline (PBS) 1 tablet of PBS dissolved in every 100ml 
distilled water. Filtered before use in 
tissue culture. 
Serum free medium Normal growth medium, minus the FBS. 
Stem Cell Medium (SCM) 372 ml Low Glucose DMEM plus 2.5ml 
heparin, 116ml F-12 Ham, 10ml B27 
supplement and (added fresh) 20ȝg/ml 
EGF and FGF. 
1x Tris Acetate EDTA (TAE) 100ml 10x TAE stock and 900ml distilled 
water. 
Table 2.5: Medium and reagents used in this project 
 
2.7. Table of materials 
Material Cat. number Supplier 
100bp DNA ladder N3231L New England Biolabs 
2log DNA ladder N3200L New England Biolabs 
ABC kit AK-5003 Vector Laboratories 
AEC kit SK-4200  Vector Laboratories 
Agarose powder EP-0010-05 Eurogentec 
Ampicillin A5354 Sigma Aldrich 
B27 17504-044 Invitrogen 
Biotinylated antibody rabbit Į-
goat 
E0466 Dako 
Biotinylated antibody swine Į- 
rabbit 
E0353 Dako 
Bluejuice loading buffer 10816-015 Invitrogen 
Bovine serum albumin (BSA) B90015 New England Biolabs 
Casein hydrosylate 22090 Fluka 
CCK-2R primary antibody ab14440 Abcam 
CD133 primary antibody 130-092-395 Milteni 
CD44 conjugated primary 
antibody 
560532 BD Biosciences 
Chloroform C-2432 Sigma Aldrich 
Citifluor AF2 Science Services 
Citric acid C1857 Sigma Aldrich 
DAB kit K4065 Dako 
Deoxyribonucleotide 
triphosphates (dNTPs) 
DNTP-100A-1KT Sigma Aldrich 
Dimethyl sulfoxide (DMSO) D4540 Sigma Aldrich 
DMEM (low Glucose) D6046 Sigma Aldrich 
DPX 44581-100ML Sigma Aldrich 
Epidermal growth factor (EGF) 13247-051 Invitrogen 
Ethanol E7023 Sigma Aldrich 
Ethylenediaminetetraacetic acid 
(EDTA) 
E6758 Sigma Aldrich 
Exonuclease III M1811 Promega 
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F-12 Ham medium 21765 Gibco 
FastMedia LB Agar Amp #M0021 Fermentas 
Fibroblast growth factor (FGF) PHG 0026 Biosource 
Firefly luciferase substrate E1483 Promega 
Foetal Bovine Serum (FBS) F7524 Sigma Aldrich 
Formaldehyde F8775 Sigma Aldrich 
Genelute plasmid Miniprep kit PLN350 Sigma Aldrich 
Geneticin A1720 Sigma Aldrich 
L-Glutamine  G8540 Sigma Aldrich 
Glycerol G-5516 Sigma Aldrich 
Goat Į-mouse secondary FITC-
labelled antibody (AlexaFluor 
488) 
A11001 Invitrogen 
Goat Į-rabbit secondary FITC-
labelled antibody (AlexaFluor 
488) 
A11008 Invitrogen 
Goat Serum G9023 Sigma Aldrich 
Haemalum 51275-100ML Sigma Aldrich 
Heparin H1027 Sigma Aldrich 
HEPES H4034 Sigma Aldrich 
+,)ĮDQG+,)ĮVL51$V - Eurogentec [156] 
Hoechst H21486 Invitrogen 
HotStarTaq DNA Polymerase 203203 Qiagen 
Hydrogen peroxidase 323381-500ML Sigma Aldrich 
Isopropanol I9516 Sigma Aldrich 
Isopropyl-beta-D-
thiogalactopyranoside (IPTG) 
I1284 Sigma Aldrich 
Isotype conjugated control 
antibody 
558331 BD Biosciences 
Klenow DNA polymerase M2201 Promega 
Ligase, 10x Ligation buffer, ATP 600011 (T4 kit) Stratagene 
Lipofectamine 2000 11668-019 Invitrogen 
Methanol 650188 Sigma Aldrich 
MgSO4 M/1050/53 Fisher Scientific 
Molecular grade water W4502-1L Sigma Aldrich 
Mouse serum M5905 Sigma Aldrich 
NaCl S/3160/63 Fisher Scientific 
NEBuffer 4 B70045 New England Biolabs 
OptiMEM1 medium 31985-047 Invitrogen 
PBS tablets BR0014G Oxoid 
Plasmid: pGL4   
Plasmid: TA GAS I1 1.1, 1.2, 
1.3 
In house - 
Polyethylene glycol 76293 Sigma Aldrich 
Primers and probes for Taqman 
qRT-PCR and LATE-PCR 
- Eurogentec 
Prolong® Gold P36930 Invitrogen 
QIAquick gel extraction kit 28704 Qiagen 
Quantitect Reverse 
Transcription kit 
205311 Qiagen 
qPCR Core kit for SYBR® 
Green I 
RT-SN10-05 Eurogentec 
Rabbit serum R9133 Sigma Aldrich 
Random hexamers N8080127 Invitrogen 
Restriction Endonuclease (RE): 
NcoI, XhoI, XmaI  
R01935, R01465, 
R01805 
New England Biolabs 
Restriction Endonuclease (RE): 
SacI 
R606E Promega 
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RPMI 1640 medium R0883 Sigma Aldrich 
S1 nuclease M5761 Promega 
Safeview nucleic acid stain NBS-SV1 NBS Biologicals 
Silencer siRNA construction kit AM1620 Ambion 
siPORT Amine AM4503 Ambion 
siRNA: gastrin - Eurogentec 
siRNA: negative SR-CL000-005 Eurogentec 
siRNA: scrambled gastrin - Eurogentec 
siRNA: scrambled gastrin 
TAMRA-labelled 
- Eurogentec 
SOC medium S1797 Sigma Aldrich 
SuperScript II Reverse 
Transcriptase kit 
18064-022 Invitrogen 
Swine serum sc-2486 Santa Cruz Biotech 
10x TAE  T9650 Sigma Aldrich 
TOPO TA Cloning® Kit K4650-01 Invitrogen 
TRI reagent T9424 Sigma Aldrich 
Trigene TM308 Medichem International 
Trypan blue dye T6146 Sigma Aldrich 
Trypsin-EDTA T3924 Sigma Aldrich 
Universal negative control for 
mouse 
IS750 Dako 
Uracil N-glycosylase (UNG) RT-0610-15 Eurogentec 
VectaMount H-5501 Vector Laboratories 
X-gal (5-Bromo-4-chloro-3-
LQGRO\Oȕ-D-galactopyranoside) 
B6024 Sigma Aldrich 
XL1-Blue 
competent/supercompetent cells 
200249/200236 Stratagene 
Yeast extract Y-1625 Sigma Aldrich 
Table 2.6: Materials used in this project 
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Chapter 3 Detection of the 
CCK-2R 
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3.1. CCK-2R expression  
Reported levels of CCK-2R gene and protein expression in cancer cells 
vary widely in the literature [72]. The aim of this chapter was to 
investigate CCK-2R gene expression in a panel of cell-lines, using a 
new method for real-time PCR, and to validate this technique using 
RNAi. Protein expression was also investigated and correlated with 
gene expression. 
 
3.2. CCK-2R expression in a panel of cell-lines 
CCK-2R expression was initially investigated in a panel of cancer cell-
lines including gastric, colorectal, pancreatic, oesophageal and SCLC 
cells using a Taqman probe in qRT-PCR. The primers used have been 
previously published by Liu et al. [157]. Several controls were devised 
to assess the assay; in-house CCK-2R-transfected cell-lines were used 
as positive controls, and NIH3T3 mouse fibroblast cells were used as a 
negative control, since there is low homology between the primers used 
and the mouse CCK-2R gene. Together these provide an important 
measure of the sensitivity of the assay. 
 
A cDNA negative control was included in the qRT-PCR for each cell-
line. This consisted of the cDNA synthesis sample with RNA but no 
primers or enzyme, and therefore should not have contained any DNA. 
This control must show a Ct value of at least 10 cycles higher than that 
of the equivalent positive cDNA sample, to confirm that genomic DNA 
(gDNA) contamination is not present. This is a particular problem for 
detection of CCK-2R due to the primers being designed over intron 2, 
which is only 167bp long. The amplicon itself is 86bp, illustrating that 
the reaction could amplify this together with the intron without a long 
extension time, if gDNA is present in the cDNA sample. Unfortunately 
the samples from MGLVA-1 (gastric) and PAN-1 (pancreatic) cells had 
this contamination and therefore are not shown in Figure 3.1.  
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Three human CCK-2R-transfected cell-lines (Figure 3.1a) were tested 
along with their vector controls (VCs), or if these were not available, 
wild-type (wt) cells. The transfected lines showed the highest 
expression levels, as expected, and all three showed at least 10,000-
fold more expression of the receptor than their VC/wt (p<0.05). This 
indicates that the assay detects CCK-2R mRNA. The negative control 
used; the wild-type mouse fibroblast cell-line, NIH3T3, did not show any 
expression of human CCK-2R, showing the specificity of the Taqman 
qRT-PCR. Figure 3.1 shows these results, using the 2-ǻCt method [155] 
which provides a measure of the expression of CCK-2R relative to the 
housekeeping gene, HPRT [158].  
a) b) 
 
Figure 3.1: Expression of CCK-2R by Taqman qRT-PCR 
Logarithmic graphs showing the expression of CCK-2R (2-ǻCt) relative to the 
housekeeping gene, HPRT, in a panel of cell-lines, using Taqman qRT-PCR. CCK-
2R-transfected cell-lines are shown in a), while b) shows endogenous expression in 
wild-type cells. For each cell-line, data was obtained for three cDNA replicates. The 
black bars represent the 95% confidence interval, and a * above the bar indicates that 
it is significantly different (p<0.05) to all other bars (on both graphs, except OE33-
CCK-2R and H209 which are not statistically different in terms of CCK-2R expression). 
 
Five wild-type cell-lines showed endogenous CCK-2R expression; 
HT29 and LoVo (colorectal), OE19 and OE33 (oesophageal) and H209 
(SCLC). SCLC cells were included in the study since they have been 
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previously shown to express CCK-2R by our and other groups, by use 
of classical RT-PCR [159]. Except for H209 cells, endogenous 
expression of the CCK-2R seems to be 100-fold lower than in 
transfected OE33-CCK-2R cells. Compared to NIH3T3-CCK-2R cells, 
the level of the endogenous receptor gene in H209 cells is 10,000-fold 
lower. 
 
However, HCT116 (colorectal) and AGS vector control (gastric) cells did 
not show any expression despite the findings of several inhibitor studies 
which suggest that the receptor is present [74, 139]. This result 
suggests that Taqman qRT-PCR is not sensitive enough to detect the 
level of CCK-2R gene activity occurring in these cell-lines. 
 
3.3. CCK-2R Taqman assay sensitivity studies 
In order to test the sensitivity of the CCK-2R Taqman assay formally, 
RNA was prepared from a series of dilutions of AGS-CCK-2R cells in 
untransfected CCK-2R-negative AGS cells, so that the concentration of 
total RNA in the samples remained the same throughout, while the 
CCK-2R RNA was titrated out. Figure 3.2 shows that the Taqman qRT-
PCR could consistently detect signal when the CCK-2R was diluted to 
1:1.0E+02. At 1:1.0E+03, however, the results become less uniform, as 
can be seen by the increased size of the confidence interval at this ratio 
and beyond. By the 1:1.0E+06 dilution CCK-2R expression could not be 
detected.  
 
The proportion of wells where a Ct value was detected is also indicated 
in Figure 3.2. Beyond the 1:1.0E+02 dilution some Ct values were 
classified µXQGHWHFWDEOH¶E\ WKH$%,VRIWZDUH7KHUHIRUHDYDOXHRI
was used as the Taqman qRT-PCR was run to 40 cycles, but the Ct 
values may be larger than this. This indicates that expression of the 
CCK-2R gene is at the limit of detection of the assay. The proportion of 
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positive wells (with a Ct <40) decreases with increasing dilution as 
predicted by the Poisson distribution. For example, in the bar chart 
within Figure 3.2, it can be seen that with a 1:1.0E+05 dilution of the 
CCK-2R, the receptor was detectable in a total of 2 out of 12 samples (it 
was not detected at all in the third experiment).  
 
Figure 3.2: CCK-2R Taqman sensitivity studies 
AGS-CCK-2R cells were diluted in AGS cells to produce the dilution series. The 
experiment was repeated three times, but not all of the ratios were tested each time. 
The bar chart illustrates the % of wells in which the Ct value was <40. The line graph 
with error bars demonstrates the expression of CCK-2R relative to HPRT (2-ǻCt) on a 
logarithmic scale. The error bars represent the 95% confidence interval. 
 
The 1:1.0E+05 dilution did not yield any results at all in experiment 2 
and 3 (Figure 3.2). The differences that occur beyond the 1:1.0E+02 
dilution suggest that this is the limit of detection in the assay, and that 
perhaps a more sensitive assay should be established.  
 
3.4. The LATE-PCR assay 
A Linear-after-the-exponential (LATE-) PCR was developed to increase 
the sensitivity of qRT-PCR. This is extremely relevant to detection of 
CCK-2R mRNA expression since it seems to be present in very low 
concentrations even in cells where it has been shown to have a 
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biological effect [13, 74, 138, 139]. LATE-PCR uses different 
concentrations of each primer to yield primarily single-stranded product 
(Figure 3.3). This means that the specially designed single-stranded 
probe can bind easily, therefore reducing the amount of DNA needed 
before a signal is detected. 
 
Figure 3.3: The steps of LATE-PCR 
Two primers, at different concentrations, are added to the sample of cDNA being 
tested for gene expression. These are the limiting (L) primer at a concentration of 
50nM, which will be depleted quickly and an excess (X) primer at a concentration of 
1µM, to carry on the reaction. The process of LATE-PCR briefly produces a double-
stranded product, then when the L primer is depleted, single-stranded product is 
formed. The specially designed single-stranded molecular probe binds to this product 
easily, causing the separation of the quencher from the fluorophore. The fluorophore 
fluoresces allowing the PCR machine to detect the signal, and software analysis 
shows the PCR cycle at which this first occurs as the Ct value. 
 
Template 
X Primer L Primer 
Template plus primers 
LATE-PCR 
Plus  
molecular 
probe 
Fluorophore 
Quencher 
Software 
analysis 
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3.4.1. Primer design for LATE-PCR 
In LATE-PCR, one primer is at a limiting (L), and one at an excess (X), 
concentration. Their melting temperatures (Tm) are important and must 
obey the rule TmL±TmX 0 to ensure that the reaction is efficient [160]. 
The amplicon for this assay was generated from the qRT-PCR CCK-2R 
(Taqman) and HPRT (Sybr Green, since the extended HPRT Taqman 
primers and probe did not show any detection) primers used above 
[157]. The Tm of the amplicon was calculated using the nearest-
neighbour formula detailed in Pierce et al. [142], as were those of the 
primers at a limiting or excess concentration (since this changes the 
Tm). It was recommended that the primer with the highest Tm at a 
limiting concentration should be allocated as the limiting primer; in both 
cases this was the reverse primer. This Tm needed to be close to that 
RI WKH DPSOLFRQ ZKLFK LQYROYHG LQFUHDVLQJ WKH ¶ HQG RI HDFK SULPHU
significantly in order to increase the primer Tm.  
 
3.4.2. Design of the molecular probe 
Two probes were designed to complement the product formed using the 
excess primer. Two types of probe were tested based on two different 
designs published by the group that first developed LATE-PCR. Both 
were investigated because LATE-PCR is a new technique and has only 
previously been applied to a very limited set of genes. A relatively high 
Tm probe is necessary in qRT-PCR for quick annealing with the 
product, while it is single-stranded; however, during LATE-PCR, since 
the product is almost exclusively single-stranded, a low Tm probe could 
also perform. In Sanchez et al. [160] they explain why the low Tm probe 
should be the more effective of the two since it would bind to the 
product slowly and therefore be more specific, create lower background 
and not reduce the efficiency of the reaction. 
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Figure 3.4: The mechanism of action of a 
molecular beacon  
When the molecular beacon (probe) binds to a 
sequence the fluorophore and quencher are 
forced apart allowing the fluorophore to 
fluoresce. This fluorescence is detected by the 
real-time PCR machine at a certain cycle 
QXPEHUZKLFKJLYHVHDFKVDPSOHDµ&WYDOXH¶
[161]. 
 
 
One probe was based on the papers by Pierce et al. [142, 162, 163] 
with a stem of length 6bp (Figure 3.4) and body Tm between 48°C and 
52°C; the second design was based on Sanchez et al. [160], and this 
probe had a shorter stem structure of 5bp in length, but a similar body 
7P7KHILUVWRI WKHVHZLOOEHUHIHUUHGWRDV WKH µKLJK7P¶SUREHVLQFH
WKH HQWLUH SUREH 7P LV KLJK a& DQG WKH VHFRQG DV WKH µORZ 7P¶
SUREHVLQFH LWVHQWLUH7P LVDURXQG&7PFDOFXODWLRQVE\ µ0HOWLQJ¶
programme in [164]). The activity of the high Tm and low Tm probes, for 
the CCK-2R, are compared below. 
 
3.4.3. Optimisation of the primers (and probe) 
Three forward and reverse primers, of increasing length, were chosen 
for each target, due to their predicted interaction; Pierce et al. [142] 
found that TmL±TmX VHHPHGWRJLYHKLJKHIILFLHQF\ WR WKHLU/$7(-
PCR, therefore our primer pairs were chosen to obey this rule. 
However, in order to investigate this in LATE-PCR for the genes CCK-
2R and HPRT, all nine combinations of the primers for each target were 
analysed for activity using Sybr Green qRT-PCR, on AGS-CCK-2R 
cDNA to give a consistent level of gene activity for detection.  
 
Ct values obtained are shown in Table 3.1. The pair which produced the 
lowest Ct values was chosen, since this meant the earliest detection of 
the PCR product. For CCK-2R, FcRc was the chosen combination since 
Stem 
Body 
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this produced a low Ct value, an undetectable negative control and had 
the desired Tm ratio (Table 3.1).  
 
Sybr Green qRT-PCR for HPRT produced very similar results for all the 
primer pairs so the probe was introduced in the optimisation process. 
This led to the FcRc pair being chosen since they showed the lowest Ct 
value. Interestingly the selected pair for both CCK-2R and HPRT was 
that predicted to be the best, being the longest primers of their set, with 
the highest Tm¶V. This also meant that the TmL±TmX UXOHZDVWUXH
for both targets: CCK-2R TmL±TmX = 5 and HPRT TmL±TmX = 9 (Table 
3.2). 
F 
primer 
R 
primer 
CCK-2R 
(Sybr Ct) 
CCK-2R 
(negative 
control) 
HPRT 
(Sybr Ct) 
HPRT 
(negative 
control) 
HPRT 
(Probe Ct) 
Fa Ra U U 24 U 39 
Fa Rb 19 U 24 U 36 
Fa Rc 19 U 23 U 37 
Fb Ra 32 (1/3 U) U 24 U 32 
Fb Rb 19 28 24 U 31 
Fb Rc 19 32 23 U 33 
Fc Ra 31-34 31 not done not done not done 
Fc Rb 19 31 25 U 30 
Fc Rc 19 U 25 U 30 
Table 3.1: Optimisation of the primers for LATE-PCR 
U is undetectable. 
 
Primer Concentration Sequence Tm (°C) 
CCK-2R Fc Excess GGCACATTCATCTTTGGCACCGTCA
TC 
63 
CCK-2R Rc Limiting CGCTCCAGTGCGATGGCCACGAGG
CTTAGC 
68 
HPRT Fc Excess ACCTAATCATTATGCTGAGGATTTG
GAAAGGGTGT 
61 
HPRT Rc Limiting GAGGGCTACAATGTGATGGCCTCC
CATCTCCTTCATCAC 
70 
Table 3.2: The primers chosen for use in CCK-2R and HPRT LATE-PCR 
 
The LATE-PCR assay was run using the chosen primer pairs and the 
specially designed molecular probes. The amplification curves for this 
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assay did not look exactly as did those for standard qRT-PCR; these 
were more S-shaped and with a plateau at the top (Figure 3.5a). Figure 
3.5b shows what the amplification plots for LATE-PCR first looked like: 
they did not always run along the x-axis before the exponential phase. 
Sanchez et al. [160] show several figures explaining that the 
concentration and ratio of primers are very important to the appearance 
of the graph in LATE-PCR; so it was possible that further optimisation 
was necessary.  
a) b) 
 
 
c) 
 
 
 
Figure 3.5: Amplification plots in qRT-PCR 
a) Gastrin, CD133 and HPRT Sybr Green qRT-PCR, and b) & c) CCK-2R and HPRT 
LATE-PCR on a sample of HT29 cDNA. The graph in b) has been plotted with the 
automatic baseline (3-15), whereas in c) this has been changed to 1-10 cycles; this 
causes the software to ignore the data which was acquired while the limiting primer 
was still causing double-stranded product to form. The comparison of the amplification 
plots shows that CCK-2R LATE-PCR produces a different shape of graph. 
 
Primer and probe concentrations were tested, since those used for the 
Sybr Green testing had been taken from the literature [142]. The 
concentrations used in Pierce et al. [142] were, the X primer at 1µM, the 
L primer at 50nM and the probe at 1µM. However, for both assays, 
these primer concentrations were found to give the best amplification 
curves, and it was found that changing the baseline of the graphs in the 
software caused the data to form the expected S-shaped amplification 
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plot (Figure 3.5c). Despite the optimisation, the Ct values for CCK-2R 
LATE-PCR were far higher (up to 15 cycles higher) than those for 
HPRT, which reflected the very low gene expression compared to that 
of HPRT. 
 
3.5. Determining the sensitivity of the LATE-PCR assay 
The LATE-PCR was repeated on the same samples used for the 
Taqman assay, in order to determine its sensitivity. This new assay was 
run for 60 cycles, since this longer run (compared to the Taqman 40-
cycle run) was recommended by Pierce et al. [142]. The Taqman assay 
shown in Figure 3.6 was also run for 60 cycles in order to compare 
them precisely.  
 
Figure 3.6: Comparison between LATE-PCR and the CCK-2R Taqman assay  
Two different LATE-PCR probes were used: low Tm (based on Sanchez et al. [160]) 
and high Tm (based on Pierce et al. [142]). AGS-CCK-2R cells were diluted in AGS 
cells in series to produce the ratio samples. The bar chart illustrates the % of wells 
with Ct values of < 60. The line graph shows the expression of CCK-2R relative to 
HPRT (2-ǻCt) on a logarithmic scale. The error bars represent the 95% confidence 
interval. 
 
The LATE-PCR method is able to detect the CCK-2R at lower 
concentrations than the Taqman qRT-PCR (Figure 3.6). Both probes for 
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LATE-PCR detected the receptor at a dilution of 1:1.0E+04, whereas 
the results for the Taqman assay produced far bigger error bars at this 
concentration.  
a) R2 = 0.99, Slope = 1.03 ± 0.04 b) R2 = 0.99, Slope = 0.65 ± 0.01 
  
c) R2 = 0.99, Slope = 6.26 ± 0.24  
 
 
Figure 3.7: Linear correlations performed on the CCK-2R expression data from Figure 3.6 
The R2 value and slope are described above each graph for a) low Tm LATE-PCR, b) 
high Tm LATE-PCR and c) Taqman qRT-PCR. The error bars represent the 95% 
confidence intervals for the PCR data. 
 
The low Tm LATE probe detected the CCK-2R most consistently at the 
two lowest concentrations (Figure 3.6), with the smallest confidence 
intervals, suggesting this probe is more sensitive than the high Tm 
probe. The CCK-2R expression data were used to perform a linear 
correlation with the concentration of CCK-2R cDNA present in the 
samples (Figure 3.7). The linear correlation shows that although all 
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three methods have R2 values of 0.99, their slopes are very different. 
The low Tm probe produces a line with a slope of 1, indicating a ten-fold 
change in signal for a ten-fold change in dilution, whereas this was not 
the case when the high Tm and Taqman probes were used (Figure 3.7).  
 
From Figure 3.6 the sensitivity cut-off point for each assay is: 
1. Low Tm LATE-PCR probe at 1:1.0E+06 
2. High Tm LATE-PCR probe at 1:1.0E+04 
3. Taqman qRT-PCR at 1:1.0E+02. 
 
This means that the best LATE-PCR assay is 10,000-fold more 
sensitive than the CCK-2R Taqman qRT-PCR.  
 
3.6. CCK-2R gene expression in a cell-line panel using 
LATE-PCR 
LATE-PCR was used to investigate CCK-2R mRNA expression in the 
panel of cell-lines tested above (Section 3.2), plus additions, to 
determine whether this more sensitive method enabled detection of 
CCK-2R in cell-lines which were negative by the Taqman assay, but in 
which biological assays had suggested that the receptor was expressed 
[13, 74, 138, 139]. 
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a) 
 
b) 
 
Figure 3.8: Logarithmic graph showing the relative expression of CCK-2R (2-ǻCt) in a 
panel of cell-lines, using LATE-PCR 
A range of cancer types are represented on separate graphs; a) endogenous 
expression and b) stably-transfected cell-line results. Each cell-line was assayed in 
triplicate using cDNA from 2 different passages of the cell-line, representing 
independent replicates and the black bars represent the SEM (one-way ANOVA 
showed none of the bars in each graph to be significantly different to any other). 
 
Figure 3.8 illustrates the results of the LATE-PCR assay on a cancer 
cell-line panel. Most of the cell-lines tested did express CCK-2R; 
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however the level of that expression varies dramatically, shown by the 
log scale of the graphs. Each cancer group, e.g. colorectal, does not 
contain enough samples to show a trend, however, there are some 
individual cell-lines which contain a high endogenous level of CCK-2R, 
for example H209 (SCLC). This cell-line correlates to the high 
expression shown in the Taqman assay, above, as do the other cell-
lines tested in both assays (p<0.001; Figure 3.9). 
R2 = 0.93, Slope = 0.63 ± 0.07 
 
Figure 3.9: Linear correlations performed on the CCK-2R expression data obtained using 
Taqman qRT-PCR and LATE-PCR 
The R2 value and slope are described above the graph, and the error bars represent 
the SEM of the data sets. 
 
The colorectal cell-lines in Figure 3.8 show consistently high CCK-2R 
expression, whereas the gastric cell-lines are the lowest in terms of 
expression. The lung, pancreatic, oesophageal, melanoma, breast and 
ovarian cell-lines all show fairly similar levels of CCK-2R expression (2-
ǻCt
 at ~10-4). The exception to this is H209 cells with 100-fold higher 
expression, the second highest level in the cell-line panel tested, but 
this was expected since they have been previously shown to express 
CCK-2R by our and other groups [159]. Also the glioma cells show 
considerable variation, from no expression in BT4 cells to ~10-4 in U251 
cells.  
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A panel of stably-transfected cell-lines was also tested in LATE-PCR 
and shown in Figure 3.8b. The transfected AGS cell-lines showed far 
more gene expression than the vector controls shown in Figure 3.8a 
(1x107-fold, p<0.0001), and the OE33-CCK-2R cell-line had 100 times 
more activity than the wild-type OE33 cells in Figure 3.8a (p<0.01). 
Vector control mouse NIH3T3 cells had no expression of human CCK-
2R as anticipated, but the transfected NIH3T3 cell-line showed high 
expression (Figure 3.8). 
 
Each cell-line was tested four times (two pellets from two passages 
being the closest to independent replicates possible), and each cell-line 
shows no significant difference between these replicates by the one-
way ANOVA statistical test.  
 
While testing these cell-lines, gDNA contamination sometimes became 
a problem in LATE-PCR, especially in cell-lines where CCK-2R 
expression was low. In order to combat this, a special cDNA synthesis 
kit was used for reverse transcription, the Qiagen QuantiTect Reverse 
Transcription kit. This kit includes a step to remove gDNA before 
starting the cDNA synthesis reaction. Also the LATE-PCR conditions 
were changed slightly, eliminating the extension and detection step 
from the first ten cycles, in order that any gDNA still present would not 
be amplified.  
 
3.7. CCK-2R expression in primary tumour samples 
CCK-2R gene expression has been demonstrated in many human 
cancer cell-lines, but in order to confirm the value of LATE-PCR, it was 
also tested on primary tumour samples. A number of primary tumour 
and adjacent normal samples were obtained and used under ethical 
approval from Nottingham Research Ethics Committee, Reference 
08/H0403/37. These samples were biopsies taken by surgeons at 
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Nottingham University Hospitals. The normal tissue; colonic epithelium, 
liver epithelium or lung parenchyma, was taken from at least 50mm 
away from the tumour site and any large blood vessels were removed 
before processing. Solid tumour and normal sample RNA was extracted 
by Dr Richard Argent and Mr Alexander Reece-Smith, who also 
performed cDNA synthesis.  In the current project these cDNA samples 
were analysed by LATE-PCR for CCK-2R expression. The purpose of 
this study was to validate LATE-PCR in primary samples and to 
correlate gene expression between  
 normal and tumour tissue 
 primary tumour site and corresponding metastasis 
 whole tumour tissue and cancer-associated fibroblast cells. 
 
a) b) 
 
 
Figure 3.10: CCK-2R gene expression in tumour samples 
Logarithmic dot plot showing the expression of CCK-2R (2-ǻCt) in a) normal and tumour 
tissue of the colon primary, liver metastasis from colon and lung primary, and b) with 
colon and liver fibroblasts (fibs) selected for from the samples and tested separately. 
The black line represents the median for each subset (** indicates p<0.01). 
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Samples Number of 
samples 
Proportion of 
positive values 
Proportion of 
positive values 
Colorectal 15 46.7% 
36.0% 
Primary tumour (colo) 13 38.5% 
Liver 30 16.7% 
Liver met from colo 25 40.0% 
Lung 14 14.3% 
Lung primary 14 71.4% 
Colorectal fibs 3 0.0% 
22.0% Primary fibs 3 33.3% Liver fibs 14 7.1% 
Liver met fibs 12 41.7% 
Table 3.3: Number of sample and the proportion of positive values in each of the sample 
groups displayed in Figure 3.10 
 
Figure 3.10 shows the CCK-2R gene expression levels in normal tissue 
and tumour tissue (mixture of epithelial and fibroblast cells) of the colon, 
liver and lung (a), and also in the fibroblast complement of the colon 
and liver (b). The samples below the dotted line in both graphs in Figure 
3.10 represent the negative samples, where CCK-2R expression is 
below the detection of the LATE-PCR assay. This was determined from 
the sensitivity cut-off points described in section 3.8 above, at around 
1x106. The total number of samples tested is shown in Table 3.3, giving 
an indication of the number of negative values shown on each graph in 
Figure 3.10. The proportion of positive expression values in the whole 
tumour tissue data is 36% (Table 3.3), which is around average for the 
individual data sets, except the lung primary tumour where 71.4% of the 
samples were positive for CCK-2R. 
 
Using the one-way ANOVA the lung primary tumour sample shows 
significantly higher (100-fold) CCK-2R expression to that of the normal 
lung. The other pairs were shown to be statistically similar. The 
fibroblast samples were also shown to be similar to that of whole tissue, 
although there are not enough samples in these groups to perform a 
proper calculation. Gastrin gene expression was investigated in the 
same samples (Figure 3.11), in order to perform a correlation. 
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3.7.1. Gastrin expression  
The one-way ANOVA test shows significantly higher gastrin gene 
expression in the normal and metastatic liver tissue compared to the 
equivalent colorectal samples in Figure 3.11. The difference between 
the gastrin expression in colorectal primary and liver metastasis tissues 
is negated by the fact that the normal liver shows higher expression 
than the colon. None of the other samples were statistically different 
from each other. The number of samples in each group in Figure 3.11 is 
shown in Table 3.3, since they are the same samples as those used for 
Figure 3.10. 
a) b) 
 
 
Figure 3.11: Gastrin gene expression in tumour samples 
Logarithmic dot plot showing the expression of gastrin (2-ǻCt) in a) normal and tumour 
tissue of the colon primary, liver metastasis from colon and lung primary, and b) with 
colon and liver fibroblasts (fibs) selected for from the samples and tested separately. 
The black line represents the median for each subset (**indicates p<0.005). 
 
3.7.2. The correlation between CCK-2R and gastrin 
expression  
Linear regression analysis carried out in GraphPad Prism showed a 
positive correlation between CCK-2R and gastrin expression in the 
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primary colorectal tumour by linear regression analysis (p<0.0001; 
Figure 3.12). The normal colorectal scatter graph is shown as an 
example of non-correlated data (p=0.50), and the liver and lung 
samples were not shown since these also lacked correlation. 
 a) R2 =0.04, Slope = -0.41 ± 0.58  b) R2 = 0.99, Slope = 5.91 ± 0.14 
 
 
Figure 3.12: Correlation between CCK-2R and gastrin expression in tumour samples 
Scatter plots showing the linear regression lines between CCK-2R and gastrin gene 
expression in the tumour samples; a) normal colorectal, b) primary colorectal tumour. 
The R2 value and slope are described above the graph, showing that the correlation is 
significant in b) (p<0.0001). 
 
The normal colorectal samples showed no correlation, which is 
interesting in itself, since tumourigenesis presumably causes the 
relationship between CCK-2R and gastrin gene expression to develop. 
Grade of tumour (data available for colorectal and liver), age/gender of 
the patient (all samples) and smoker status (lung alone) data was 
converted to a number rank in order to correlate it with CCK-2R gene 
expression. An example of this conversion can be demonstrated using 
grade of tumour where grade A = 1; grade B = 2; grade C1 = 3 etc. 
These calculations, however, produced no correlations. None of the 
patients had been treated with chemotherapy for their cancer, so a 
correlation with drug use could not be investigated. 
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3.8. Validation of LATE-PCR using siRNA molecules 
directed towards the CCK-2R 
In order to validate LATE-PCR as a method of detecting the CCK-2R, 
the receptor was knocked-down in several cell-lines using siRNA. If 
LATE-PCR could show that the CCK-2R had been down-regulated in 
these cell-lines then it would not only demonstrate its specificity for 
CCK-2R but also that LATE-PCR is sensitive enough to detect a 
change in the, already low, CCK-2R expression shown in some cells. 
 
3.8.1. siRNA design 
RNA interference was employed in order to study the effects of 
knocking down the CCK-2R. siRNAs were designed to target different 
regions of the receptor, using a number of algorithms available on the 
internet (Dharmacon [165], Genscript [166] and siSEARCH). Each 
yielded a list of potential siRNAs, in order of worth according to the 
conditions stipulated by the algorithm; for example if a siRNA needed 
sense strand modification to reduce sense strand uptake this would be 
ranked lower by the Dharmacon algorithm (Table 3.4). For the CCK-2R, 
a list of possible siRNAs was obtained using each of these algorithms 
(Table 3.4), and then compared to each other. Only Dharmacon and 
Genscript produced consistent sequences so these were used and the 
siSEARCH siRNAs do not appear in Table 3.4, which lists the siRNA 
sequences and features. 
 
The human CCK-5 JHQH LV ES ORQJ DQG WKH H[WUHPH ¶ DQG ¶
ends of the sequence were avoided due to lack of conserved residues 
and the risk of polymorphisms being present [165]. Four siRNAs were 
chosen, to target sequences around 300bp apart along the gene (Table 
3.4; CCK1, 2, 3 & 4).  
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siRNA 
sequence 
Dharmacon 
(score) 
Low 
seed 
freq? 
Need 
sense 
mod? 
Genscript 
(score) 
Start 
position 
G/C 
content 
Name 
of 
siRNA 
GAGAATTGGA
GCTGGCCAT 
Yes (2nd) No No Yes (1st) 342 53% CCK1 
GATGAGCGTT
GGAGGAAAT 
Yes (1st) No No Yes (2nd) 391 47%  
GCTTCGCTGT
CCAGGCTTA 
Yes (22nd) No No Yes (3rd) 1484 58%  
AGTGACAGCG
ACAGCCAAA 
Yes (16th) No No Yes (6th) 956 53% CCK2 
TGCGAATGTT
GCTGGTGAT 
Yes (50th) No No Yes (7th) 1188 47%  
TCATTCACTTG
CTGAGCTA 
Yes (17th) No No Yes (8th) 1314 42% CCK3 
CCATCGCACT
GGAGCGGTA 
Yes (3rd) Yes No No 633 63% CCK4 
Table 3.4: Table showing the comparison of siRNA sequences from the algorithms of 
Dharmacon and Genscript. 
The last column indicates those siRNAs ordered and tested by transfection into AGS-
CCK-2R cells. 
 
3.8.2. siRNA transfection efficiency 
In order to investigate knock-down of the receptor, these siRNAs were 
transfected into those cells showing expression of the CCK-2R in the 
LATE-PCR assay. Before transfecting the cells with the CCK-2R 
siRNAs, the transfection efficiency was examined using a fluorescent 
TAMRA-labelled siRNA. The cells were visualised under a fluorescent 
microscope, with a blue nuclear stain, Hoechst. Where the siRNA had 
entered the cells, it was revealed as red fluorescence. By measuring 
the percentage of nuclei with associated siRNA, the transfection 
efficiency was determined in AGS-CCK-2R, HCT116 and H209 cells 
(Figure 3.13) and in the other cells to be transfected (not shown). The 
AGS-CCK-2R and HCT116 cells were transfected using the standard 
siPORT Amine protocol, whereas the H209 cells were reverse 
transfected using the same transfection agent because these cells grow 
in suspension; however, it seems to be as effective as the standard 
protocol for the other cell-lines. The distribution of the siRNA between 
cells is similar in HCT116 and AGS-CCK-2R populations, whereas in 
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H209 cells it appears that some cells have more siRNA within them: the 
red fluorescence is brighter around their nuclei (white arrow in Figure 
3.13). 
a) AGS-CCK-2R cells b) HCT116 cells c) H209 cells  
   
Figure 3.13: TAMRA-siRNA transfected cells 
a) AGS-CCK-2R cells, b) HCT116 cells, c) H209 cells, all transfected with a 
fluorescent TAMRA-labelled siRNA. The siRNA is red, and the nuclei have been 
stained blue with Hoechst. The first two cell-lines were transfected using the standard 
protocol, whereas the H209 cells were reverse transfected as they grow in 
suspension. The white arrow indicates a H209 cell with more siRNA within it than the 
average. 
 
Figure 3.13 illustrates that the transfection efficiency was around 90% in 
the three cell-lines shown above and this was the case in the other cell-
lines tested, except for SW620 cells where it was around 50%. It was 
assumed that the CCK-2R targeted siRNAs would enter the same 
percentage of cells as the TAMRA-labelled siRNA. 
 
3.9. Knockdown of the CCK-2R in AGS-CCK-2R cells 
The aim of developing CCK-2R-targeted siRNAs was to reduce 
receptor expression, to validate the LATE-PCR assay and understand 
what effects knock-down has on the cell. Four CCK-2R siRNAs were 
made in-house by annealing sense and antisense RNA 
oligonucleotides. These were transfected into AGS-CCK-2R cells, along 
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with a negative siRNA, and analysed by Taqman qRT-PCR, since 
receptor expression in these cells should be high enough to be detected 
by this assay. LATE-PCR was used if the Taqman assay became 
inadequate. The negative siRNA should not have targeted any genes, 
and so should control for any change which is due to the transfection 
reagent, siPORT Amine, or non-specific effects of siRNA. Three of the 
CCK-2R siRNAs produced significant knock-down, compared to the 
negative control. CCK1 was the most successful siRNA, reducing 
expression of CCK-2R to 32% (p<0.05) of that in the scrambled siRNA-
transfected control, whereas the others only resulted in reduction to 40 
and 65% of the control expression (Figure 3.14). 
Figure 3.14: Percentage 
expression of the CCK-2R in 
AGS-CCK-2R cells when 
transfected with in-house 
siRNAs designed to target the 
receptor 
The method of detection of the 
CCK-2R is Taqman qRT-PCR, 
and the results are an average 
of three repeats. The siRNAs 
CCK1 and 4 are most effective 
at down-regulation; all three 
CCK-2R siRNAs cause 
significant knockdown (* indic-
ates p<0.05) compared with the 
negative control siRNA. The 
black bars represent the stan-
dard error of the mean (SEM). 
 
CCK4 was also able to produce satisfactory knock-down to 36% of the 
control (Figure 3.14; p<0.05). One of the final two CCK-2R siRNAs did 
produce significant down-regulation (CCK3: 46% of control; p<0.05) but 
was not investigated further, due to having less activity than CCK1 and 
4. 
 
Since siRNAs made in-house from oligonucleotides are usually found to 
be less effective than those purchased commercially, the two most 
efficient siRNAs were ordered for further studies. CCK1 and CCK4 were 
commercially synthesised as CCK tg1 and CCK tg4, respectively, and 
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these were once more transfected into AGS-CCK-2R cells. Figure 3.15 
shows that both commercially-made siRNAs are more effective at 
down-regulating the CCK-2R compared to the corresponding in-house 
siRNA.  
Figure 3.15: Percentage 
expression of the CCK-2R in 
AGS-CCK-2R cells when 
transfected with commercial 
siRNAs targeting the receptor 
The method of detection of the 
CCK-2R is Taqman qRT-PCR, 
and the results are an average 
of three repeats with the black 
bars representing the SEM. 
Both siRNAs cause significant 
knockdown (** indicates 
p<0.005).  
 
 
The commercially-made siRNAs reduced CCK-2R expression to 17% 
(CCK tg4; p<0.005) and 25% (CCK tg1; p<0.005) of control siRNA-
transfected cells. This is an improvement on the result in Figure 3.14, 
where the equivalent in-house siRNAs caused 36% and 32% 
expression respectively. Since these siRNAs are obviously causing 
down-regulation of the CCK-2R mRNA in a stably transfected cell-line, 
they were then tested in cells showing endogenous receptor 
expression. 
 
3.9.1. Knock-down of the CCK-2R in other cells 
The two commercial CCK-2R siRNAs were initially transfected into the 
SCLC cell-line, H209, since these cells have been shown to express the 
highest level of endogenous CCK-2R in the cell-line panel screened. 
H209 cells also demonstrated excellent transfection efficiency (Figure 
3.13) in this experiment, despite the reverse transfection method 
necessary for these suspension cells, and so the samples were tested 
by LATE-PCR for knock-down of the CCK-2R (Figure 3.16). 
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Figure 3.16: Percentage 
expression of the CCK-2R in H209 
cells when transfected with 
commercial (CCK tg1 & 4) and in-
house (CCK4) siRNAs 
The method of detection of the 
CCK-2R is LATE-PCR, and the 
results are an average of three 
repeats with the black bars 
representing the SEM.  The 
commercial siRNAs are most 
effective at down-regulation (* 
indicates p<0.05). 
 
 
These results confirm that the CCK-2R siRNAs result in knock-down of 
the receptor in H209 cells, with both commercial siRNAs reducing 
expression to 15% of control expression (p<0.05). This is similar to that 
seen in AGS-CCK-2R cells (Figure 3.15) above. Figure 3.16 shows that 
no significant knockdown was achieved when the CCK4 siRNA made 
in-house was used. 
 
The same cDNA samples were tested using the Taqman assay, but the 
results were inadequate. The fact that LATE-PCR could detect siRNA 
activity, with similar trends to those shown in AGS-CCK-2R cells, i.e. 
the commercial siRNAs produce more down-regulation than the in-
house versions, is further proof that this new assay is far more 
sensitive.  
 
Since the LATE-PCR could detect CCK-2R expression in siRNA-
transfected cells with high endogenous expression, this method was 
tested in a panel of cell-lines. This panel was chosen as a subset of that 
above, using a high, medium and low-expressing cell-line within the 
colorectal, glioma and lung cancer cell-lines. Colorectal cell-lines 
showed mixed results (Figure 3.17a), with good knock-down by both 
commercial siRNAs in HCT116 and HT29, but no down-regulation in 
H209 cells
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Colorectal cancer cell-lines
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SW620 cells. Figure 3.8a indicates that the CCK-2R expression levels 
in each of these cell-lines are similar. Transfection efficiency was found 
to be reduced (~50%) in SW620 cells; however this does not account 
for the total lack of knock-down seen in these cells. HCT116 and HT29 
CCK-2R expression could be knocked down to at least 11% and 22% of 
the control, respectively (p<0.005). 
a) 
 
b) 
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Lung cancer cell-lines
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Figure 3.17: Percentage expression of the CCK-2R in cancer cell-lines when transfected 
with commercial siRNAs made to target the receptor 
The graphs show a) colorectal, b) glioma and c) lung cell-lines. The method of 
detection of the CCK-2R is LATE-PCR, and the results are an average of three 
repeats with the black bars representing the SEM (* indicates p<0.05, ** indicates 
p<0.005). 
 
Two CCK-2R-expressing glioblastoma cell-lines, U251 and U373, were 
also selected (Figure 3.17b). U373 cells showed good knock-down with 
the CCK-2R siRNAs especially CCK tg1, which caused expression to 
drop to 11% of the control level (p<0.005). In U251 cells CCK tg4 
allowed only 11% of normal CCK-2R expression, and CCK tg1 
knocked-down expression to 13% (p<0.005).  
 
The third set of cells in the panel was the lung cell-lines, of which H209 
is shown in Figure 3.16. Both CCK-2R siRNAs cause significant down-
regulation of the receptor in A549 and HOP-62 cells; which show 3% 
and 5% (CCK tg 4) and 3% and 32% (CCK tg 1) expression 
respectively, all with p<0.05 (Figure 3.17c). As well as being a method 
of validation for LATE-PCR, these siRNA molecules were designed to 
investigate the functional effect of knocking down the CCK-2R.  
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3.10. The effect of CCK-2R knock-down on expression of 
other genes 
Gastrin and CD133 gene expression were investigated in five of the 
cell-lines shown in Section 3.17 above, which had been transiently 
transfected with CCK-2R siRNA (CCK tg1) for 24 hours. Gastrin and the 
CCK-2R are linked in an autocrine loop [137], suggesting that if one is 
knocked down, the other will be affected, however, this does not seem 
to be the case here. CD133 expression may have been influenced by 
CCK-2R knock-down if it was affecting cancer stem cell differentiation.  
Figure 3.18: The effect 
of knocking down CCK-
2R on gastrin and 
CD133 gene expression 
The results are the 
mean of two 
experiments, and the 
error bars show the 
SEM. 
 
 
 
 
 
CCK-2R knock-down does not seem to affect gastrin or CD133 gene 
expression significantly (Figure 3.18). 
 
3.11. CCK-2R expression at the single cell level 
CCK-2R is up-regulated in cancer cells, and in order to see where it is 
expressed in these cells an experiment was designed to show the 
expression in real time. The expression of CCK-2R mRNA could be 
evenly distributed throughout the cell population, or it could be restricted 
to certain cells. This question might be answered by transfecting the 
fluorescent molecular probes designed for LATE-PCR directly into cells, 
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and visualising them with microscopy and apparatus such as the 
Flexstation, since they would fluoresce when bound to mRNA.  
 
Initially the HPRT LATE-PCR probe was used, since expression of 
HPRT would be more widespread than that of CCK-2R. 400nmol of 
probe was added to each well for all the probe transfections described. 
The first results are shown in Figure 3.19, where the HPRT probe can 
be seen inside a few of the cells (~20%). 
 
Figure 3.19: Fluorescent photograph of HCT116 cells transfected with a HPRT LATE-PCR 
molecular probe 
The transfection reagent is siPORT Amine, the nuclei are stained with DAPI (blue) and 
the probe shows as green fluorescence due to its fluorophore. 
 
In the second experiment all four LATE-PCR probes (low and high Tm, 
HPRT and CCK-2R) were transfected into HCT116 cells, and all four 
showed significantly more fluorescence than the control with no probe 
when siPORT Amine was used as the transfection reagent (Figure 
3.20). 
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Figure 3.20: HCT116 cells 
transfected with four 
molecular probes 
The transfection agents 
used were Lipofectamine 
and siPORT Amine, and 
each of the four LATE-
PCR probes were 
transfected separately 
into HCT116 cells. The 
data was generated by 
the Flexstation and 
normalised to the no 
probe control sample 
(value of 1), the error 
bars represent the SEM 
(* indicates p<0.05, ** 
indicates p<0.01, *** 
indicates p<0.005 
compared to equivalent 
no probe control).  
 
Since the siPORT Amine transfection showed the most promise, 
fluorescence was also assessed using the more sensitive Spectrum 
machine (Figure 3.21). This confirmed that the best result was gained 
using the high Tm CCK-2R LATE-PCR probe (not the low Tm probe, 
which was the best one for LATE-PCR). 
Figure 3.21: Spectrum 
data for HCT116 cells 
transfected with 
molecular probes 
The transfection 
agent used was 
siPORT Amine, and 
each of the four 
LATE-PCR probes 
were transfected 
separately into 
HCT116 cells. The 
data was generated 
by the Spectrum, the 
error bars represent 
the SEM (*** indicates 
p<0.005 compared to 
the no probe control).  
 
The fact that CCK-2R was being detected more readily than HPRT was 
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another housekeeping gene target, GAPDH, and also a new 
fluorophore, Dabcyl. The DDQ-GAPDH probe shown in Figure 3.22 has 
WKH µGHHSGDUNTXHQFKHU¶''4ZKLFKLVDWWDFKHGWRDOORI WKHRULJLQDO
LATE-PCR probes. 
a) b) 
  
Figure 3.22: The third molecular probe transfection 
The transfection agent used was siPORT Amine, and each of the seven molecular 
probes was transfected separately into a) HCT116 and b) PAN-1 cells. The data was 
generated by the Spectrum, the error bars represent the SEM (* indicates p<0.05, ** 
indicates p<0.01, *** indicates p<0.005 compared to the no probe control).  
 
Although the Dabcyl-GAPDH probe was successful in both cell-lines, it 
still did not surpass the CCK-2R probe in either (Figure 3.22). This 
method obviously needed further optimisation, possibly by modifying 
the probes or the transfection reagent, in order to deliver the probes 
inside the cell more efficiently.  
 
3.12. CCK-2R protein expression 
Endogenous protein levels of the CCK-2R were investigated in the 
colorectal, glioma and lung cell-lines, since this is when the CCK-2R 
facilitates cancer progression and these could be correlated with gene 
expression. In previous studies, CCK-2R protein was shown indirectly, 
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by use of inhibitors of gastrin stimulation [13, 74, 138, 139] but in this 
project it was decided to use a direct method of quantification. 
 
Live cell staining and flow cytometry were used to assess CCK-2R protein 
expression in the panel of cells. The CCK-2R antibody (Abcam ab14440) 
chosen for this work binds to the second external loop of the protein 
(residues 206-219 on Figure 1.7), allowing for live staining. A secondary 
antibody bound to Fluorescein (FITC) was used to visualise the staining in 
cytospins (green in Figure 3.23) and quantify expression in the samples by 
flow cytometry.  
a) HCT116 positive b) HCT116 negative 
c) BT4 d) HOP-62 
 
 
Figure 3.23: Cytospin pictures showing CCK-2R live-stained cells 
The cells were stained with a primary antibody to the second external loop of CCK-2R, 
and then a secondary antibody attached to FITC (green) unless stated. The cell nuclei 
were counter-stained with DAPI (blue);  a) HCT116, b) HCT116 secondary only, c) 
BT4 and d) HOP-62. 
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Both mouse and rabbit species-specific universal control antibodies were 
used initially to ensure that the primary antibodies were specific, however, 
the rabbit universal antibody was depleted during this time and a 
replacement could not be sourced, so the control for CCK-2R in these 
experiments was simply secondary antibody alone. The optimal controls 
for these experiments would be isotype-matched controls, since these 
would ensure that the control and primary antibodies bound to the same 
isotype as the primary antibody i.e. IgG. However, it is not necessary to 
use these in this experiment since, for example, the mouse universal 
control antibody binds to IgG1, the isotype of the CD133 antibody used. 
 
From the cytospin pictures in Figure 3.23, it would appear that the 
percentage of highly-stained cells is around 30% for HCT116, 35% for 
BT4 and 50% for HOP-62 cells. The negative control in Figure 3.23b 
shows no FITC expression at all, showing that the secondary antibody 
has bound only when the primary antibody was added; to the positive 
samples.  
 
Flow cytometry data was analysed in WinMDI, where a dot plot and 
histogram were drawn (Figure 3.24) and the statistics determined 
(Figure 3.25a & b). The dot plots shown in Figure 3.24ai & bi 
demonstrate forward light scatter (FS lin) against side light scatter 
(PMT1 lin), in order to get a representation of the physical properties of 
the cells.  
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a) i) Negative (secondary only) a) ii) 
  
b) i)  Positive (rabbit anti-CCK-2R) b) ii)  
  
Figure 3.24: Representing the data gained from flow cytometry 
The antibodies used were a) secondary only and b) rabbit anti-CCK-2R followed by 
secondary shown by i) dot plot of PMT1 Lin against FS Lin or ii) histogram of FITC 
expression. R1 indicates the gating used to remove dead cells from the histogram 
data. The statistics taken from the histogram; median of the whole population to show 
the shift between negative and positive, and the proportion of cells under marker 2 
(M2), which shows the highly positive cells. 
 
The R1 region was created to remove dead cells from the analysed 
population and this was used to gate the histograms in Figure 3.24aii & 
bii. The histograms were drawn to show the number of cells (events) 
displaying FITC fluorescence at increasing intensity across the x-axis. 
From the histogram, two statistics were obtained and used to generate 
the graphs in Figure 3.25; the median fluorescence of the whole 
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population, and the percentage of highly-positive cells; under marker 2 
(M2). 
 
In Figure 3.24aii & bii it was observed that the peak of the histogram 
(M1) shifts right from 101 to half-way between 101 and 102. This 
indicates that the majority of cells express the CCK-2R (CCK-2Rlo). In 
addition, there is a discrete second population of cells (CCK-2Rhi), with 
fluorescence 10-fold higher than that of the majority of cells (Figure 
3.24bii).  
 
The data was normalised using the negative control (secondary 
antibody only) values. The median FITC fluorescence (Figure 3.25a) 
shows the relative levels of protein expressed by the whole population 
of cells, which varied extensively between experiments (large error 
bars). The percentage of highly-positive cells shown in Figure 3.25b, 
however, was more reproducible and demonstrates that glioma and 
lung cells have a higher proportion of CCK-2Rhi cells than colorectal 
cells. 
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b) 
 
c) 
 
d) Med:             R2 = 0.02, Slope = 24390 ± 84288 
    % CCK-2Rhi :R2 = 0.08, Slope = -24235 ± 38020 
 
Figure 3.25: CCK-2R protein and gene expression in seven cell-lines 
Colorectal cell-lines are shown in red, glioma in green and lung in blue. Protein 
expression was measured using flow cytometry; a) median FITC fluorescence and b) 
percentage highly-positive cells (the black bars represent the SEM of three 
experiments). Gene expression is shown again (from Figure 3.8) in c) but on a linear 
scale, and d) illustrates the linear regression line between both measures of protein 
expression and gene (not significant; p>0.5).  
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Figure 3.25c illustrates the gene expression data shown in a logarithmic 
graph in Figure 3.8, on a linear scale, in order to compare it to the 
protein expression data. The linear regression lines between both 
protein measurements and the gene levels are not significant (Figure 
3.25d). 
 
3.13. Summary 
 The LATE-PCR assay is 10,000-fold more sensitive than the 
CCK-2R Taqman qRT-PCR. 
 Use of LATE-PCR demonstrates that CCK-2R mRNA is present 
in many cancer cell-lines, where previously only protein 
expression had been detected.  
 LATE-PCR has also shown CCK-2R gene expression to be 
present in cancer cells where it has not been found before, such 
as NSCLC and glioblastoma cell-lines. 
 36% of the primary tumour, and their equivalent normal, tissues 
demonstrated CCK-2R gene expression. 
 Lung tumour samples showed significantly higher expression of 
CCK-2R than the lung normal tissue.  
 There was a correlation between CCK-2R and gastrin gene 
expression in primary colorectal tumour, normal liver and liver 
metastatic tumour tissue. 
 CCK-2R siRNA molecules have been used to verify the 
specificity of LATE-PCR. 
 CCK-2R knock-down in cells did not have an effect on gastrin or 
CD133 gene expression.  
 Molecular probe transfection into cancer cell-lines needs to be 
optimised but showed initial promise, when the probe could be 
seen inside HCT116 cells. 
 A discrete population of highly CCK-2R-positive cells was 
present in each cell-line. 
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 CCK-2R gene expression could not be correlated with protein 
expression, whether this was defined as the average CCK-2R 
protein expression per cell or the percentage of CCK-2R highly-
positive cells in the population, suggesting there may be 
translational regulation of this gene.   
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Chapter 4 The regulation of 
CCK-2R expression 
                                             The regulation of CCK-2R expression                        
    
122 
 
4.1. The effect of microenvironment on CCK-2R 
expression 
The mass of cells making up a tumour form a microenvironment where 
the conditions are different to that in normal tissues.  The fact that many 
cells are packed together, causes hypoxia and nutrient deficiency 
because, although angiogenesis is encouraged within the tumour, the 
blood supply cannot be as efficient as it would be in the normal situation 
[167]. Cellular stress is a hallmark of cancer, and the hypothesis was 
that CCK-2R is up-regulated in these conditions. For example, Ashurst 
et al. found that nutrient-deprived cells showed an increase in CCK-2R 
expression [114].  
 
Initially this chapter will investigate the effect of stress on the regulation 
of CCK-2R expression, and then in the second half transcriptional 
regulation by the CCK-2R promoter will be explored. 
 
4.1.1. Serum-starvation 
The first cell stress condition investigated was nutrient deficiency. The 
cells were plated in serum-containing medium but once settled this was 
exchanged for serum-free medium and the cells incubated for 24 hours.  
Figure 4.1: Fold change in CCK-2R 
expression in serum-starvation 
 None of the colorectal or glioma 
cell-lines showed a significant 
difference between serum and 
serum-free conditions. 
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Figure 4.1 shows that no significant difference was seen between the 
two conditions, although HCT116 cells show a trend towards up-
regulation of the CCK-2R gene in serum-starvation. 
 
4.1.2. Hypoxia 
The cell-lines were also subjected to a hypoxic (1% oxygen) 
environment for 24 hours, however, this also failed to produce a 
significant change in CCK-2R gene expression (Figure 4.2). Again 
HCT116 cells showed a trend towards up-regulation of CCK-2R gene 
expression.  
Figure 4.2: Fold change in CCK-2R 
expression in hypoxia 
None of the colorectal or glioma 
cell-lines showed a significant 
difference between normoxic and 
hypoxic conditions. 
 
 
 
 
 
In preliminary experiments VEGF gene expression measured by qRT-
PCR and HIF-1Į protein expression measured by western blotting were 
used as verification of hypoxic stress in HCT116 cells (Figure 4.3). 
Since VEGF is 3-fold higher, and HIF-1Į only present in hypoxia the 
cells must be stressed, therefore this is not the reason behind the lack 
of significant up-regulation in Figure 4.2.   
 
 
 
CCK-2R expression in hypoxia
HCT116 HT29 HCTcis U251 U373
0
1
2
3
4
5
Colorectal    Glioma
Cell-line
Fo
ld
 
ch
an
ge
                                             The regulation of CCK-2R expression                        
    
124 
 
 
Figure 4.3: VEGF and HIF-1Į expression in HCT116 cells in hypoxia 
a) qRT-PCR VEGF expression increases 3-fold in hypoxia compared to normoxia and 
b) shows a western blot for HIF-1Į and actin for 2 hypoxic (H) and 2 normoxic (N) 
samples. M ± marker. 
 
4.1.3. Cytotoxic drug treatment 
A cisplatin-resistant strain of HCT116 was developed, in order to 
discover whether this process would up-regulate endogenous CCK-2R 
expression, since the process would cause stress to the cells. To create 
these drug-resistant cells, wt HCT116 cells were grown in normal 
medium plus 0.01µg/ml cisplatin for three passages. The cisplatin 
concentration was doubled every three passages, assuming that the 
cells grew at a suitable speed and had not shown too much cell death. 
If this happened the cisplatin concentration was dropped or removed 
completely, to allow the cells to recover before starting to increase the 
concentration again. The cells were considered cisplatin-resistant when 
they had grown in medium containing 1mg/ml cisplatin for three 
passages. 
 
To characterise these drug-resistant cells, an assessment of cisplatin 
IC50 was carried out. This was compared to that of wild-type HCT116 in 
order to discover whether the IC50 had increased. Figure 4.4 shows that 
the IC50 for both cell-lines was not significantly different. The cisplatin-
resistant cells did incline towards a higher IC50, but the SEM was very 
a) b) 
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large, showing the large difference between the results of the replicate 
experiments. 
Figure 4.4: The IC50 for cisplatin is 
measured for wild-type and cisplatin-
resistant HCT116 cells  
The method used is the MTT assay, 
and the result is an average of three 
repeats, with black bars representing 
the SEM. 
 
 
 
 
 
 
The two cell-lines, wild-type and cisplatin-resistant HCT116, were then 
tested in LATE-PCR for CCK-2R expression.  
Figure 4.5: Fold change CCK-2R 
expression in HCT116 cells; wild 
type and cisplatin-resistant 
The method of detection of the 
CCK-2R is LATE-PCR, and the 
results are an average of four 
repeats with the black bars 
representing the SEM (* 
indicates p<0.05).  
  
 
 
 
 
 
Figure 4.5 shows that CCK-2R was up-regulated in the cisplatin-
resistant HCT116 cell-line, by almost three-fold (p<0.05). Gastrin gene 
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expression was also investigated in these two cell-lines but did not 
show a significant difference between them (Figure 4.6). 
Figure 4.6: Fold change gastrin 
expression in HCT116 cells; wild 
type and cisplatin-resistant 
The method of detection of 
gastrin is Sybr Green qRT-
PCR, and the results are an 
average of at least three 
repeats with the black bars 
representing the SEM. 
 
 
 
 
 
The CCK-2R expression shown in the drug resistant HCT116 cells can 
be knocked down by siRNA transfection; both CCK-2R siRNA had a 
significant effect on expression levels (CCK tg1 reduced the level to 
5.3% and CCK tg4 to 23.1% of usual expression (p<0.01); Figure 4.7). 
Figure 4.7: Percentage 
expression of the CCK-2R in the 
cisplatin-resistant HCT116 cell-
line when transfected CCK-2R 
siRNA 
The method of detection of the 
CCK-2R is LATE-PCR, and the 
results are an average of two 
repeats with the black bars 
representing the SEM (** 
indicates p<0.01).  
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However, this siRNA knock-down does not affect cisplatin IC50 in either 
HCT116 cell-line (Figure 4.8), indicating that despite CCK-2R being up-
regulated, it was not involved in the mechanism of drug-resistance. 
 
Figure 4.8: The IC50 for cisplatin is measured for wild-type and cisplatin-resistant HCT116 
cells transfected with a CCK-2R siRNA 
The method used is the MTT assay, and the result is an average of three repeats, with 
black bars representing the SEM. 
 
4.2. Studies with the CCK-2R putative promoter 
There is very little information in the literature on the regulation of the 
CCK-2R. In many cell-lines CCK-2R gene expression is low, while a 
number of biological effects of gastrin, via the CCK-2R, have been 
documented [13, 72, 74, 138, 139]. This could be due to regulation of 
the CCK-2R, or an indirect cause. In the only paper on the CCK-2R 
promoter, Ashurst & colleagues found that serum-starvation increased 
promoter activity in their large CCK-2R constructs [114]. We have also 
investigated the activity of the CCK-2R promoter, using reporter assays 
as we postulate that the low gene expression may be due to 
transcriptional regulation. 
 
Initially plasmids were produced containing the putative CCK-2R 
promoter. Primers were designed to amplify 5kb of DNA upstream of 
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the CCK-2R start codon (named F and R), and classical PCR was used 
to amplify this fragment using H209 gDNA as a template. Unfortunately 
this did not produce any amplified DNA, so new primers were created to 
amplify sections 1, 2 and 3kb upstream from the start codon (Figure 
4.9).  
   Lane  Primer pair    Expected product     
           size (bp)  
1 Marker (2log)   -  
2 F1+R              ~1000 
3 F2+R              ~2000 
4 F3+R              ~3000 
5 F1+R1           ~1000 
6 F2+R2            ~2000 
7 F4+R3            ~3000 
 
 
 
Figure 4.9: Agarose gel showing classical PCR products for each of the primer pairs 
The PCR was run with Q solution. 
 
The six PCR products (the four largest fragments are shown in Figure 
4.9) were cloned into separate pCR®II-TOPO® plasmids, transformed 
and digested with NcoI and XmaI to determine their orientation (Figure 
2.1). All six were then digested out of TOPO with XhoI and SacI (or 
HindIII if in the opposite orientation), and ligated into pGL4, which had 
been cut with the same restriction endonucleases (Figure 2.1). These 
constructs form a library of CCK-2R promoter fragments (Figure 4.10), 
ranging from 250-2000bp in size, including some deletion mutants 
which do not contain the first ~250bp of promoter sequence. 
 
The pGL4 promoter constructs were given names to reflect the amount 
of the promoter present in each one. The largest construct was named 
CCK2R-2070, since it contained 2070bp of the sequence before the 
CCK-2R start codon (Figure 4.10). The second construct is labelled 
CCK2R-2070ǻ287, because it contains the same DNA as the first one 
with 287bp of DNA proximal to the CCK-2R gene deleted. The rest are 
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named similarly, and contain increasingly shorter sections of the CCK-
2R promoter. 
 
 
 
 
 
 
 
 
 
Figure 4.10: Diagram showing the relationship between the CCK-2R promoter constructs 
made during this project 
 
4.2.1. Sequencing the CCK-2R promoter constructs 
All six of the promoter constructs were sequenced, and had at least 
97% homology to the start of the CCK-2R Ensembl [168] sequence. 
The differences between the sequences (highlighted in green in Figure 
A in the Appendix) are mainly restricted to just one construct, and are 
therefore possibly due to an artefact of the classical PCR. The large TC 
repeat section in particular shows several variations between the 
Ensembl sequence and that of the constructs, and this may be due to 
the inaccuracy of the sequencing reaction in those areas where there 
are large stretches of CT or CG repeats.  
 
4.2.2. Results with the CCK-2R promoter constructs 
All six CCK-2R promoter constructs were transfected into a panel of 
cancer cell-lines, along with pGL4 as a negative control, to compare the 
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activity of the promoter in these cells, using luciferase expression as a 
UHDGRXW ȕ-galactosidase DNA was co-transfected simultaneously with 
each plasmid, in order to control for differences in transfection efficiency 
between wells.  The results for each construct were also normalised 
using the activity seen in the empty vector control, in order that fold 
change in promoter activity could be shown.  
 
Figure 4.11 shows the results in colorectal carcinoma cell-lines, 
HCT116, HT29 and SW620. These three cell-lines all showed 
significant promoter activity when transfected with the two smallest 
constructs, CCK2R-479 and CCK2R-250. However, this activity varied 
between cell-lines. HCT116 cells showed 46 times the amount of 
control activity with CCK2R-479 and a further ten-fold increase with 
CCK2R-250 (p<0.005). HT29 and SW620 cells showed similar activity 
with both these constructs; ~90 (p<0.005) and 60 (p<0.05) times the 
activity of the control, respectively. In addition to this, HCT116 and 
HT29 cells showed 21 and 33 (p<0.05) times control activity with the 
CCK2R-1057 construct. 
 
Both deletion constructs and the largest whole promoter construct, 
CCK2R-2070, showed no significant activity in all three cell-lines, 
leading to the conclusion that the proximal 500 bases are the most 
crucial to promoter activity. There may also be repressor elements 
upstream of this important point, causing the two larger constructs to 
have less activity than the two smallest ones. 
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c) 
 
Figure 4.11: CCK-2R promoter activity in 3 colorectal cell-lines 
a) HCT116, b) HT29 and c) SW620, measured using luciferase activity normalised by 
ȕ-galactosidase activity. The results are also normalised to the activity seen in the 
empty vector, pGL4 (shown on the graphs with a value of 1). Each bar shows an 
average of four experiments, with the black error bars representing the SEM (* 
indicates p<0.05, ** indicates p<0.005). 
 
Three glioma cell-lines were also transfected with the CCK-2R promoter 
constructs (Figure 4.12). BT4, U251 and U373 cells all showed 
significant promoter activity in the two smallest constructs; however 
these values vary considerably between cell-lines. BT4 and U251 
promoter activity was 20-30 times (p<0.05) the control, whereas U373 
activity was just 3 times (p<0.005) for both constructs. Interestingly 
CCK2R-1057, which was active in the colorectal lines, did not show 
significant activity in any glioma cell-line.  
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c) 
 
Figure 4.12: CCK-2R promoter activity in 3 glioma cell-lines 
a) BT4, b) U251 and c) U373 (note the lower y-axis maximum), measured using 
OXFLIHUDVH DFWLYLW\ QRUPDOLVHG E\ ȕ-galactosidase activity. The results are also 
normalised to the activity seen in the empty vector, pGL4 (shown on the graphs with a 
value of 1). Each bar shows an average of four experiments, with the black error bars 
representing the SEM (* indicates p<0.05, ** indicates p<0.005). 
 
Two lung cell-lines were tested and showed very different results; the 
A549 cells demonstrated the same pattern as the glioma and colorectal 
cells, with significant activity in the 1, 0.5 and 0.25kb constructs 
(p<0.05), whereas HOP-62 cells showed no activity at all when 
transfected with any of the promoter plasmids, compared to the empty 
vector (Figure 4.13).  
 
 
 
 
 
 
 
U373 cells
pG
L4
CC
K2
R
-2
07
0
28
7
CC
K2
R
-2
07
0
CC
K2
R
-1
05
7
26
0
CC
K2
R
-1
05
7
CC
K2
R
-4
79
CC
K2
R
-2
50
0
2
4
6
8
**
**
CCK-2R construct
Fo
ld
 
c
ha
n
ge
 
in
 
pr
o
m
o
te
r 
a
c
tiv
ity
                                             The regulation of CCK-2R expression                        
    
135 
 
a) 
 
b) 
 
Figure 4.13: CCK-2R promoter activity in 3 lung cell-lines 
a) A549 and b) HOP- PHDVXUHG XVLQJ OXFLIHUDVH DFWLYLW\ QRUPDOLVHG E\ ȕ-
galactosidase activity. The results are also normalised to the activity seen in the empty 
vector, pGL4 (shown on the graphs with a value of 1). Each bar shows an average of 
four experiments, with the black error bars representing the SEM (* indicates p<0.05, 
** indicates p<0.005). 
 
4.3. Correlation of CCK-2R promoter activity with gene 
expression  
CCK-2R gene expression varies considerably between cancer types 
and between cell-lines representing each cancer group. Figure 4.14 
shows the gene expression levels (previously seen on a logarithmic 
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graph in Section 3.6) of the panel of cell-lines selected for the promoter 
studies, compared to the activity seen with the smallest promoter 
construct. Gene expression is shown on a linear, rather than 
logarithmic, scale in Figure 4.14 due to the smaller range in expression 
across this smaller panel of cell-lines. In Figure 4.14 it is clear that the 
colorectal cell-lines, U251 and A549 have higher levels of expression 
than U373 and HOP-62 cells. BT4 cells show no expression at all, 
representing a good control for the correlation with promoter activity. 
 
Figure 4.14: Comparing promoter activity to CCK-2R gene expression  
Each experiment was carried out at least three times; promoter activity of the smallest 
construct, CCK-2R-250, (the black bars represent the SEM) on the left y-axis; data 
from Section 3.6 demonstrating the relative expression of CCK-2R (2-ǻ&W) using LATE-
PCR (the black bars represent the 95% confidence interval), on the right y-axis. 
 
However, the pattern for promoter activity was different for CCK2R-250, 
which was the most active promoter construct; five of the eight cell-lines 
tested were within 30-90 times control activity (HT29, SW620, BT4 and 
U251 cells; p<0.05). HCT116 cells showed very high promoter activity 
at 430-fold and A549 cells showed lower activity at ~6-fold (p<0.005). 
Over the cell-line panel this does not correlate with gene expression 
(linear regression; p=0.82) since BT4 cells show no endogenous 
expression of CCK-2R, but high promoter activity. However, U373 and 
HOP-62 cells do show low expression and low or no promoter activity at 
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all. CCK-2R protein expression is not related to promoter activity either, 
due to the fact that HOP-62 cells have similar protein levels to the other 
cell-lines and HCT116 cells do not have high protein.  
 
4.4. The effect of hypoxia on CCK-2R promoter activity 
Cellular stress is a very important factor in cancer progression. Stress 
did not affect CCK-2R gene expression but since this is not necessarily 
correlated with promoter activity it was possible that the stress 
condition, hypoxia, would have an effect on the activity of the promoter.  
 
Figure 4.15: CCK-2R promoter activity in 3 colorectal (red bars) and 3 glioma (green bars) 
cell-lines in hypoxia 
Hypoxic activity is compared to normoxic activity at 1. This is measured using 
luciferase activity norPDOLVHG E\ ȕ-galactosidase activity. The results are also 
normalised to the activity seen in the empty vector, pGL4. Each bar shows an average 
of four experiments, with the black error bars representing the SEM. 
 
To test this idea an experiment was carried out with the colorectal and 
glioma cell-lines shown in the promoter studies above. This involved 
placing the transfected cells in hypoxia (1% oxygen) for 16 hours 
(previously found to be an optimal time-frame for hypoxic stress; HIF 
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induction, in our laboratory), a day after transfection. Figure 4.15 
illustrates that a hypoxic environment does not have a significant effect 
on CCK-2R promoter activity in any of the six cell-lines.  
 
4.5. Summary 
 CCK-2R gene expression was up-regulated in a drug-resistant 
colorectal cell-line, but not by stress in the form of serum-
starvation or hypoxia. 
 However, knock-down of CCK-2R did not affect cisplatin IC50, 
indicating that the receptor is not directly involved in the 
development of drug-resistance, but may be a surrogate marker. 
 The 500bp region proximal to the start codon for the CCK-2R 
gene has been demonstrated to be active when transiently 
transfected into colorectal, glioma and lung cancer cell-lines.  
 However, this activity is not correlated to gene or protein 
expression levels of the receptor.  
 Our results show serum-starvation and hypoxia do not up-
regulate promoter activity.  
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Chapter 5 CCK-2R as a 
marker of cancer stem cells 
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5.1. Introduction 
The environment in which a tumour cell lives has a major role in the 
development, survival and metastasis sites for that tumour [169]. In the 
normal stem cell niche, cell number is tightly regulated by balancing 
self-renewal with differentiation of daughter cells [170]. This leads to 
replenishment of the stem cell population but not the expansion which 
would lead to tumour growth. This regulation is achieved via paracrine 
signalling and feedback mechanisms [171]. However, these processes 
are deregulated when cancer cells form a cancer stem cell niche, 
allowing constant self-renewal without differentiation (Figure 5.1). 
 
Figure 5.1: Stem cell division 
A normal stem cell (NSC) divides asymmetrically into one NSC and one progenitor cell 
(PC) or transit-amplifying cell (TAC) which will then produce differentiated cells (DC). If 
the NSC is genetically altered cancer stem cells (CSC) can be formed, allowing far 
more CSC to be produced in symmetric division. CSCs can also give rise to PC/TAC, 
which are non-tumourigenic. Image from [171].  
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Cancer stem cells have been difficult to characterise due to 
contradictory studies demonstrating the relevance or irrelevance of 
specific markers or features, especially in colorectal cancer cells [33, 
52].  
 
As discussed in Chapter 1 many possible CSC markers have been 
described in the literature, but there is not yet a single marker or feature 
which defines the universal CSC. This makes it very difficult to choose a 
marker to measure cancer stemness, and so several have been used 
below, including CD133, ȕ-catenin (as a marker of Wnt activity [172]) 
and CD44. 
 
5.2. 3D cell culture 
Many of the CSC markers described in Chapter 1 are highly expressed 
in a discrete population of cells [53], as seen in this project with the 
CCK-2R. In order to investigate whether these CCK-2Rhi cells are a 
specific subset i.e. the cancer stem cell subset, cancer cell-lines were 
grown as 3D sphere structures. This method selects for stemness [45], 
meaning that if CCK-2R increased in these conditions, it would be 
linked to CSC formation or maintenance.  
 
Growing cells in 3D culture; encouraging them to grow into spherical 
structures, is a much better model of the tumour environment, than 
growing 2D cell monolayers, since tumours themselves are three-
dimensional complex structures [173]. In their review, Smalley et al., 
state that cytoskeletal organisation, gene expression and the conditions 
of the microenvironment are significantly different in the same cells 
grown in 2D or 3D culture [174], and that 3D-cultured cells more closely 
mimic the in vivo situation [43, 45, 175]. In order to achieve a 3D culture 
of the cell-lines of interest in this project, the cells were re-suspended in 
µVWHPFHOOPHGLXP¶ or SCM, a special low glucose DMEM mixed with 
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B27, F12-HAM and heparin, supplemented with EGF and FGF every 
three days.  
 
This is different to the spheroid structures being grown by other groups, 
where cell-lines were grown in agar or had a similar structure to support 
them, such as a basement membrane matrix [174]. 
 
The cells in this SCM grew into sphere-shaped structures, which looked 
very different to the flat monolayers usually seen in these cells (Figure 
5.2). They often lifted from the culture plate and floated freely in the 
medium. The rate of formation, growth and the phenotype of the 
spheres differed across the cell-lines; however, all the colorectal, glioma 
and lung cell-lines tested formed 3D structures under the same 
conditions of nutrients and atmosphere (Figure 5.2). The colorectal cell-
lines, HCT116 and HT29 grew into round structures made up of all the 
cells present in the culture. These then grew larger, becoming more 
defined at the edges as they grew, which is shown by the darker line 
around the larger spheres in the micrograph (Figure 5.2a & b). These 
VWUXFWXUHV ZHUH FKDUDFWHUL]HG DV µFRORVSKHUHV¶ [173]. The other 
colospheres, formed from SW620 cells, did not look the same, in that 
they were irregularly shaped and did not display a defined outer edge, 
so it was unclear whether these were colospheres or just clumps of 
cells. The cisplatin-resistant HCT116 cell-line produced similar 
colospheres to the wild-type HCT116 cells (Figure 5.2d). 
 
Neural cell-lines were the first cells to be grown as spheres, in the early 
¶Vand were defined as neurospheres [176, 177]. The three glioma 
cell-lines used in this project formed neurospheres (Figure 5.2e, f & g), 
which looked quite different to the colospheres (Figure 5.2a, b, c & d), 
but fairly similar to the lung spheres grown (Figure 5.2h & i). The lung 
and neurosphere structures did not utilise all of the cells in culture 
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(some were left as monolayers), and although they formed clearly-
defined masses, these had branches, unlike the colospheres.  
a) HCT116 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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b) HT29 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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c) SW620 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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d) HCT116 cisplatin-resistant 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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e) BT4 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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f) U251 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
  
 
  
                                             CCK-2R as a marker of cancer stem cells                        
    
149 
 
g) U373 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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h) A549 
Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
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i) HOP-62 
i)          Monolayer Day 4 sphere 
  
Day 7 sphere Day 10 sphere 
  
Figure 5.2: Sphere structures formed from various cancer cell-lines 
Live photographs of a) HCT116, b) HT29, c) SW620, d) HCT116 cisplatin-resistant, e) 
BT4, f) U251, g) U373, h) A549 and i) HOP-62 cells; taken with the Nikon Eclipse Ti 
microscope at 10x magnification. 
 
5.3. CCK-2R expression in sphere cultures 
CCK-2R gene expression was tested in the sphere-forming cells shown 
in Figure 5.2 compared to the same cell-line grown in monolayer 
culture. The day the cells were plated in SCM was taken as day one. A 
one-way ANOVA performed on the data from each cell-line showed 
significant up-regulation of expression in spheres compared to 
monolayers in U373, A549 and HOP-62 cells at day ten, and the latter 
at day seven as well (Figure 5.3).  
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e)  f) 
  
g) h) 
  
Figure 5.3: CCK-2R gene expression in sphere-forming cells and those grown as a 
monolayer 
Logarithmic graphs showing CCK-2R gene expression in a) HCT116, b) HT29, c) 
SW620, d) HCT116 cisplatin-resistant, e) U251, f) U373, g) A549 and h) HOP-62 
cells. BT4 cells (sphere and monolayer) did not show any expression of the receptor. 
The method of detection for the CCK-2R is LATE-PCR and the error bars represent 
the SEM from at least three replicates (* indicates p<0.05). 
 
No significant difference between the expression in spheres and 
monolayers was shown by this statistical test in the colorectal cell-lines 
and U251. However, the two-way ANOVA showed that CCK-2R 
expression increased significantly with time in HCT116, HCT116 
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cisplatin-resistant and U251 cells (p<0.05). It also correlated with the 
one-way ANOVA since CCK-2R expression increased significantly with 
sphere-forming in HOP-62 cells (p<0.05) and both parameters in U373 
and A549 cells (p<0.05). The fact that HCT116 cells (wild-type and 
cisplatin-resistant) showed increased CCK-2R expression at day ten 
regardless of 2D or 3D culture may correspond with the trend for 
HCT116 cells to up-regulate CCK-2R in stress conditions (Section 4.1 
above). 
 
CCK-2R protein expression was also tested at day 10 of sphere-
forming, in six of the cell-lines. SW620 cells were not included due to 
their sphere structures being very different and therefore not obviously 
3D and the A549 cells grew very slowly so could not be included either. 
Protein expression was shown by two different methods; flow cytometry 
and paraffin staining, due to the fact that the former would show total 
CCK-2R protein expression in the sphere and monolayer cultures 
(Figure 5.4) and the latter the expression pattern through each sphere 
(Figure 5.5).  
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a) 
 
b) 
 
Figure 5.4: CCK-2R protein expression in sphere and monolayer cultures shown by flow 
cytometry 
The method of detection for CCK-2R protein is live cell staining, followed by flow 
cytometry; shown by a) median FITC measurement and b) percentage of highly-
positive cells. The negative samples (secondary antibody only) were used to 
normalise the data and the error bars represent the SEM from at least three replicates 
(except BT4 and U251 monolayer; * indicates p<0.05, ** indicates p<0.01, *** 
indicates p<0.005). 
 
Live cell staining with an antibody to the second external loop of CCK-
2R, followed by flow cytometry gave a measure of total CCK-2R 
expression in each population at day 10 (Figure 5.4). Figure 5.4 showed 
that a: expression of CCK-2R and b: the number of cells expressing a 
high level of CCK-2R, were very different values for each cell-line. The 
three colorectal cell-lines all showed significantly higher receptor 
expression in 3D culture (p<0.05); however, this was not true when the 
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percentage of highly-positive cells was examined. BT4 and HOP-62 
cells also displayed higher CCK-2R expression in sphere-forming cells, 
but U251 cells showed similar levels for 2D and 3D culture (Figure 5.4). 
This method gives no indication of where the positive cells are in the 
sphere, so in order to gain this insight; the spheres were embedded in 
paraffin wax and stained on slides (Figure 5.5). 
a) b) c) d) 
    
e) f) g)   
   
 
Figure 5.5: Paraffin staining for CCK-2R 
Sphere structures were formed from cells and stained with a CCK-2R antibody (or the 
negative control with rabbit serum); a) HCT116, b) HCT116 negative, c) HT29, d) 
cisplatin-resistant HCT116, e) BT4, f) U251 and g) HOP-62.The scale of the 
photographs is shown by the marker for 200µm. 
 
Figure 5.5b shows an example of a negative control stained sphere. In 
the positive samples, the smaller spheres showed a higher percentage 
of CCK-2R staining than the larger spheres, and staining was most 
obvious in the cells around the outer edges of the sphere (Figure 5.5). 
This staining was analysed using QWin software, to find out the 
percentage staining across each sphere (Figure 5.6). HT29 and BT4 
cells showed the highest percentage of staining (27 & 17% 
respectively), corroborated by the micrographs in Figure 5.5.  
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Figure 5.6: CCK-2R protein 
expression in sphere cultures 
shown by staining analysis 
The method of detection for 
CCK-2R protein is paraffin 
staining for a rabbit anti-CCK-2R 
antibody and the error bars 
represent the SEM from an 
average of all the stained 
spheres on each slide. 
 
 
 
In addition to CCK-2R, the sphere cultures were tested for various stem 
cell markers, such as CD133 and CD44, and also the ligand gastrin to 
see whether these were up-regulated with the receptor. 
 
5.4. Gastrin expression in sphere cultures 
Gastrin was up-regulated at the gene level in monolayer HCT116 cells 
on day 4 (p<0.01; Figure B in the Appendix); however, there was no 
significant difference between spheres and monolayer cells in other 
cell-lines. The two-way ANOVA test also shows that time and culture 
methods did not have a significant impact on gastrin gene expression. 
 
Comparing the gastrin gene expression graphs to the CCK-2R 
equivalents, the colorectal cell-lines showed very similar trends, except 
the cisplatin-resistant HCT116 cells, where gastrin was uniform across 
the graph and CCK-2R was up-regulated at day 10 (in both 2D and 3D 
culture). BT4 cells did not show expression of CCK-2R by LATE-PCR 
(despite displaying CCK-2R protein expression), and gastrin expression 
seems to have decreased by day 10. U251 and A549 cells showed up-
regulation of CCK-2R at day 10 (p<0.05), but not of gastrin. However, 
U373 cells showed up-regulation of both CCK-2R and gastrin mRNA on 
days 7 and 10, even if the gastrin expression was not significant. The 
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lung cells, HOP-62, actually showed the opposite effect in that gastrin 
decreased in spheres at day 7 and 10, in conflict with the CCK-2R 
expression. 
 
5.5. CD133 expression in sphere cultures 
CD133, the most widely attributed cancer stem cell marker, was not 
significantly up-regulated in any of the cell-lines shown in Figure C in 
the Appendix. This was unexpected, especially in lung and 
neurospheres where CD133 is an accepted CSC marker, due to the 
fact that 3D culture should select for the cancer stem cells. However, 
these cells may differentiate after division, resulting in a similar CD133 
expression profile to monolayer cells. The two-way ANOVA shows that 
time was a significant factor affecting CD133 expression in HCT116 and 
HCT116 cisplatin-resistant cells (p<0.05), and sphere-forming increased 
CD133 gene expression in HT29 and U251 cells (p<0.05). Otherwise 
the test showed no significance.  
 
HT29 cells showed up-regulation of CD133 gene expression in spheres 
at days 7 and 10, but this was not similar to CCK-2R expression. As in 
the CCK-2R LATE-PCR, BT4 cells showed no expression of CD133 in 
qRT-PCR, despite exhibiting protein expression. The other glioma cells 
and lung cells showed uniform CD133 gene expression across sphere-
forming/time, with no relation to the CCK-2R expression graphs.  
 
CD133 protein expression in day 10 spheres was measured by flow 
cytometry (Figure 5.7). This marker was up-regulated in monolayers 
(p<0.05), compared to sphere-forming cells in colorectal cells, where 
CD133 is a contested CSC marker. BT4 cells showed a non-significant 
increase in CD133 protein expression in sphere-forming cells. U251 
and HOP-62 cells showed no significant difference between the two 
populations.  
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a) 
 
b) 
 
Figure 5.7: CD133 expression in sphere and monolayer cultures shown by flow cytometry 
The method of detection for CD133 protein is live cell staining, followed by flow 
cytometry; shown by a) median FITC measurement and b) percentage of highly- 
positive cells. The negative samples (mouse universal antibody) were used to 
normalise the data and the error bars represent the SEM from at least three replicates 
(except BT4 and U251 monolayer; * indicates p<0.05, ** indicates p<0.01). 
 
The colorectal cells showed a negative relationship between CCK-2R 
and CD133 protein expression, and the other cell-lines demonstrated 
no correlation (p=0.78 for correlation of all medians). 
 
5.6. ȕ-catenin expression in sphere cultures 
Wnt signalling is often up-regulated in CSCs and this leads to the 
localisation of ȕ-catenin protein to the nucleus, where it links to 
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transcription factors which activate target genes, such as c-myc and 
survivin [53, 172]. Figure D in the Appendix shows examples of spheres 
formed from different cell types stained for ȕ-catenin.  
 
The staining shown for ȕ-catenin was varied between spheres of a cell-
line population, however, within each individual sphere it appeared to 
be uniform, and cytoplasmic not nuclear (Figure D in the Appendix).  
 
5.7. CD44 expression in sphere cultures 
CD44 has been suggested to be a CSC marker in some cancers, e.g. 
colorectal carcinoma. This protein was detected by flow cytometry, 
using a conjugated primary antibody in live cell staining. This 
experiment was only completed on two cell-lines, HT29 and HOP-62, 
due to lack of time (Figure 5.8).  
 
The median expression of CD44 protein showed that this is up-
regulated in HOP-62 2D cultures, and not changed by sphere-forming in 
HT29 cells (Figure 5.8). These results supported the hypothesis that 
CD44 alone is not a CSC marker in colorectal or lung cancer. There 
was no relationship between CD44 and CCK-2R protein expression. 
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a) 
 
b) 
 
Figure 5.8: CD44 expression in sphere and monolayer cultures shown by flow cytometry 
The method of detection for CD44 protein is live cell staining, followed by flow 
cytometry; shown by a) median FITC measurement and b) percentage of highly-
positive cells. The negative samples (conjugated isotype antibody) were used to 
normalise the data and the error bars represent the SEM from two replicates (* 
indicates p<0.05). 
 
5.8. The effect of sphere-forming on CCK-2R promoter 
activity 
Since CCK-2R expression is up-regulated in sphere-forming cells, the 
effect of this process on CCK-2R promoter activity was assessed. 
However, the cells show no significant difference in promoter activity 
between 3D and 2D culture (Figure 5.9).  
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a) b) 
 
 
c) d) 
 
 
Figure 5.9: CCK-2R promoter activity in sphere-forming cells 
In two colorectal a) HCT116, b) HT29 and two glioma c) U251, d) U373 cell-lines, in 
sphere and monolayer culture. Promoter activity was measured using luciferase 
DFWLYLW\QRUPDOLVHGE\ȕ-galactosidase activity. The results were also normalised to the 
activity seen in the empty vector, pGL4. In the colorectal graphs, each bar shows an 
average of three experiments, with the black error bars representing the SEM, but 
there were no significant differences between activity in sphere or monolayer culture. 
 
5.9. The effect of CCK-2R knock-down on sphere-
formation 
In order to investigate the functional role of CCK-2R the siRNA 
designed previously (CCK tg1) were used to knock-down the CCK-2R, 
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before forming spheres from these transfected cells. However, this was 
unsuccessful due to greatly reduced sphere-forming (by the CCK-2R 
and negative siRNA-transfected cells) and the concern that transient 
knock-down may not have been achieved for the whole ten days of 
sphere-forming, which was necessary to show an effect on CCK-2R 
gene expression. 
 
A new experiment was devised using a CCK-2R antagonist to inhibit the 
receptor at the protein level instead, to prevent signalling through the 
receptor while sphere-forming took place. This was achieved using (R)-
1-[2,3-Dihydro-1-¶-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodia-
zepin-3-yl]-3-(3-methylphenyl)urea, better known as YM022, a very 
selective CCK-2R inhibitor [178]. This experiment was carried out in five 
cell-lines, encompassing three cancer types, colorectal (Figure E in the 
Appendix), glioma and lung (Figure 5.11). The inhibitor was added at 
day 1, 4 and 7 in the <0JURXSDWGD\DQGLQWKHµ<0#GD\
¶ JURXS DQG QRW DW DOO LQ WKH XQWUHDWHG FRQWURO JURXS The cells were 
photographed each day between day 2 and 10, but otherwise left in the 
incubator in 6-well plates at 37°C and 5% CO2. 
 
The staining analysis was carried out in QWin software for the Leica 
microscope. Each sphere in the photograph was highlighted, and then 
the software used to measure the area of each as shown in Figure 5.10. 
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a) 
 
b) 
 
Figure 5.10: An example of the analysis of sphere-forming 
 
In all the colorectal cells, number of spheres was low on day 2, and 
then stayed at a fairly constant number from day 3 onwards (Figure E in 
the Appendix). Sphere area gradually built up towards day 5, and then 
levelled out after day 6. Interestingly the HCT116 spheres were fewer in 
number than their cisplatin-resistant counterparts, but the sphere areas 
were slightly higher (in Figure E in the Appendix aii & cii the graphs 
have the same y-axis maximum (2x106) allowing direct comparison), 
showing that the resistant cells produced more, smaller, spheres. HT29 
cells produced larger spheres (in Figure E in the Appendix bii the y-axis 
has a maximum of 5x106) and more of them, possibly indicating a more 
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virulent cancer phenotype. Using the repeated measures one-way 
ANOVA statistical test, there was no significant difference between 
sphere number or area with the three treatments in any of the colorectal 
cell-lines. 
a) i) 
 
a) ii) 
 
b) i) 
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b) ii) 
 
Figure 5.11: Total number and area of spheres formed each day in a glioma and a lung 
cell-line 
The cells were a) HOP-62 and b) U251 cells, with i) showing total number of spheres 
and ii) showing total area of spheres (note the different y-axis maximums). Data 
acquired from 10 photographs taken at 10x magnification for each condition on each 
day. These were also compared to their monolayer equivalents on each day. The bars 
show the mean of at least two experiments and the black error bars represent the 
SEM (* indicates p<0.05, ** indicates p<0.01). 
 
In Figure 5.11aii the lung cell-line, HOP-62, was shown to produce 
smaller spheres than the other four cell-lines (y-axis maximum is only 
3x105). In both HOP-62 and U251 cells both number and area of 
spheres stayed low until day 4, with HOP-62 increasing at day 5 and 
then continued constant. U251 cells showed a more normal distribution 
with the peak of sphere-forming being day 7.  
 
Using the repeated measures one-way ANOVA statistical test, addition 
of YM022 to the growth medium at day 1 caused HOP-62 sphere 
number to be significantly less than in the untreated cells (p<0.05). 
Sphere area was not significantly affected, but the graph in Figure 
5.11aii does show the same trend, with the YM022-treated cells being 
lower than the other two treatments until day 4. This indicated that 
inhibition of CCK-2R was reducing the cells capacity to form spheres 
between day 2 and day 4, when this capacity was restored to full 
measure.  This restoration cannot be due to lack of inhibition by YM022, 
since it was replenished on day 4. The YM022 @ day 4 group, however 
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did not show significantly different results to either of the other 
treatments. 
 
In U251 cells this effect was also shown, with the YM022 group 
showing significantly lower sphere numbers than the untreated cells 
(p<0.01) and the YM022 @ day 4 subset (p<0.05; Figure 5.11). Again 
the area graph in Figure 5.11bii showed the same trend but the data 
was not significantly different. The cells with YM022 added first at day 
4, did not show a significant difference in sphere number compared to 
the untreated cells. 
 
In summary, the knock-down of CCK-2R did not affect sphere-forming 
in colorectal cancer cells. However, inhibiting CCK-2R before HOP-62 
or U251 cells formed spheres did cause this development to be delayed 
until days 4 and 6, respectively. Adding YM022 after the first spheres 
had formed (at day 4) did not have any effect on colorectal or lung cells, 
nor did it have the same consequence as adding YM022 to HOP-62 
cells at day 1. Therefore, in the lung cell-line, YM022 delayed sphere-
forming but may have also affected sphere maintenance a small 
amount since adding YM022 at day 4 was statistically similar to both the 
YM022 and untreated groups. However, in U251 cells adding YM022 at 
day 4 was significantly different to adding it at day 1, but not compared 
to no treatment. Hence in the glioma cell-line, YM022 delayed sphere-
forming but did not affect sphere maintenance at all. 
 
5.10. Summary 
 All of the cell-lines developed into 3D sphere structures when 
plated in SCM; however these structures differed with cell-line 
and cancer type. 
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 CCK-2R gene expression was up-regulated by 3D culture of lung 
and glioma cell-lines and time was a significant factor in the 
difference between monolayer and sphere expression levels in 
colorectal and glioma cell-lines. 
 CCK-2R protein was also up-regulated in spheres at day 10, and 
seemed to be located in the outer cells of each sphere. 
 Gastrin, CD133, ȕ-catenin and CD44 expression did not seem to 
be correlated to that of CCK-2R. 
 ȕ-catenin protein did not seem to be localised to the nucleus of 
the sphere-forming cells. 
 Growing cells in 3D culture did not have an effect on CCK-2R 
promoter activity.  
 In 3D culture, inhibition of CCK-2R using YM022 successfully 
delayed sphere-formation in HOP-62 and U251 cells, indicating a 
role for the CCK-2R in glioma and lung cancer stem cell 
expansion.  
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Chapter 6 Discussion and 
conclusions 
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6.1. LATE-PCR is a sensitive method for detecting the 
CCK-2R at the gene level 
The CCK-2R is up-regulated in cancer and mediates many carcinogenic 
processes, allowing a cancer to progress rapidly. This potentially makes 
it an important biomarker in cancer, and therefore an understanding of 
the expression patterns, effects and regulation of the CCK-2R are 
important to improve our understanding of its role in this disease.  
 
The CCK-2R acts as the receptor for gastrin, a hormone shown to 
prevent apoptosis and increase angiogenesis, cell proliferation and 
metastasis in cancer cells [81]. Gastrin is also up-regulated in cancer 
cells resulting in a high degree of activation of these multiple pro-
carcinogenic pathways. Using specific CCK-2R inhibitors, it has been 
proven that carcinogenic effects can be lessened when the receptor is 
blocked [13, 74, 138, 139].  
 
CCK-2R is therefore detectable at the protein level in carcinoma cells 
but detecting its gene expression in cell-lines, and in patient tumour 
samples, is a challenge. Many studies have used classical PCR to 
detect the CCK-2R within cancer cells; however, at times important 
negative controls were not included [24], which are crucial in order to 
rule out any false positive outcomes. This is due to the small size of the 
introns within the CCK-2R gene, which allow easy amplification of CCK-
2R genomic DNA which frequently contaminates RNA preparations 
[179], within the timescales of qRT-PCR. The Taqman qRT-PCR, 
initially used to detect endogenous transcription of the receptor, could 
only do so in the minority of cancer cell-lines. In the panel of cell-lines 
tested in the present study, H209 cells (SCLC) expressed the highest 
level of endogenous CCK-2R; a result supported by the literature. 
Moody & Jensen [180] found that both the endocrine-mediated 
proliferation of SCLC caused by CCK8 and SCLC basal growth 
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(autocrine stimulation by gastrin) were inhibited by the CCK-2R 
inhibitor, CI-988 (PD134308). Another study of lung cancer cells 
showed that the CCK-2R was present in 6/7 SCLC (although this panel 
does not include H209), and not at all in non-SCLC (NSCLC), using 
classical PCR [159].  
 
Using the Taqman assay OE33 cells in the current study showed low 
expression of the receptor, whereas OE19 cells did not appear to 
express it at all. However, Harris et al. have shown that both these cell-
lines possess the CCK-2R by IHC staining and functional assays [13]. 
7KLV LQGLFDWHG WKDW SHUKDSV WKH µUHFHSWRU-QHJDWLYH¶ FHOOV LQ WKH SDQHO
show low expression and that the Taqman assay was not sensitive 
enough to detect these. 
 
A novel method, LATE-PCR, which is based on asymmetric PCR, was 
established in the current thesis. LATE-PCR was originally developed 
by a group headed by Wangh [162], in order to detect small mutations 
in genes which convey two serious human conditions; Tay-Sachs 
disease and cystic fibrosis [160]. Both of these disorders are caused by 
a 3 or 4 base pair change in a single gene, which is detectable from the 
single cell of each embryo, tested via a sensitive assay such as LATE-
PCR [162]. As with the CCK-2R, there is a very small amount of the 
molecule of interest (CCK-2R mRNA or embryo DNA) present, and yet 
the protein produced is of critical importance to the cell.  
 
LATE-PCR was found to be 10,000-fold more sensitive at detecting the 
CCK-2R than the Taqman assay. Using LATE-PCR all of the human 
cell-lines in the panel were shown to be CCK-2R-positive, as opposed 
to the 5/7 shown as positive with the Taqman assay. The cell-line panel 
was extended to include other cancer types such as breast carcinoma 
and glioblastoma, but H209 cells still had the highest endogenous 
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expression; at least 10-fold higher than the other cell-lines. The 3T3 wt 
cell-line was used as a negative control, because it is derived from 
mouse fibroblast cells and therefore should not contain human CCK-2R 
mRNA. The LATE-PCR assay showed this cell-line as undetectable as 
it had in the Taqman assay providing support for the specificity of this 
assay.  
 
When dilutions of CCK-2R mRNA were tested by the LATE-PCR assay, 
it produced a linear regression line with a slope of 1.03, showing a ten-
fold change in signal for a ten-fold change in dilution. In the entire panel 
of 35 human cancer cell-lines, two were found to have no expression of 
CCK-2R; ST16 (gastric) and BT4 (paediatric glioma). In the cell-lines 
with CCK-2R expression the extremes were shown by H209 cells with 
high relative expression levels (2-ǻCt) of 10-2, and AGS (gastric) cells 
with 2-ǻCt at 10-6. The other colorectal, gastric, pancreatic, oesophageal, 
glioma, lung, ovarian, melanoma and breast cell-lines had relative 
expression levels of between 10-3 and 10-5.               
 
The gastric cell-lines had extremely low expression of CCK-2R, which 
was unexpected due to the large role this receptor plays in normal 
stomach tissue [135]. This trend was taken to the extreme by ST16 
cells, where no receptor was detected; showing that either no CCK-2R 
mRNA is present or that the assay cut-off point is too high to detect its 
very low level expression. In this project A549, EKVX, H23 and HOP-
62; all NSCLC cells, have been found to express CCK-2R, whereas no 
NSCLC cell-lines had been shown to express CCK-2R before [159]. 
This shows the sensitivity of LATE-PCR in detecting the CCK-2R where 
it has not been found previously. 
 
Matheiu & colleagues [181] state that no human glioblastoma cell-lines 
have been found to express the CCK-2R, and yet gastrin can modulate 
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apoptosis, proliferation and motility of these cells in vitro [31]. It is 
possible that this effect is not mediated via the CCK-2R, of course, 
since other gastrin receptors, including CCK-2R isoforms, have been 
described [182]; however, this seems unlikely since the brain is one of 
only two sites where the CCK-2R is highly-expressed in non-malignant 
tissue [135]. Consequently, including the human glioblastoma cell-lines 
was a high priority since the new assay might be able to give insight 
into how gastrin mediates its effects in this cell-type. As with the 
NSCLC, these cells were found to express CCK-2R mRNA, with U251 
and U373 cells at the upper and lower ends, respectively, of the normal 
range found in the cell-line panel (2-ǻCt between 10-3 and 10-5). This 
demonstrates that the CCK-2R is present in gliomas and may mediate 
the effects of gastrin in this tumour-type. 
 
Another interesting result is shown in the paediatric glioma cell-line, 
BT4, where no expression of CCK-2R was found. This cell-line also 
yielded no gene expression of CD133, which was unexpected due to 
the apparent necessity of CD133+ cancer stem cells in the formation of 
adult gliomas [46]. The other paediatric glioma cell-line in the panel was 
OLIG1 [45], which showed CCK-2R gene expression in only one 
passage (of two), and no CD133 expression in either passage (results 
not shown).  This indicates that perhaps both CCK-2R and CD133 are 
different in the brains of children and adults, and that our primers are 
not able to detect them reliably in the paediatric situation. A study by Ma 
et al. showed that CD133 mRNA expression could be detected by real-
time RT-PCR in primary astrocytoma samples, some (14/72) of which 
were paediatric [183]. We assume that CD133 expression was found in 
these paediatric samples, since they do not say otherwise and also that 
CD133 expression is similar in astrocytomas to glioblastomas. In the 
current project both CCK-2R and CD133 protein have been shown to 
be present in these cell-lines.  
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The fact that the CCK-2R could have a different conformation in BT4 
cells broaches the possibility that a different receptor isoform could be 
encoded in these cells. Detection methods, such as radiolabelled 
peptide targeting, for the well-known CCK-2Ri4sv have been validated 
in colorectal cancer [101, 105] and LATE-PCR could be adapted to 
target the retained intron 4 (being aware of the potential for gDNA 
amplification). However, this and the other isoforms described in the 
literature [121-123] would be detected by the LATE-PCR described in 
Chapter 3, and so should not be present in BT4 cells. Perhaps there is 
yet another isoform, or maybe paediatric brain tumours take low 
expression of CCK-2R mRNA to an extreme below even the level of 
detection of the present LATE-PCR assay.  
 
A further way to investigate why expression of CCK-2R is different 
within cancer groups would be to look at a correlation with their 
mutational status. The CCK-2R mediates the link between gastrin and 
the Wnt pathway [184, 185], where many oncogenes are found e.g. ȕ-
catenin. There may be a relationship between the expression of the 
CCK-2R and certain oncogenes, which could not be investigated 
without this highly sensitive method for detecting CCK-2R mRNA. If this 
were the case it would confirm the need for a therapeutic approach to 
CCK-2R knock-down. 
 
In order to validate the LATE-PCR assay, siRNA molecules targeting 
the CCK-2R were designed and optimised to knock-down the receptor. 
These siRNAs were very successful, reducing CCK-2R expression to 
between 3 and 30% of the control in gastric, colorectal, glioma and lung 
cancer cell-lines. This reduced expression could be detected by LATE-
PCR whereas the Taqman assay failed to perceive the signal. 
 
                                                              Discussion and conclusions                        
    
175 
 
The siRNA molecules were also created with the aim of investigating 
the biological effect of CCK-2R knock-down on cancer cells. The ligand 
for CCK-2R, gastrin, was investigated at the gene level since these two 
molecules are linked in an autocrine loop [137, 186]. No difference was 
found in gastrin gene expression between cells displaying CCK-2R 
knock-down for 24 hours and the negative control siRNA-transfected 
cells. CD133 gene expression was also investigated to test the 
hypothesis that CCK-2R is involved in cancer stem cell growth or 
maintenance. However, again at 24 hours, there was no change with 
the decrease in CCK-2R gene expression. These results may have 
been due to the length of the experiment, since CCK-2R protein levels 
may not be affected within 24 hours. It seems the genes investigated 
are not linked to CCK-2R at the transcriptional level, but they may be 
translationally linked. If the CCK-2R mRNA needs to be translated to 
protein to affect either gene or protein levels of gastrin/CD133 this may 
need more than 24 hours. 
 
During optimisation of the flow cytometry protocol used in this project, 
CCK-2R protein expression was investigated following receptor siRNA-
transfection. This initial experiment failed to show a change in cell-
surface protein expression (by live cell staining) up to seven days after 
knock-down, and due to time constraints this was not explored further 
once an effective flow cytometry procedure was in use. This problem 
highlights the need for a more reliable method of knock-down than the 
transient transfection, which may not reduce CCK-2R mRNA levels 
sufficiently that translation is stopped entirely. Since translation of CCK-
2R is likely to be very efficient (see Section 6.2 below), a superior 
method for removal of CCK-2R transcription, such as a viral inducible 
knock-out construct, should be investigated. This would allow the cells 
to recover from transfection before further studies were carried out, and 
enable analysis over a longer time period to be investigated. An 
example of this system is the inducible knock-out of PTEN in breast 
cancer cells, where total knock-out caused growth suppression and cell 
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death [187]. The inducible construct provided a way around this 
problem, allowing PTEN to be turned off at a point where the 
mechanism of growth suppression could be monitored and investigated 
[187, 188].  
 
LATE-PCR has allowed the design and use of CCK-2R siRNA in these 
cancer cell-lines. With advances in siRNA technology taking place, it is 
becoming more likely these molecules could be used as therapeutic 
agents [189] and it is possible that knock-down of the CCK-2R in a 
clinical setting could be an appropriate treatment for specific forms of 
cancer. Combined with the specificity of LATE-PCR, it may be possible 
to determine whether a certain individual would respond to this 
treatment, therefore allowing a personalised therapeutic recipe to be 
designed. 
 
6.2. CCK-2R protein expression is not correlated to gene 
expression  
CCK-2R protein expression was investigated in a smaller panel of cell-
lines, comprising colorectal, glioma and lung cancers. These cell-lines 
were chosen due to the fact that each of these cancer groups 
encompassed cells with high, low and average CCK-2R gene 
expression; in order to give an insight into whether gene expression 
was linked to translation. Protein expression was visualised and 
quantified using live cell staining with an antibody to an external loop of 
CCK-2R, followed by flow cytometry. Two populations of cells were 
found within each cell-line; one weakly-positive and the other strongly-
positive, possibly indicating diverse differentiation among the cells. A 
similar situation was shown in various cell-lines, where strong 
expression of CD133 has been associated with resistance to apoptosis 
and the CSC subset [190]. This hypothesis is investigated further in 
Section 6.4 below. 
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Two values were obtained from the flow cytometric analysis; the median 
fluorescence for the whole population, and the percentage of highly-
positive cells in the population. The percentage value was more 
reproducible between replicates and therefore showed tighter error bars 
than the medians. It was also cancer-type specific, with colorectal cells 
showing a population of ~20% highly-positive cells and glioma and lung 
cells showing around 40%. The staining was verified by carrying out 
negative controls with only secondary antibody added, and by 
undertaking a primary antibody dilution experiment. The negative 
control samples always had far lower FITC fluorescence and dilution of 
the primary antibody reduced fluorescence clearly showing that the 
antibody binding was specific for the CCK-2R. 
 
The protein expression showed a three-fold range compared to the 
four-log range in gene expression, leading to a linear regression line 
which was almost horizontal since gene expression varied and protein 
expression was fairly similar across the panel. Therefore CCK-2R gene 
expression could not be correlated with protein expression. Since 
protein expression is easily detectable it is not clear why the level of 
gene expression is so low in the cell-line panel. It was hypothesised that 
the LATE-PCR results could demonstrate one of three different 
scenarios; a low level of receptor mRNA in all cells, a large amount of 
mRNA in just a few cells or a mixed population of cells; most with a very 
low level of mRNA and a few that have a large amount present. Since 
the flow cytometry results in this thesis show the whole population to 
express the receptor protein, it would appear that the CCK-2R mRNA is 
present in all the cells, but perhaps it is not distributed equally. This 
could be investigated if the protocol to transfect the LATE-PCR 
molecular probes into the cancer cells could be optimised to show 
where and how much mRNA is in each cell. 
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The fact that protein is being made from low levels of mRNA in most or 
all of the cell population suggests that the gene is being translated very 
efficiently. Many oncogenes are up-regulated due to a tumourigenic 
increase in the mRNA cap-binding protein, eIF-4E, which allows 
translation to happen more swiftly [191]. This has been demonstrated 
on anti-apoptotic proteins in lung [192] and growth promoting proteins in 
colon cancer [193] along with many others [191]. It is possible that eIF-
4E may be responsible for the efficient translation of the CCK-2R, and 
this could be explored using qRT-PCR. 
 
Korner et al. also found a non-linear relationship between CCK-2R gene 
and protein expression, assessed using qRT-PCR and receptor binding 
site autoradiography, respectively [194]. They suggest that these 
findings may be due to translational regulation or collecting the receptor 
protein into intracellular pools [194, 195]. However, the latter 
explanation would not tie in with the current project as it indicates that 
the protein would not be on the cell surface and therefore could not be 
detected by live cell staining. Perhaps receptor protein levels and 
amount of receptor binding sites in colorectal tumours are also not 
correlated. Although unlikely in normal cells where translation is tightly 
controlled, this is a possibility in cancer cells since regulatory pathways 
are often damaged. 
 
Another hypothesis is that the CCK-2R mRNA is very unstable, 
therefore making detection difficult. mRNA stability is usually tightly 
controlled by the communication between cis-acting elements and 
trans-acting factors [196]. mRNA molecules can be long-lived or they 
may be degraded directly following transcription, which can happen in 
the immune response [197]. Here the expression of cytokines and 
growth factors must be tightly controlled, with translation being turned 
on and off rapidly to enable a swift response with no autoimmune 
symptoms. This is achieved through transcriptional and post-
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transcriptional regulation. However in carcinogenesis, post-
transcriptional regulation can be disrupted, for example an AU-rich 
element (ARE) binding protein, HuR, is up-regulated in colon cancer, 
allowing the stabilisation of COX-2, and consequently an increase in 
angiogenesis and invasion of neighbouring tissues by the tumour cells 
[198].  
 
This hypothesis may also explain why promoter activity was not related 
to gene or protein expression in this project. If the CCK-2R gene is 
being transcribed quickly but the transcript is being rapidly degraded 
then the fact that the promoter is active would bear no relation to the 
amount of mRNA present. The most apparent case was that of BT4 
cells where promoter activity was 30 times that of the control, despite a 
lack of any gene expression detected by LATE-PCR. However, in real-
time PCR assays, mRNA transcribed by the cell is measured at a 
certain time-point. These assays are limited in that they cannot 
demonstrate what happens to temporal mRNA expression.  
 
Therefore RNA stability may play a major role in the regulation of the 
CCK-2R, and this could be investigated in further work. Cheneval & 
colleagues review several methods for studying mRNA stability, 
including the use of a branched DNA assay to directly measure mRNA 
at different time-points and a chimeric gene sequence to show 
transcript abundance after inhibition of transcription, compared to a 
house-keeping gene [196]. Real-time PCR is a sensitive and reliable 
method to find out the half-life of mRNA molecules with low expression, 
measuring these relative to total RNA [199]. 
 
Translational control may also be important to consider since even 
small amounts of mRNA may be translated to yield significant amounts 
of protein, and such mechanisms may come into play in stress 
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conditions. For example, it has been found that in hypoxia, translation of 
most mRNAs is down-regulated, but that of activating transcription 
factor 4 (ATF4) is enhanced as a survival mechanism [200]. ATF4 then 
activates genes involved in the stress response, such as those required 
for DNA damage repair. In order to investigate the possibility that stress 
conditions change CCK-2R promoter activity, the constructs were 
tested in hypoxia and serum-starvation. As before, with the gene 
expression studies, no difference in promoter activity was found in 
either of these conditions, after 24 hours. This could be investigated 
further, using longer time-frames, together with analysis of stress 
proteins to confirm the level to which the cells are stressed. 
 
Once gene and protein expression levels of CCK-2R had been 
established, it was decided to investigate the location of CCK-2R 
transcripts in the cell. mRNA should be strongly associated with 
ribosomes in order to ensure efficient translation, but it has also been 
suggested that molecules with low mRNA and high protein may have 
their mRNA stored in the nucleus [201]. In order to try to localise the 
CCK-2R mRNA inside the cell, a method was devised to transfect the 
fluorescent LATE-PCR probes directly into the cells. These probes 
would then fluoresce and identify the location of the mRNA under a 
microscope. Unfortunately, although the method showed initial promise, 
it was abandoned due to lack of effectiveness with housekeeping genes 
HPRT and GAPDH. The protocol needs further optimisation, focusing 
on the transfection reagent and possibly modification of the probes to 
encourage transfection. A review of the current methods used to 
increase transfection efficiency is provided by He et al. [202], for 
example adding poly(ethylene-imine), PEI, to the probes, to enhance 
cell uptake. Another possibility would be to add a lipid molecule to the 
probe, forming a complex in a more acceptable shape, again improving 
uptake across the cell membrane [202]. 
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LATE-PCR has demonstrated that CCK-2R can be detected at the 
mRNA level in cancer cell-lines, where previous studies had only found 
the receptor protein, but it was important to test this assay in primary 
tissues. It is possible that expression is artificially low in vitro, as 
opposed to in vivo where environmental effects could cause up-
regulation. Colorectal primary tumours, liver metastases and lung 
primary tumours were tested along with their equivalent normal tissue, 
and all the groups were found to have some samples with expression of 
CCK-2R mRNA. This was extremely low in normal lung tissue, 
however, and the lung primary tumour samples showed significantly 
increased (100-fold) CCK-2R gene expression compared to the normal 
tissue. It was also the opposite of the CCK-2R expression in the cell-
line panel, where colorectal cells show higher expression than lung cell-
lines (except the SCLC line, H209). This may be an indicator that the 
cell-lines do not truly represent the in vivo situation. 
 
Korner et al. corroborate these results, in that they found CCK-2R 
receptor mRNA in colorectal, liver and lung tumour tissue (again slightly 
higher in lung than colorectal tumours) as well as in colorectal and liver 
normal tissue samples [194]. They did not find CCK-2R at all in the lung 
normal mucosa. Their lung tumour samples were a mixture of SCLC 
and NSCLC, whereas those examined in this study were NSCLC 
subtypes including adenocarcinoma and squamous cell carcinomas. 
Other groups have found high expression of CCK-2R in lung cancers, 
(SCLC) but they have not investigated the expression in equivalent 
normal tissue [203, 204]. Clearly further work must be carried out to 
discover whether CCK-2R could be a prognostic marker in lung cancer, 
and if this knowledge could be used therapeutically.  
 
The evaluation of a putative prognostic marker is a complicated 
process. In this case it could be carried out either retrospectively; with 
samples already collected and stored, or prospectively; by enrolling 
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patients as they are diagnosed with lung cancer [205]. The second is a 
superior method, since it allows the collection of relevant patient data 
and uses unbiased selection; however, it would take much longer, since 
lung cancer is a disease with a long duration. Other factors to consider 
are the ethics of the study and sufficient sample size to provide an 
accurate and adequate answer to the hypothesis in question [205]. 
 
Gastrin gene expression was also investigated in these primary 
tumours and although there were no significant differences between 
tumour and normal tissue, there were some correlations with CCK-2R 
expression. The primary colorectal tumour showed a link between 
expression of these two genes, whereas normal colorectal (and all the 
other sample groups) did not. Gastrin and the CCK-2R are linked in an 
autocrine loop in gastric carcinoma cells [137], and these results 
suggest that there is a connection between expression of these 
molecules in colon cancer cells. The fact that they are not linked in 
colorectal normal tissue, but are in colorectal carcinoma tissue implies 
that the relationship is promoted by tumourigenesis. Zhou et al. blocked 
the autocrine loop in gastric cells, by knocking down the CCK-2R and 
by counteracting the secreted gastrin they found in the culture medium, 
thus reducing cell proliferation [137]. This could be considered as a 
further study to continue the work of the current project in colorectal 
carcinoma cells.  
 
6.3. The expression of CCK-2R is regulated via its 
proximal promoter and up-regulated by drug 
resistance  
The regulation of the CCK-2R is not well-researched; however, this 
topic does seem to be gaining interest. Since we began this project, 
Ashurst et al. [114] published a study using CCK-2R reporter 
constructs. They used these constructs to determine those sections of 
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the putative CCK-2R promoter which could maintain transcription, and 
to establish the importance of the consensus binding sites for several 
transcription factors found within it (see Section 1.6). They also found 
that environmental factors such as serum-starvation can have an effect 
on the promoter. 
 
The constructs designed in this project have shown that the 500bp 
proximal to the start codon for the CCK-2R gene are active when 
transiently transfected into colorectal, glioma and lung cancer cell-lines. 
The constructs containing 500 or 250bp before the start codon for CCK-
2R had most activity in all the cell-lines. The 1kb construct, CCK2R-
1057, was also found to have promoter activity in the colorectal and 
A549 cells, but this was always much less than that of the smaller 
constructs. The 1kb deletion construct, which contains the same 
fragment as CCK2R-1057 minus the 260bp closest to the start codon, 
has no activity at all, corroborating the major role for this small section 
of proximal promoter. 
 
This research could be explored further using computer programmes 
such as ALGGEN PROMO [206], to predict transcription factor binding 
sites. This information could then be used to decipher which parts of the 
500bp are most critical to promotion of the CCK-2R gene. A further way 
to investigate the transcriptional regulation of the CCK-2R would be to 
incorporate GFP into the promoter constructs; to develop a dual 
reporter in order to study the location of promoter activity within the cell 
population, in real time [207].   
 
Within the tumour environment, conditions such as oxygen 
concentration [208] and nutrient availability [209] are reduced, due to 
decreased vasculature [167]. In order to simulate these stress 
conditions, colorectal and glioma cell-lines were grown in hypoxia (1% 
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oxygen) or serum-free medium, and their CCK-2R gene expression was 
compared to that of cells growing in normal conditions. HCT116 cells 
showed a trend of two-fold CCK-2R gene up-regulation in both hypoxia 
and serum-starvation, but there were no significant differences in 
expression in any of the cell-lines. Transcription of the CCK-2R gene 
does not seem to be affected by 24 hours of stress, and these results 
were corroborated when promoter activity also showed no significant 
differences between normal conditions and either hypoxia or serum-
starvation. 
 
Hypoxia was verified by assaying for the HIF-1Į protein and also VEGF 
gene expression, an indicator of HIF-1Į induction, but serum-starvation 
was assumed. These experiments were carried out for 24 hours, which 
may not have been sufficient time to see a change in expression levels. 
This time-point was chosen since it was enough time for Ashurst & 
colleagues to see an increase in CCK-2R expression in serum-
starvation [114]. However, that study was carried out in a rat pancreatic 
cell-line, AR42J, with a Taqman qRT-PCR assay for rat CCK-2R, which 
may not mimic exactly the human condition. If this experiment were 
repeated the cells should be stressed for longer times and stress 
proteins, such as AGR2 should be assayed for, in order to ascertain the 
level of stress in the cells [209]. Another possibility with this experiment 
is to use protein expression as the reporter for CCK-2R up-regulation, 
since this showed a more significant difference in the 3D studies (see 
Section 6.4 below), and may be affected independently of gene 
H[SUHVVLRQ $ UHSRUWHU RI WUDQVODWLRQ HQFRGLQJ *)3 LQVLGH ¶ DQG ¶
untranslated regions of the CCK-2R, could also be used for this 
purpose.  
 
Drug resistance is another characteristic of cancer cells, particularly 
CSC, and it was hypothesised that CCK-2R may be up-regulated in 
cells developing resistance to drugs. The chosen drug was cisplatin; a 
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chemotherapeutic used to treat many carcinomas, and one where drug-
resistance is very common [210]. HCT116 cells were exposed to 
increasing concentrations of cisplatin, and considered cisplatin-resistant 
when grown in 1µg/ml cisplatin for 3 passages. The cisplatin IC50 of 
these cells was compared to that of the wild-type HCT116 cells, and 
found to be higher in each experiment although this difference did not 
reach significance.  When LATE-PCR was used to detect CCK-2R gene 
expression in these cells, it was found to be almost three-fold higher 
than in the wild-type cells (p<0.05). However, knock-down of CCK-2R 
did not have an effect on cisplatin sensitivity, showing that the receptor 
is up-regulated in drug resistance but not fundamental to the 
preservation of this characteristic. This may indicate that the CCK-2R is 
a surrogate marker for drug resistance. 
 
Surrogate markers for drug-resistance are very important in cancer 
research since they can allow the prediction of drug-resistance before 
the event. GRP78 over-expression was found to be linked to resistance 
to adriamycin in breast cancer, consequently if a patient displayed this 
characteristic then alternative therapies were considered [211]. A new 
surrogate marker has recently emerged during studies of ovarian 
carcinoma; 18F-FLT PET uptake correlates with mTOR inhibition in 
cisplatin-resistant tumours [212]. Further studies with the CCK-2R could 
be carried out, using qRT-PCR to determine the gene expression 
profiles of known drug-resistant primary tumour samples to see whether 
a correlation exists. 
 
6.4. Expression of the CCK-2R is up-regulated by, and 
involved in, growth of cells as tumour spheres 
Cancer cell-lines are classically grown in 2D monolayer culture; 
however, the literature is beginning to show that this method is not 
representative of the in vivo condition. In the human body solid tumours 
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are 3D structures comprised of many different cell types and 
environments, often including a hypoxic centre. If tumour cells could be 
grown in 3D, then they could more truly represent the natural situation 
[173, 174]. Lee et al. have demonstrated the similarity of 3D models 
and real tumours, in terms of gene profiling [44], compared to 2D 
models in primary glioma tissue. The genes profiled included CSC 
markers such as CD133 and Sox2, proliferation markers and CNS 
development markers. The spheres were formed from primary tumour 
samples, unlike those in our study, and they suggest that transformed 
cell-lines lose their CSC subset over many passages [44]. However, 
they do reference several studies, e.g. [213], where CSC have been 
found within tumour cell-lines, and so suggest that these cells may be 
encouraged to grow back from a very small population or indeed re-
emerge from differentiated cells in the correct conditions for their 
growth. 
 
There are several methods in the literature to achieve the goal of 
growing tumour cell-lines as 3D structures. The method used in our 
study, and that described above, involved using a serum-free medium, 
supplemented with EGF and FGF (SCM), to encourage sphere growth 
and to select for stem-like cells. In the literature the first neurospheres 
were formed in this way; Reynolds and Weiss discovered that neural 
cells grown with EGF formed clusters of cells, and that these cells 
differentiated into more than one cell-type, proving their stem cell 
capability [176]. This method uses serum-free conditions to limit the 
normal differentiation of cells in serum-containing medium, and Lee et 
al. also found that telomerase activity was maintained in this special 
medium [44]. Telomerase is an enzyme which adds sections of DNA to 
the end of chromosomes which are otherwise lost during replication, 
allowing a cell to continue replicating far longer than those without 
telomerase. This activity and the limitation of differentiation are stem 
cell characteristics, and therefore in tumour cell-lines the SCM method 
is enriching for cancer stem cells. Another tumourigenic, and possibly 
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CSC, characteristic is the ability to invade nearby tissues and the 
xenografts made by Lee et al. from sphere-forming cells had far more 
capacity for metastasis than did xenografts of cells grown in 2D [44].  
 
Neural cells are not the only cell type to display similarities to the in vivo 
situation when grown as spheres. Tumour cells from the colon which 
were maintained in 3D culture using the SCM method produced 
tumours with the same pattern of ȕ-catenin and cytokeratin 20 (CK20; a 
differentiation marker) expression, and histological features, when 
transplanted into mice [47]. Equivalent cells grown in 2D culture 
conditions did not show these characteristics and the CD133+ subset 
was selected against, unlike in 3D culture [47]. Lowthers et al. grew 
HT29 and two other colorectal cell-lines as tumour spheres in SCM, and 
found that these cells were far more resistant to the drug ceramide than 
those grown as monolayers [214]. Interestingly when they investigated 
whether this was due to lack of perfusion through the densely-packed 
cells in the sphere they concluded it was not, because 5FU and 
cisplatin were found to be equally effective in both their 2D and 3D 
cultures [214]. Therefore it would seem that growing cells as spheres 
does not induce resistance to all drugs. 
 
An alternative method for 3D culture is to provide a support basement 
membrane matrix for the cells to grow around, forming spheroids. The 
terms sphere [44, 47, 173, 176] and spheroid [174, 175] are both used 
in the literature to describe a 3D cellular structure in vitro; however, in 
this project the two terms will distinguish between those formed using a 
serum-free medium or a support matrix, respectively. Smalley et al. 
describe that they have seen large differences in mRNA profiles 
between 2D and 3D cell cultures [174], and that fibroblasts grown on a 
matrix show a morphology much like that in vivo, however the rigidity of 
the matrix can cause cell organisation and signalling to change. This is 
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a weakness of the method since the characteristics which can be 
altered by the matrix are those being measured. 
 
Two other sphere-forming methods were examined by Liu et al. where 
cells were encouraged to aggregate by the application of ultrasound 
waves [215] or gyratory force [216] to the culture medium[175]. The 
ultrasound waves caused the medium to vibrate pushing the cells 
towards the middle of the well, and allowing the aggregates thus formed 
to be grown in normal growth medium [215]. The gyratory method also 
allows this with the cells being grown in rotating vessels [216]. A549 
cells grown in this 3D culture mimicked primary tumour immune 
responses; they had increased lipopolysaccharide receptors for 
detecting bacterial molecules [175]. However, the gyratory method was 
first developed to form aggregates of liver cells in order to investigate 
the processes carried out by 3D multi-cell-type models compared to the 
original organ [216]. This is a very different goal to enriching for cancer 
stem cells in tumour cell populations, since existing cells are forced to 
aggregate rather than growing a sphere from one, or very few, cells. 
Both these models would be useful if one were to investigate the 
interactions of different cell-types within a tumour population, but are of 
little use when studying the cells which initiate a tumour, as in this 
project. 
 
In the current study sphere cultures made from colorectal, glioma and 
lung cell-lines were investigated, since these cell-lines showed differing 
amounts of endogenous CCK-2R gene expression. If CCK-2R 
expression was linked to the CSC phenotype then higher levels of CCK-
2R endogenous expression may relate to larger spheres or an increase 
in CCK-2R expression in those spheres. CCK-2R gene expression was 
found to be increased in day 10 spheres in U373, A549 and HOP-62 
cells. These spheres adhered to the plate almost up to day 10 of 
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growth, were perfectly round and showed filaments while they were 
attached to the plate.  
 
In HCT116 (wild-type and cisplatin-resistant), HT29 and U251 cells 
there was an increase in CCK-2R expression by day 10 but this was 
mirrored in the monolayer cultures, possibly due to the fact that these 
had reached 90% confluency by that time. The colospheres grown from 
HCT116 and HT29 cells were rounded, had a well-defined outer edge 
and floated in the medium soon after formation. They were much larger 
than those formed from lung or glioma cell-lines, indicating that 
morphology, i.e. a smaller, more adherent sphere, may be related to 
CCK-2R up-regulation. This is also interesting since Vermeulen et al. 
hypothesise that HCT116 cells do not contain a CSC subset and 
therefore should not produce spheres [53]. U251 spheres looked 
different from the colospheres, and more similar to those of BT4; 
irregularly shaped but with a defined edge, but CCK-2R gene 
expression could not be detected in BT4 cells at any time or culture. 
Possible reasons for the lack of expression are discussed in Section 6.1 
above. 
 
CCK-2R protein expression was significantly up-regulated in spheres 
formed from HCT116, HT29, BT4 and U373 compared to 2D culture, 
and the trend was also shown in U251 cells, although this was not 
significant. These results were shown by the median FITC fluorescence 
by membrane-staining, and the values for percentage of CCK-2R-hi cells 
show the same trend but not the same significance. This would indicate 
that the cells in the sphere cultures express CCK-2R more strongly, 
rather than there being significantly more cells expressing CCK-2R 
overall, than in the 2D culture.  
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Paraffin-staining showed that CCK-2R expression is highest in smaller 
spheres, and that it is mostly restricted to the cells at the edge of the 
sphere. Yeung et al. investigated CSC and differentiation markers in 
their colorectal spheroids and found that Ki67 was expressed at the 
outer edges of the structures [217]. This was expected as it shows that 
the rapidly dividing cells are at the outer edges, with the CSCs at the 
centre; if this were the case, it would mean that the cells which highly 
express CCK-2R are not the CSC subset.  
 
The centre of a sphere/spheroid is more hypoxic than the edge and 
many studies have shown hypoxia to select for CSCs [218]. Acker & 
colleagues reported that the pO2 of the centre of a sphere was much 
lower than that of the outer cells, especially of colospheres such as 
those formed by HT29 cells [219]. The current finding that CCK-2R is 
not found at the centre of the sphere corroborates the result in Chapter 
5, where CCK-2R was not found to be significantly up-regulated in 
hypoxia. The fact that the larger spheres, those formed by colorectal 
cells; assumed to have more hypoxic centres, show less up-regulation 
of CCK-2R gene expression than the smaller lung and glioma ones also 
points to this conclusion. 
 
A further result to confirm the finding that CCK-2R is not expressed in 
the CSC subset is that CCK-2R expression is not correlated to that of 
CD133, CD44 or nuclear ȕ-catenin in the spheres. CD133 protein was 
up-regulated six-fold in BT4 spheres, did not change in U251 or HOP-
62 spheres and was actually down-regulated in the colospheres. 
CD133, CD44 and nuclear ȕ-catenin are accepted CSC markers, at 
least for glioma and lung cancer, and are highly implicated in colon 
carcinoma too [43, 46-48, 57, 58]. Unexpectedly, CCK-2R and gastrin 
gene expression are not related either, despite the autocrine loop which 
links them in gastric cancers and glioma (U87 cells) [137, 186]. This 
non-correlation had been found earlier in monolayer cells, so the 
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autocrine loop may be present at the protein level only or may require 
gastrin stimulation in the cell-lines used in this project. Growing cells in 
3D had no effect on receptor promoter activity despite the up-regulation 
of CCK-2R transcription in these conditions.  
 
Many groups have used the SCM method to investigate CSC within 
several different types of tumours, although they have not looked at 
CCK-2R expression. Hussein et al. reported that neurospheres formed 
from paediatric glioma, ependymoma and other brain tumours 
contained a stem cell subset with Sox-2 and membrane CD133 
expression [45]. This study was carried out in the same way as ours, by 
re-suspending monolayer cells in SCM. Immunofluorescence (IF) 
showed them that although CD133 protein overall had not been up-
regulated, membranous CD133 had been increased four-fold [45]. This 
corroborates with the present project where paediatric BT4 spheres 
showed up-regulation of CD133 protein, but does not match with the 
adult U251 sphere result. Qiang et al. found that CD133 protein 
increased from 4 to 6% of cells at day 10 of sphere growth in U251 cells 
treated the same way, but they do not state that this difference was 
significant [220]. This may indicate that within glioma cells at least, 
paediatric cells have a higher percentage of CSC present, and are 
therefore more tumourigenic than their adult counterparts. 
 
In a study described above, Ricci-Vitiani et al. found that all the cells 
within their colospheres maintained CD133 expression and lacked 
CK20, demonstrating that they were not differentiating [47]. However, in 
another study, again with spheres grown direct from primary colon 
tumour tissue in SCM, the cells within the spheres were found to have 
different phenotypes; a small number of stem cells were maintained 
with many differentiated cells making up the rest of the sphere [221]. 
This is a more likely occurrence since CSC divide into one stem cell 
and one daughter cell; it should be impossible to maintain a CSC-only 
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population. This heterogeneous population theory is borne out by the 
finding in our sphere cultures that CCK-2R protein expression is higher 
in certain cells rather than expressed in more cells within the spheres. 
However, it appears from the location of those cells that they are not the 
CSC subset.  
 
Vermeulen et al. showed very low levels of nuclear ȕ-catenin in their 
spheres by IF [221], which may shed light on our finding that ȕ-catenin 
is cytoplasmic in the tumour spheres. Unfortunately they do not suggest 
a reason for the lack of stemness in some of their sphere cultures, other 
than that the CSC niche may play a role in deciding when the cells 
differentiate and lose their CSC characteristics. This cannot be applied 
to our project since the CSC niche would not be present in in vitro 
culture. The IHC staining for ȕ-catenin carried out in this project has not 
been verified, although positive control (pancreatic carcinoma) tissue 
was used for optimisation. Also the method for embedding the spheres 
in paraffin may need further modification to ensure the preservation of 
the spheres and therefore the accuracy of the staining. ȕ-catenin 
expression could be investigated further using the IF protocol described 
by Vermeulen et al. [221].  
 
Our data on colorectal monolayer cells expressing higher levels of 
membranous CD133 protein than those grown as spheres is at odds 
with the established literature [47, 221]. This could be due to the 
antibody not recognising the correct epitope on the CD133 protein, 
however, this is unlikely as it was taken into consideration. The antibody 
used for the staining recognised the AC133 epitope of the CD133 
molecule [222], which has been proved to be vital when distinguishing 
CSC, since this is lost in differentiated cells [223]. Another possible 
explanation is that the colospheres were grown from cells which were at 
too high a passage and therefore terminally differentiated, but if this 
was the case they should not have grown into spheres. 
                                                              Discussion and conclusions                        
    
193 
 
Lung tumour spheres formed from lung cancer cell-lines in SCM have 
been found to contain cells more resistant to cisplatin than cells grown 
as a monolayer and to exhibit nuclear ȕ-catenin expression [224]. 
These lung sphere cells were enriched for CD133 and Oct4, and could 
produce xenograft tumours with significantly less cells than those grown 
in 2D culture [224]. This draws attention to the fact that there are many 
other CSC markers which have been suggested to imply a CSC 
phenotype; not just Oct4 but Nestin, Sox-2, Lgr5, ALDH1, CD166 and 
ABCG2 [43, 52, 54, 55] , which could be used to further investigate the 
CSC subset within the tumour spheres in this project. By far the best 
method to conclusively test whether the CCK-2R-hi cells are the CSC 
subset would be to isolate them and grow xenograft tumours in 
immunodeficient mice. If the CCK-2R-hi cells can produce tumours from 
100-1000 cells then this would place them in the tumour-initiating-cell 
category and therefore they would be CSC [52]. 
 
In order to investigate whether lack of CCK-2R signalling had any effect 
on sphere-formation or maintenance, an experiment was carried out 
using an inhibitor of CCK-2R signalling, YM022, a highly selective 
antagonist for the CCK-2R [178]. Initially siRNA-transfected cells (both 
CCK-2R siRNA and the control negative siRNA) were used but they 
grew into spheres at such a slow rate that no effect of CCK-2R knock-
down could be observed. Using siRNA knock-down would have raised 
concerns because transient transfection may not have kept CCK-2R 
expression low enough for the time-frames involved in sphere-forming 
(ten days in this project). If the gene had returned to full transcription 
before the end of the experiment the results would have been skewed. 
Also, as discussed above, CCK-2R may demonstrate very efficient 
translation which may not have been ceased completely, whereas a 
protein inhibitor should stop the signalling pathway immediately and can 
be refreshed. 
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The results in HOP-62 cells indicate that CCK-2R inhibition delays 
sphere growth and may interfere in sphere maintenance too. Up until 
day 4 the YM022 group showed less sphere growth compared to the 
others, but after day 5 sphere measurements in all three groups 
became similar, illustrating that the YM022-treated cells formed spheres 
very quickly between day 4 and 5, just after YM022 was replenished. In 
the glioma cell-line, U251, CCK-2R inhibition does not affect sphere 
maintenance but does reduce the ability to form spheres. These 
findings suggest that the CCK-2R may be involved in tumour 
expansion. Results in the colorectal cell-lines, HCT116, HT29 and 
cisplatin-resistant HCT116, showed that YM022 treatment caused no 
significant differences in sphere number or area over time. The 
monolayer cells treated with YM022 at the same time did not show any 
effects. 
 
YM022 was added at intervals of 72 hours, since this was when the 
growth factors were replenished. The literature does not state a half-life 
for YM022 however, meaning that it is possible that this time-period 
would allow for peaks and troughs of CCK-2R signalling. Further 
investigations in vitro and in vivo are needed to fully understand 
whether the changes in sphere formation and maintenance are related 
to tumour growth or the CSC subset. These could include the creation 
of inducible knock-out constructs, allowing CCK-2R signalling to be 
reliably removed during in vitro growth studies. Since the gold standard 
in validating CSC markers is the ability of these cells to produce a 
tumour in vivo this should also be tested, initially by investigating CCK-
2R expression in xenograft tumours using LATE-PCR and flow 
cytometry, comparing it to that of cell-lines and primary tumours. This 
could be followed up using the knock-out constructs to see whether lack 
of CCK-2R signalling can inhibit xenograft growth. If molecular probes 
could be optimised to show the location of the CCK-2R inside these 
cells, further work could also include finding out where the CCK-2R-hi 
cells are within the tumour, and whether this changes over time. 
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6.5. Conclusions  
The CCK-2R is an important receptor in the carcinogenic process. In 
this project it has been shown to be expressed, at the gene level, in 
cancer cells of a number of different origins, by a new, highly sensitive, 
real-time PCR method; LATE-PCR. Expression has been 
demonstrated, where previously it was thought not to occur, for 
example in NSCLC and glioblastoma cells. Gene level detection of 
critical cancer biomarkers is vital in order to better understand how 
these proteins are made and used in the initiation and progression of 
this disease. Now that LATE-PCR has been used to this purpose, it 
could also be applied to discover whether there are other low-level 
expression mRNAs which are critical in cancer biology. 
 
CCK-2R has long been known to be up-regulated at the protein level in 
primary tumour cells; however, in this project gene expression levels 
were shown to be elevated in lung tumours compared to equivalent 
normal samples. If we are to find out whether CCK-2R is a therapeutic 
marker in lung cancer, investigating the regulation of the CCK-2R is 
clearly important.  This includes transcriptional regulation, where the 
500bp of the promoter proximal to the CCK-2R gene are highly active in 
several different cancer cell-lines, and post-transcriptional or 
translational regulation since mRNA and protein levels do not correlate.  
 
CCK-2R was expressed at a high level in a subset of each cell-line 
population, but the lack of correlation between CCK-2R and some CSC 
markers, indicates that this is not the CSC subset. The rapidly-dividing 
cells at the outer edge of the sphere show the highest CCK-2R protein 
expression, not those in the hypoxic centre. CCK-2R gene expression 
was, however, up-regulated by both 3D culture of cancer cell-lines and 
drug-resistance in a colorectal cell-line. This project also showed that 
inhibition of CCK-2R signalling can inhibit sphere growth and possibly 
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sphere maintenance in lung and glioma cell-lines, suggesting a role for 
the CCK-2R in tumour expansion. 
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